KOL | Roger F Butterworth∗Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada | Department of Medicine, University of Montreal, Montreal, Canada | ... |
Kol melanjutkan untuk Roger F Butterworth∗
| Year | |
|---|---|
| 2021 | Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada |
| 2020 | Department of Medicine, University of Montreal, Montreal, Canada |
| 2019 | Department of Medicine, University of Montreal, 45143 Cabot Trail, B0C 1H0, Englishtown, NS, Canada University of Montreal (St-Luc Hospital), Montreal, QC |
| 2018 | CHUM St-Luc Hospital and Department of Medicine, University of Montreal, Canada. University of Montreal (St-Luc Hospital), Montreal, Québec, Canada |
| 2015 | Department of Medicine, University of Montreal, Montreal, Quebec, Canada |
| 2014 | Neuroscience Research Unit, Hopital St-Luc (CHUM) and Department of Medicine, University of Montreal, Montreal, QC H2W 3J4, Canada |
| 2013 | Neuroscience Research Unit, Hôpital St-Luc (CHUM), 1058 Rue St-Denis, H2X 3J4, Montreal, QC, Canada |
| 2012 | Neuroscience Research Unit, Saint-Luc Hospital (CHUM), University of Montreal, Montreal, Quebec, Canada |
| 2011 | Department of Medicine, University of Montreal, Neuroscience Research Unit, Montreal, Quebec, Canada |
| 2010 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), University of Montreal, 1058 St. Denis Street, Montreal, Quebec, Canada |
| 2009 | Neuroscience Research Unit, Hôpital Saint‐Luc, CHUM, Montreal, QC, Canada |
| 2008 | Neuroscience Research Unit, Université de Montréal, Montreal, QC, Canada |
| 2007 | Neuroscience Research Unit, CHUM (Campus Saint-Luc), University of Montreal, 1058, Saint-Denis Street, H2X 3J4, Montreal, Quebec, Canada |
| 2006 | Neuroscience Research Unit, University of Montreal (CHUM), Hôpital Saint-Luc, 1058 St-Denis Street, Montreal, Que., Canada H2X 3J4 |
| 2005 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), Montréal, Quebec, Canada |
| 2004 | Neuroscience Research Unit, Montreal, Quebec, Canada |
Roger F Butterworth∗: Statistik pengaruh
Jalankan laporan
| Concept | World rank |
|---|---|
| nakatpase activity thalamus | #1 |
| receptors pca | #1 |
| alf neuroinflammation | #1 |
| nh4ac rats | #1 |
| therapy refractive tle | #1 |
| removal bloodborne ammonia | #1 |
| deterioration neurological status | #1 |
| hypokinesia et495 | #1 |
| fluid taurine | #1 |
| increased brain ammonia | #1 |
| cirrhosis nature | #1 |
| prevention brain | #1 |
| spine neurochemical | #1 |
| manganese deposition | #1 |
| flunitrazepam modulation | #1 |
| brain ammonia pca | #1 |
| thiamine deficiency decreases | #1 |
| degree pss | #1 |
| pfco | #1 |
| increased gabaergic | #1 |
| ptbr brain | #1 |
| portacaval shunting activities | #1 |
| neurological symptoms normalisation | #1 |
| csf concentrations ammonia | #1 |
| neurotransmitter alterations prevention | #1 |
| nac neurological complications | #1 |
| liver diseases range | #1 |
| ammonia toxins | #1 |
| symptoms wernicke | #1 |
| lola reductions | #1 |
| glutamine synthetase activities | #1 |
| brain ammonia measurement | #1 |
| lornithinelaspartate prevention | #1 |
| encephalopathy brain edema | #1 |
| alf rats expression | #1 |
| glutamate originating | #1 |
| encephalopathy new | #1 |
| alf studies | #1 |
| azoxymethane mouse model | #1 |
| hepatic coma patients | #1 |
| mild hypothermia onset | #1 |
| vulnerable medial | #1 |
| acute male microglia | #1 |
| nimesulide thiamine deficiency | #1 |
| pse probenecid | #1 |
| hepatic devascularization | #1 |
| animal model encephalopathy | #1 |
| neurosteroid modulatory | #1 |
| brain regions pyrithiamine | #1 |
| shunting hyperammonemia rats | #1 |
| encephalopathy thiamine | #1 |
| prevention ohe | #1 |
| deficiency selective | #1 |
| experimental model metabolic | #1 |
| brain pregnant rats | #1 |
| ptbrs binding | #1 |
| alf azoxymethane | #1 |
| dansyl chloride microassay | #1 |
| mg2dependentatpase | #1 |
| 202 55 nm | #1 |
| etanercept decreased plasma | #1 |
| precoma coma stages | #1 |
| surgical rna | #1 |
| hepatic encephalopathy neurobiology | #1 |
| ohe mhe patients | #1 |
| death wernicke | #1 |
| coma pathophysiologic basis | #1 |
| normothermic alf rats | #1 |
| portacaval shunted | #1 |
| p005 5mm nh4cl | #1 |
| wellestablished actions | #1 |
| neuronal crosstalk | #1 |
| caudate putamen sum | #1 |
| pca penicillamine | #1 |
| brain edema rats | #1 |
| ampa sites | #1 |
| focal lactic acidosis | #1 |
| dopamine thiamine deficiency | #1 |
| ldopa octopamine | #1 |
| coa levels brain | #1 |
| cirrhotic patients densities | #1 |
| pregnenolone brain tissue | #1 |
| pca activities | #1 |
| 3hpk11195 ligands | #1 |
| pss degree | #1 |
| 90 fmol protein | #1 |
| 3acetyl pyridine rats | #1 |
| alf rats | #1 |
| action acute hyperammonemia | #1 |
| metabolic scavengers | #1 |
| portacavalshunting | #1 |
| cirrhotic patients cau | #1 |
| cns wernickekorsakoff | #1 |
| animal hepatectomy hepatitis | #1 |
| therapeutic efficacy lcarnitine | #1 |
| astrocytic accumulation | #1 |
| manganese extrapyramidal symptoms | #1 |
| wernickes encephalopathy aids | #1 |
| hypoglycaemia onset | #1 |
| alf brain edema | #1 |
| predilection neuropathologic damage | #1 |
| ammonia brain | #1 |
| pfco cau | #1 |
| thiamine deficiency humans | #1 |
| 3h 11195 | #1 |
| onset hypoglycaemic convulsions | #1 |
| daily injections thiamine | #1 |
| ” benzodiazepine | #1 |
| control alf37 | #1 |
| alf precise role | #1 |
| hypermmonemia | #1 |
| αkgdh onset | #1 |
| thiamine interactions | #1 |
| enzyme activities loss | #1 |
| hepatic coma bbb | #1 |
| increased blood manganese | #1 |
| alterations increased expression | #1 |
| dying hepatic | #1 |
| liver pca | #1 |
| astrocyte morphology alterations | #1 |
| friedreich gilbert | #1 |
| encephalopathy alanine | #1 |
| region selective alterations | #1 |
| serum lad friedreich | #1 |
| alcoholic peripheral neuropathy | #1 |
| selective damage pdhc | #1 |
| ammonium acetate administration | #1 |
| treatment mild encephalopathy | #1 |
| occludin medial thalamus | #1 |
| pse csf lactate | #1 |
| increased brain | #1 |
| stages igg immunohistochemistry | #1 |
| manganese etiology | #1 |
| investigator predictions | #1 |
| lola efficacy | #1 |
| cuznsod cox2 | #1 |
| humans gabaa steroids | #1 |
| antiparkinson drugs hypokinesia | #1 |
| grc integrity | #1 |
| brains pcs rats | #1 |
| l‐3hnitroarginine | #1 |
| isoquinolinebinding moiety | #1 |
| comatose rats | #1 |
| hyperammonemia aaas | #1 |
| 3hpk11195 rats | #1 |
| material equal | #1 |
| rat sustained hyperammonemia | #1 |
| protective findings | #1 |
| region‐selective alterations | #1 |
| cerebral γ‐aminobutyric acid | #1 |
| glutamate exposure ammonia | #1 |
| osmotic disturbance | #1 |
| liver pathology increases | #1 |
| nac normalization | #1 |
| alf hepatic | #1 |
| encephalopathy neuropsychiatric | #1 |
| matkowskyj | #1 |
| decreased detoxification ammonia | #1 |
| hypothermia ammonia | #1 |
| seesection | #1 |
| taurine electrolyte balance | #1 |
| ptbr densities | #1 |
| free coa atp | #1 |
| densities 3hpk11195 sites | #1 |
| pglycoprotein willebrand factor | #1 |
| lola nash | #1 |
| 3hpk11195 binding sites | #1 |
| hepatic encephalopathy activation | #1 |
| 5mm nh4cl p0001 | #1 |
| human brain ammonia | #1 |
| stroke forms | #1 |
| congenital hyperammonemia nakatpase | #1 |
| endogenous opioid brain | #1 |
| altered thiamine neurochemistry | #1 |
| hyperammonemic spf mice | #1 |
| ptbr complex | #1 |
| etanercepttreated alf mice | #1 |
| selective increases | #1 |
| increased densities | #1 |
| brain portacaval anastomosis | #1 |
| atp acetyl coa | #1 |
| hypoglycaemic convulsions | #1 |
| efficacy lola | #1 |
| reversible symptoms | #1 |
| mild hypothermia delay | #1 |
| downregulation glutamate transporter | #1 |
| cns pca | #1 |
| neuroinflammation alf | #1 |
| cerebral cortex hypokinesia | #1 |
| brain major | #1 |
| experimental wernicke | #1 |
| agents metabolic potential | #1 |
| akinesia rats | #1 |
| ω3 receptor | #1 |
| direct hepatoprotective effects | #1 |
| findings ammonia | #1 |
| tk activity onset | #1 |
| alf mild hypothermia | #1 |
| pca increased densities | #1 |
| disease outcome prevention | #1 |
| cirrhosis brain dysfunction | #1 |
| weeks portacaval | #1 |
| encephalopathy cau | #1 |
| hippocampus cirrhotic patients | #1 |
| alf include | #1 |
| csf lactate pse | #1 |
| prior detoxification liver | #1 |
| mechanisms brain edema | #1 |
| 11 thiamine deficiency | #1 |
| animal liver failure | #1 |
| loss tdpase activities | #1 |
| blood ammonia concentrations | #1 |
| brain altered expression | #1 |
| ammonium acetate challenge | #1 |
| hepatic microcirculation patients | #1 |
| overt encephalopathy alterations | #1 |
| rtpcr experiments betaactin | #1 |
| thiaminedeficient encephalopathy | #1 |
| hepatic encephalopathy activities | #1 |
| acute symptomatic animals | #1 |
| portacaval shunting hyperammonemia | #1 |
| kgdh decreased | #1 |
| activation ptbr | #1 |
| nmda receptor alf | #1 |
| glt1 transporter proteins | #1 |
| cerebral cortex pca | #1 |
| liver failure neuroinflammation | #1 |
| vivo cerebral microdialysis | #1 |
| primary energy failure | #1 |
| sodium benzoate atp | #1 |
| congenital otc deficiencies | #1 |
| thiaminedeficient medium | #1 |
| 062 009 liter | #1 |
| accumulate brain | #1 |
| neuroinflammation cns complications | #1 |
| portalsystemic encephalopathy pse | #1 |
| microglial activation protective | #1 |
| reduction bbb breakdown | #1 |
| nnos expression result | #1 |
| cerebrospinal fluid ammonia | #1 |
| postshunt myelopathy | #1 |
| pfco cirrhotic patients | #1 |
| alf increases | #1 |
| etanercept treatment reduction | #1 |
| lola effective | #1 |
| portocaval shunting activities | #1 |
| csf concentrations bzrls | #1 |
| ammoniaprecipitated coma | #1 |
| experimental thiamine | #1 |
| lornithinelaspartate therapeutic efficacy | #1 |
| reflex pdhc activities | #1 |
| brain congenital | #1 |
| flunitrazepam hepatic | #1 |
| azoxymethane mouse | #1 |
| ammonia intoxication rats | #1 |
| modulation nitric oxide | #1 |
| inhibition bloodbrain transfer | #1 |
| brains spf mice | #1 |
| brains alf rats | #1 |
| distribution l3hnoarg | #1 |
| haloperidol humans haloperiodol | #1 |
| taurine medium | #1 |
| coma stages | #1 |
| metabolites term fluorescence | #1 |
| encephalopathy activities | #1 |
| atp free coa | #1 |
| 3hnisoxetine sites | #1 |
| spf mice | #1 |
| pca brainstem | #1 |
| prevents brain | #1 |
| cell damage mechanisms | #1 |
| hyperammonemic pathologies | #1 |
| protein coma stages | #1 |
| acute neurons mechanisms | #1 |
| h1 receptor density | #1 |
| 3hkainate sites | #1 |
| binding sites 3hpk11195 | #1 |
| cerebellar concentration | #1 |
| pbgd rat model | #1 |
| alcoholic peripheral | #1 |
| neuropsychiatric disorder evidence | #1 |
| rats acute | #1 |
| nh4 forms neurons | #1 |
| type astrocytosis | #1 |
| nacl calcium | #1 |
| synthesis intercellular transport | #1 |
| stress alf | #1 |
| major role mechanisms | #1 |
| glial filament network | #1 |
| experimental alf increases | #1 |
| encephalopathy male | #1 |
| friedreichs ataxia dehydrogenase | #1 |
| brain ptbr | #1 |
| pathogenesis wernickekorsakoff syndrome | #1 |
| investigator neurological disorders | #1 |
| frontal cortex fco | #1 |
| died hepatic | #1 |
| immunohistochemistry spraguedawley statistics | #1 |
| congenital acquired hyperammonemia | #1 |
| homogenates cirrhotic patients | #1 |
| reduction circulating neurotoxins | #1 |
| cerebral hepatic levels | #1 |
| proinflammatory mechanisms | #1 |
| brain herniation alf | #1 |
| alcoholic manganese | #1 |
| thiamine deficiency implications | #1 |
| inhibitors acute hyperammonemia | #1 |
| veratramines action parachlorophenylalanine | #1 |
| brain levels tmp | #1 |
| brain portacaval | #1 |
| hypokinesia stereotaxic microinjection | #1 |
| older cirrhotic patients | #1 |
| rats varying degrees | #1 |
| nonvulnerable frontal cortex | #1 |
| alf mice deletion | #1 |
| capacity ammonia removal | #1 |
| ω3 receptor 3hpk11195 | #1 |
| presence brain extracts | #1 |
| modulators hepatic | #1 |
| term fluorescence phenomenon | #1 |
| brain gaba uptake | #1 |
| dawley thiamine | #1 |
| taurine hepatic encephalopathy | #1 |
| increased gabaergic tone | #1 |
| encephalopathy pse | #1 |
| abnormal pyruvate oxidation | #1 |
| jadad cochrane ohe | #1 |
| encephalopathy il1beta | #1 |
| ammoniainduced reduction | #1 |
| alcohol‐thiamine interactions | #1 |
| pglycoprotein mild hypothermia | #1 |
| microsomes medium | #1 |
| surgical probenecid | #1 |
| thalamus pyrithiamine treatment | #1 |
| expression glyt1 transporter | #1 |
| mechanisms wemickes encephalopathy | #1 |
| neuronastrocytic trafficking | #1 |
| increased binding sites | #1 |
| encephalopathy | #1 |
| circulating neurotoxins | #1 |
| prevention brain edema | #1 |
| glutaminecycle | #1 |
| alf evidence | #1 |
| pathogenesis hyperammonemic syndromes | #1 |
| ammonia cns function | #1 |
| wks spraguedawley receptors | #1 |
| failure alanine | #1 |
| central thiamine | #1 |
| ammonia mechanisms | #1 |
| nac aom | #1 |
| lola treatment | #1 |
| acids aaas | #1 |
| azoxymethane toxicity | #1 |
| cyclase content | #1 |
| markedly impaired | #1 |
| increased brain content | #1 |
| selectively decreased | #1 |
| 3htryptamine receptors | #1 |
| aom mice | #1 |
| freechoice drinking paradigm | #1 |
| alterations pse | #1 |
| neurological disorders selection | #1 |
| amines hepatic | #1 |
| deficiency binding | #1 |
| hyperammonemic sparse | #1 |
| ptbribp | #1 |
| ligand3h | #1 |
| pca rats | #1 |
| ammonia normal conditions | #1 |
| encephalopathy cirrhosis | #1 |
| 8 cirrhotic patients | #1 |
| hyperammonaemia brain function | #1 |
| symptomatic pyrithiamine | #1 |
| gabaaassociated receptors | #1 |
| pse neurotransmitter agents | #1 |
| animals thiamine deficiency | #1 |
| clf alf | #1 |
| pbgd mrna expression | #1 |
| thiamine phosphatases | #1 |
| cloned rat ptbr | #1 |
| glucose loading precipitates | #1 |
| edema formation mnsod | #1 |
| reversal neurological symptoms | #1 |
| hepatic devascularized rats | #1 |
| electroencephalogram tracings | #1 |
| peripheral‐type benzodiazepine receptors | #1 |
| pathogenetic defect | #1 |
| hyperammonemic disorders | #1 |
| isomorphic model predictions | #1 |
| manifest altered expression | #1 |
| alf relation | #1 |
| alf hypothermia | #1 |
| encephalopathy humans opioid | #1 |
| surgical rna messenger | #1 |
| thiaminedeficient brain | #1 |
| benzodiazepine site contrast | #1 |
| gut ammonia | #1 |
| update hepatic encephalopathy | #1 |
| protective portacavalshunted rats | #1 |
| loss transporter sites | #1 |
| congenital ornithine | #1 |
| ptbr expression pathogenesis | #1 |
| cox2 cuznsod mrna | #1 |
| serotonin precursor metabolite | #1 |
| alterations brain glutamate | #1 |
| glucose loading decreases | #1 |
| pca loss | #1 |
| disorder isomorphic model | #1 |
| pfco brain tissue | #1 |
| spf mutant | #1 |
| radioenzymatic assays activities | #1 |
| neuroinflammatory response alf | #1 |
| frontal cortex exp | #1 |
| 15–1788 pharmacokinetics | #1 |
| liver spleen ratios | #1 |
| rat wernickes encephalopathy | #1 |
| ptbribp frontal cortex | #1 |
| circulating ammonia | #1 |
| increased activities tdpase | #1 |
| raphe serotonin serotonin | #1 |
| evidence thiamine deprivation | #1 |
| dipeptides hepatic | #1 |
| tissue distribution neuropathology | #1 |
| maob cerebellum | #1 |
| r071–084 | #1 |
| cultured cells mrna | #1 |
| loss 3hcitalopram sites | #1 |
| increased glutamine synthesis | #1 |
| progression prevention | #1 |
| portacaval anastomosis | #1 |
| diabetes ataxia humans | #1 |
| ptbr nnos | #1 |
| 15–1788 pharmacokinetics cirrhosis | #1 |
| cns relation | #1 |
| 32°c–35°c | #1 |
| brain edema increases | #1 |
| l‐3harginine | #1 |
| unchanged brain | #1 |
| maob encephalopathy humans | #1 |
| abstract5fluoromethylornithine | #1 |
| spontaneous release glutamate | #1 |
| distribution 3htryptamine | #1 |
| humans wernickes encephalopathy | #1 |
| ammoniainduced decrease | #1 |
| hypothesis hepatic encephalopathy | #1 |
| pathogenesis pse | #1 |
| aom nac | #1 |
| clinicallydefined entities | #1 |
| chronic thiamine deprivation | #1 |
| thiamine deficiency 23 | #1 |
| fasting intravenous injection | #1 |
| encephalopathy prevention | #1 |
| thalamus cirrhotic patients | #1 |
| pons gaba content | #1 |
| hepatic encephalopathies | #1 |
| nh4cl glutamates hippocampus | #1 |
| alzheimer type astrocytosis | #1 |
| dismutase hyperglycemic | #1 |
| mmt manganese phosphate | #1 |
| liver failure muscle | #1 |
| finding loss | #1 |
| alterations brain dopamine | #1 |
| encephalopathy nitrogen | #1 |
| subclass sites | #1 |
| astrocytes ammonia levels | #1 |
| surgical portacaval anastomosis | #1 |
| brain distribution rats | #1 |
| inhibitory nh4cl | #1 |
| experimental pse | #1 |
| rats direct evidence | #1 |
| cox2 cuznsod | #1 |
| neuroinhibitory steroid | #1 |
| ptbr expression | #1 |
| thiamine‐dependent enzymes | #1 |
| lcarnitine doses | #1 |
| male pyrithiamine | #1 |
| neurobiology hepatic encephalopathy | #1 |
| etanercept il6 levels | #1 |
| deficiency transketolase | #1 |
| hypothermia delay | #1 |
| varying degrees pss | #1 |
| pyrithiamine | #1 |
| antagonist pyrithiamine | #1 |
| hepatic encephalopathy relationship | #1 |
| hereferences | #1 |
| mm nacl nacl | #1 |
| encephalopathy central | #1 |
| additional bloodborne ammonia | #1 |
| pss dopamine hepatic | #1 |
| tissues spf mice | #1 |
| relationship blood manganese | #1 |
| pdhc activities | #1 |
| induction epileptic patients | #1 |
| pcs rats protective | #1 |
| treatment lola | #1 |
| spectrum neuropsychiatric abnormalities | #1 |
| rats coma | #1 |
| pse increased densities | #1 |
| autopsied brain samples | #1 |
| chronic hyperammonemic syndromes | #1 |
| lornithine laspartate lola | #1 |
| 100 microm manganese | #1 |
| fur spf | #1 |
| psychometric testing falls | #1 |
| 10 microm flumazenil | #1 |
| atp free coenzyme | #1 |
| widespread alterations | #1 |
| pallidal binding sites | #1 |
| development nutritional recommendations | #1 |
| spf mice activities | #1 |
| prevention ammoniaprecipitated coma | #1 |
| brain ammonia concentrations | #1 |
| normal conditions gut | #1 |
| thiamine daily administration | #1 |
| oxygenase1 hepatic | #1 |
| 70 tk | #1 |
| ptbr sites | #1 |
| cirrhosis extrapyramidal symptoms | #1 |
| deficiency wernicke | #1 |
| ammonia increased production | #1 |
| iotal6 | #1 |
| rats alf | #1 |
| findings therapeutic efficacy | #1 |
| 5mm nh4cl | #1 |
| specific l3hnoarg binding | #1 |
| bbb permeability alf | #1 |
| tdpase encephalopathy humans | #1 |
| increased levels allopregnanolone | #1 |
| reduction mild hypothermia | #1 |
| mitochondrial enzyme αkgdh | #1 |
| encephalopathy alcoholic | #1 |
| ammonia central | #1 |
| wernickekorsakoff syndrome disturbances | #1 |
| inflammation thiamine deficiency | #1 |
| plasma clearance halflife | #1 |
| liver failure modulation | #1 |
| aom animal hypothermia | #1 |
| pca portacaval shunt | #1 |
| integrity gabaa receptors | #1 |
| portacaval pcs rats | #1 |
| 1 lola | #1 |
| disorders ammonia metabolism | #1 |
| cerebral aminoacids | #1 |
| mrnas ampa receptor | #1 |
| compounds pyrithiamine | #1 |
| experimental thiamine deficiency | #1 |
| nacetylcysteine cerebral complications | #1 |
| wernickes encephalopathy humans | #1 |
| 24 hours pca | #1 |
| loss nmda | #1 |
| neuronal thalamus | #1 |
| thiamine deficiency synthesis | #1 |
| encephalopathy hypothermia | #1 |
| measurement aqp4 levels | #1 |
| bloodborne ammonia | #1 |
| ldopa trace amines | #1 |
| sgc activation lymphocytes | #1 |
| capacity cerebral cortex | #1 |
| brain thiamine metabolism | #1 |
| chronic hyperammonemia syndromes | #1 |
| neurosteroids pregnenolone allopregnanolone | #1 |
| genes astrocytic proteins | #1 |
| pons thiamine treatment | #1 |
| 3865 258 nm | #1 |
| that11cpk11195 | #1 |
| therapy ornithine transcarbamylase | #1 |
| 3hmuscimol binding studies | #1 |
| serum lad patients | #1 |
| lcarnitinetreated | #1 |
| pharmaceutical benzodiazepine | #1 |
| pbz receptor densities | #1 |
| brain liver failure | #1 |
| edema energy | #1 |
| serotonin transporter deficit | #1 |
| rats hepatic devascularization | #1 |
| lactate brain regions | #1 |
| edema encephalopathy | #1 |
| seasonal ataxia | #1 |
| loss thiamine | #1 |
| nonsclerotic tle patients | #1 |
| pse lornithinelaspartate | #1 |
| effects ammonia | #1 |
| 6hydroxydopamine anterolateral hypothalamus | #1 |
| vicious cycle sarcopenia | #1 |
| transketolase enzyme activities | #1 |
| initial reports pathogenesis | #1 |
| inherited ataxias characteristics | #1 |
| electroencephalogram tracings patients | #1 |
| thalamus thiamine | #1 |
| alf rats precoma | #1 |
| sites thiamine | #1 |
| lornithine laspartate ammonia | #1 |
| viral hepatitis alf | #1 |
| ammonia increased expression | #1 |
| failure amino | #1 |
| platelet taurine uptake | #1 |
| friedreichs ataxia thiaminedeficient | #1 |
| pathogenesis cerebral complications | #1 |
| pallidal signal hyperintensity | #1 |
| rats fpc | #1 |
| decreased tdp concentrations | #1 |
| 44433a | #1 |
| tdpase tdpase activities | #1 |
| binding sites cerebellum | #1 |
| ethanol nutritional deficit | #1 |
| brain dysfunction pse | #1 |
| ptbr mrna levels | #1 |
| prophylaxis reductions | #1 |
| liver normal cd1 | #1 |
| cox2 ca1 subfield | #1 |
| affinity ptbr | #1 |
| neuroprotection onset | #1 |
| restricted transfer glutamine | #1 |
| bilirubin ataxics | #1 |
| ouabain pyrimethamine rats | #1 |
| ptbr mrna | #1 |
| encephalopathy binding | #1 |
| liver failure alterations | #1 |
| cirrhosis psychometric testing | #1 |
| ammonia proinflammatory | #1 |
| thiamine‐deficient | #1 |
| onset neurological symptoms | #1 |
| alf animals expression | #1 |
| autopsied brain tissue | #1 |
| key astrocytic proteins | #1 |
| precise role glutamine | #1 |
| normal cd1 | #1 |
| rendered ataxic | #1 |
| wernicke′s encephalopathy | #1 |
| 3htryptamine receptor | #1 |
| neurological symptoms encephalopathy | #1 |
| regional lactate levels | #1 |
| nuclei fastigial interpositus | #1 |
| receptor cirrhotic patients | #1 |
| pathophysiology cirrhosis | #1 |
| mental state grade | #1 |
| ligand3hpk11195 | #1 |
| lipoamide dehydrogenase lad | #1 |
| 3hcitalopram sites rats | #1 |
| plasma alf rats | #1 |
| bzrls | #1 |
| perivenous hepatocytes brain | #1 |
| olivopontocerebellar atrophy expression | #1 |
| ngnitrol3harginine | #1 |
| alterations receptor sites | #1 |
| l‐deprenyl treatment | #1 |
| coding key | #1 |
| hepatic microcirculation addition | #1 |
| mild hypothermia alf | #1 |
| ptbr alterations | #1 |
| predictive model investigator | #1 |
| diencephalic cerebellar | #1 |
| astrocytic glycine transporter | #1 |
| cox2 tle | #1 |
| induction astrocytic cox2 | #1 |
| fig dansyl | #1 |
| key astrocytic | #1 |
| increases glutamine | #1 |
| thiaminedependent enzymes establishment | #1 |
| pca rats pca | #1 |
| regional variation bckdh | #1 |
| decarboxylase hepatic | #1 |
| thiaminedeficient rats | #1 |
| selective reversible decreases | #1 |
| activities neuronal | #1 |
| csf lactate accumulation | #1 |
| thiaminedeficient ataxic gait | #1 |
| activities maob | #1 |
| ammonia central nervous | #1 |
| cirrhotic brain tissue | #1 |
| osmotic actions | #1 |
| astrocytic accumulation glutamine | #1 |
| aom mice nac | #1 |
| cerebellum sustained hyperammonemia | #1 |
| concentrations olfactory bulb | #1 |
| specific energy metabolism | #1 |
| rats metallic | #1 |
| maternal thiamine | #1 |
| edema complications | #1 |
| exposure proinflammatory | #1 |
| offspring animal pyruvate | #1 |
| omega 3 receptor | #1 |
| glt1 encephalopathy humans | #1 |
| nakatpase activities striatum | #1 |
| ethanol preference ratio | #1 |
| daily pyrithiamine treatment | #1 |
| 3hpk11195 binding | #1 |
| devascularized rat | #1 |
| 3hpk11195 human brain | #1 |
| glutamine synthetase capacity | #1 |
| taurines role | #1 |
| selective alterations | #1 |
| genetic xlinked deficiency | #1 |
| cerebellar amino acids | #1 |
| precoma | #1 |
| administration novo synthesis | #1 |
| 3hpk cultured astrocytes | #1 |
| pyrithiaminetreated rats | #1 |
| 3h8ohdpat frontal cortex | #1 |
| tmpase tdpase | #1 |
| astrocyticneuronal cross | #1 |
| pathogenesis clinic | #1 |
| expression astrocytic | #1 |
| nacl taurine | #1 |
| doses lcarnitine | #1 |
| early astrocytic response | #1 |
| severe liver atrophy | #1 |
| mhe life | #1 |
| increased activities maoa | #1 |
| cirrhotic patients benzodiazepines | #1 |
| genes brain edema | #1 |
| ammonia acute | #1 |
| hepatic encephalopathy authors | #1 |
| heneuropathology | #1 |
| rats ouabain pyrimethamine | #1 |
| failure ammonia | #1 |
| loss gfap expression | #1 |
| neuroinflammationinflammation | #1 |
| l3hnoarg binding | #1 |
| pca portacaval | #1 |
| caudate putamen concentrations | #1 |
| ammonia major roles | #1 |
| increased csf lactate | #1 |
| fco cirrhotic patients | #1 |
| brain human experimental | #1 |
| novo synthesis aspartate | #1 |
| igg extravasation expression | #1 |
| microglia neuroinflammatory response | #1 |
| maoa activities cerebellum | #1 |
| encephalopathy vivo | #1 |
| acute hyperammonemia activation | #1 |
| poor nutrition vitamin | #1 |
| taurine microsomes | #1 |
| akgdh | #1 |
| thiaminedeficient mothers | #1 |
| establishment adult activities | #1 |
| edema cytokines | #1 |
| previous exposure benzodiazepines | #1 |
| metabolism ammonia | #1 |
| expression ptbrs | #1 |
| primary astrocytopathy | #1 |
| brains increased concentrations | #1 |
| 001 cerebral | #1 |
| progression thiamine deficiency | #1 |
| tnfα delayed progression | #1 |
| autopsied frontal cortex | #1 |
| hyperammonemic syndromes | #1 |
| liver failure ucds | #1 |
| portacavalshunted pcs rats | #1 |
| alf37 | #1 |
| 15–1788 kinetics | #1 |
| rats insulin hypoglycaemia | #1 |
| glut1 alf | #1 |
| pugh score iii | #1 |
| restricted transfer cell | #1 |
| findings neuroinflammatory response | #1 |
| encephalopathy alf | #1 |
| sparsefur spf mice | #1 |
| congenitally hyperammonemic | #1 |
| dehydrogenase complex transketolase | #1 |
| cerebral disorder | #1 |
| muscarinic thiamine | #1 |
| assessment locomotor activities | #1 |
| cerebellar concentration aspartate | #1 |
| age time interval | #1 |
| thalamus symptomatic | #1 |
| response alf | #1 |
| precipitation severe stages | #1 |
| locomotor activities difference | #1 |
| pyrithiamine quinuclidinyl | #1 |
| ammonia mrna | #1 |
| ligase hepatic | #1 |
| regions pyrithiamine | #1 |
| ammoniainduced inhibition | #1 |
| pdhc step | #1 |
| thiamine deficiency encephalopathy | #1 |
| ” benzodiazepine receptors | #1 |
| alf messenger | #1 |
| dehydrogenase αkgdh | #1 |
| fumazenil | #1 |
| 7 thiaminedeficient medium | #1 |
| pca beta endorphin | #1 |
| findings manganese | #1 |
| lumbar gray matter | #1 |
| experimental portal | #1 |
| regionselective alterations | #1 |
| ligand3hpirenzepine | #1 |
| liver failure increases | #1 |
| thiamine deficiency bckdh | #1 |
| alf glucose | #1 |
| portacavalshunted rats protective | #1 |
| receptors thiamine | #1 |
| lola mental state | #1 |
| caudate putamen 57 | #1 |
| csf portacaval anastomosis | #1 |
| pse altered expression | #1 |
| pbg pbgd | #1 |
| alf alterations | #1 |
| pregnanolone brain chemistry | #1 |
| cau lobe hepatic | #1 |
| manganese phosphate mmt | #1 |
| hippocampal sclerosis induction | #1 |
| concomitantly increased | #1 |
| borne ammonia | #1 |
| pathogenesis brain edema | #1 |
| microglia evidence | #1 |
| mild hypothermia prevention | #1 |
| blood ammonia improvement | #1 |
| ouabain doses | #1 |
| coma edema stages | #1 |
| αkgdh | #1 |
| rats pca | #1 |
| stress encephalopathy | #1 |
| congenital otc | #1 |
| hepatic abnormality characteristics | #1 |
| ptbr | #1 |
| pyrithiamine pyruvate | #1 |
| brain consequent increases | #1 |
| igg extravasation reduction | #1 |
| activation brain ptbr | #1 |
| hypothermia brain | #1 |
| hepatic glt1 | #1 |
| 15–1788 | #1 |
| medium kcl | #1 |
| mbr astrocytes | #1 |
| encephalopathy selective loss | #1 |
| alf therapeutic | #1 |
| hypothermia prevents | #1 |
| failure thiamine | #1 |
| cerebellum 22 | #1 |
| ammonia increased | #1 |
| pathogenesis hepatic | #1 |
| onset brain edema | #1 |
| peripheral steroidal sources | #1 |
| molecular standpoint | #1 |
| expression ptbr | #1 |
| expression hyperglycemic | #1 |
| therapeutic efficacy prevention | #1 |
| thiaminedeficient medium 7 | #1 |
| iii flumazenil | #1 |
| liver pca rats | #1 |
| oxotremorine particle size | #1 |
| muscarinic m1 sites | #1 |
| in3hpk11195 binding sites | #1 |
| neuromodulatory site | #1 |
| muscle portacaval shunting | #1 |
| sgc cerebral cortex | #1 |
| pathophysiology hepatic | #1 |
| ptbrs | #1 |
| ammonialowering strategies | #1 |
| encephalopathy alf rats | #1 |
| astrocyte undergoes | #1 |
| encephalopathy expression | #1 |
| veratramines action | #1 |
| decreased expression glt1 | #1 |
| parkinsonism cirrhosis | #1 |
| daily injections ldeprenyl | #1 |
| failure hepatic | #1 |
| pbz binding site | #1 |
| shunting hyperammonemia | #1 |
| aom treatment alf | #1 |
| brain ammonia reduction | #1 |
| hyperammonemia accounts | #1 |
| cytokines mild | #1 |
| thalamus thiaminedeficient rats | #1 |
| regionselective reductions | #1 |
| increased brain concentrations | #1 |
| csf benzodiazepine | #1 |
| brain edema encephalopathy | #1 |
| ldeprenyl thiamine deficiency | #1 |
| focal lactic | #1 |
| alf animal hypothermia | #1 |
| selectively increased | #1 |
| patient olivopontocerebellar atrophy | #1 |
| brain hepatic | #1 |
| absence wernickes encephalopathy | #1 |
| cox2 il1beta mrna | #1 |
| effective approach prevention | #1 |
| 3hpk11195 | #1 |
| glut1 expression alf | #1 |
| alcoholthiamine interactions | #1 |
| pca ethanol | #1 |
| thiamine deficiency | #1 |
| deficiency prior | #1 |
| αkgdh activities | #1 |
| proinflammatory mechanisms pathogenesis | #1 |
| brain prominent neurotoxin | #1 |
| increased synthesis cell | #1 |
| malnutrition hepatic failure | #1 |
| loss 3hnisoxetine sites | #1 |
| shunted rat | #1 |
| pca encephalopathy humans | #1 |
| failure brain | #1 |
| effective urea cycle | #1 |
| exclusion brain diseases | #1 |
| disorder thiamine deficiency | #1 |
| rats thiamine deficiency | #1 |
| reflex selective decreases | #1 |
| cell swelling major | #1 |
| shunted dogs | #1 |
| dawley ammonia | #1 |
| polyclonal antibody glt1 | #1 |
| isoquinoline benzodiazepine ligands | #1 |
| thiamine deficiency alcoholics | #1 |
| mhe clinical practice | #1 |
| autopsy cirrhotic | #1 |
| cirrhosis ammonia hepatic | #1 |
| pca operation | #1 |
| shunted rats presence | #1 |
| 2 mm ammonia | #1 |
| severity akinesia | #1 |
| brain pca rats | #1 |
| testis densities | #1 |
| glast protein day | #1 |
| neurotransmitter function | #1 |
| nh4oac administration | #1 |
| cell increased synthesis | #1 |
| pse findings | #1 |
| tdpase activities loss | #1 |
| encephalopathy cerebral edema | #1 |
| rats antisense elements | #1 |
| increased activity katpase | #1 |
| inhibitory ammonium ions | #1 |
| alf37 alf37 degrees | #1 |
| fastigial interpositus | #1 |
| disproportionately levels | #1 |
| coma stages encephalopathy | #1 |
| dawley amino | #1 |
| cerebral levels glutamine | #1 |
| bzrls cirrhotic patients | #1 |
| liver failure upregulation | #1 |
| severe encephalopathy coma | #1 |
| novo lactate synthesis | #1 |
| exposure azoxymethane | #1 |
| congenital otc deficiency | #1 |
| mbr decreased expression | #1 |
| reactive gliosis contrast | #1 |
| chat loss | #1 |
| thiamine neurochemistry | #1 |
| “peripheraltype | #1 |
| routine neurological evaluation | #1 |
| glast spraguedawley statistics | #1 |
| pathogenesis wernicke | #1 |
| neuroinflammatory mechanisms pathogenesis | #1 |
| nh4 neurons | #1 |
| rtpcr experiments messenger | #1 |
| thiaminedeficient animals | #1 |
| sgc activation brain | #1 |
| ouabain pyrimethamine | #1 |
| selective ptbr ligand | #1 |
| rate thiamine turnover | #1 |
| pfco frontal cortex | #1 |
| gabaa ammonia animals | #1 |
| aqp4 proinflammatory mediators | #1 |
| gabaa neurosteroids | #1 |
| pathogenesis wernicke encephalopathy | #1 |
| ohe cirrhosis | #1 |
| opioid encephalopathy humans | #1 |
| 3hcitalopram sites | #1 |
| encephalopathy histamine humans | #1 |
| azoxymethane brain | #1 |
| oatreated rats | #1 |
| lipopolysaccharide precipitates | #1 |
| brain glutamine severity | #1 |
| 25mm nh4cl | #1 |
| cirrhosis vicious cycle | #1 |
| liver spf mice | #1 |
| spraguedawley statistics immunohistochemistry | #1 |
| thdoc brain tissue | #1 |
| content pallidum | #1 |
| densities ptbr sites | #1 |
| nonvulnerable fpc | #1 |
| result manganese deposition | #1 |
| magna catheter | #1 |
| decreased detoxification | #1 |
| ptbr ligand | #1 |
| lola prevention | #1 |
| edema acute | #1 |
| lactate medial thalamus | #1 |
| portacaval anastomosis brain | #1 |
| human hepatic encephalopathy | #1 |
| etanercept hepatic | #1 |
| evidence otc deficiency | #1 |
| pse surgical probenecid | #1 |
| encephalopathy humans pallidus | #1 |
| thiamine deficiency neurons | #1 |
| kgdh activities | #1 |
| mice encephalopathy | #1 |
| pca rats phosphate | #1 |
| transverese friedreich ataxia | #1 |
| rats probenecid treatment | #1 |
| hereditary familial hyperbilirubinemia | #1 |
| opca messenger receptors | #1 |
| thiamine monophosphatetmp | #1 |
| experimental portacaval shunt | #1 |
| severity brain edema | #1 |
| monoamines hplc | #1 |
| betaactin housekeeping gene | #1 |
| pss rats | #1 |
| neurological complications alf | #1 |
| s‐3h5‐fluorowillardiine | #1 |
| azoxymethane bloodbrain barrier | #1 |
| brain levels dheas | #1 |
| tdpase activities | #1 |
| lad platelets | #1 |
| anastomosis pca | #1 |
| pharmacological manipulation ptbr | #1 |
| liver dysfunction findings | #1 |
| ammonia glutamate uptake | #1 |
| encephalopathy increased | #1 |
| manganese pathogenesis | #1 |
| superoxide dismutase rat | #1 |
| glyt1 mrna | #1 |
| deficiency encephalopathy | #1 |
| activities thiamine | #1 |
| alf effects | #1 |
| surgical rats rats | #1 |
| alf35 | #1 |
| additional thiamine | #1 |
| histamine caudate putamen | #1 |
| pca portacaval anastomosis | #1 |
| alcoholrelated brain dysfunction | #1 |
| ammonia pca | #1 |
| medial thalamus day | #1 |
| action ro15 | #1 |
| anastomosis ammonia | #1 |
| glutamine astrocyte | #1 |
| neuroinflammation liver failure | #1 |
| enos gene deletion | #1 |
| pfco fco | #1 |
| vulnerable medial thalamus | #1 |
| dissected brain tissue | #1 |
| central thiamine antagonist | #1 |
| thiamine‐deficient rats | #1 |
| encephalopathy adult | #1 |
| modulatory sites | #1 |
| receptor ptbr | #1 |
| spf mouse | #1 |
| perivascular endothelial cells | #1 |
| stages encephalopathy | #1 |
| alf restricted transfer | #1 |
| rats surgical probenecid | #1 |
| portacaval anastomosis tips | #1 |
| alanine cerebral cortex | #1 |
| elucidation neurotransmitter | #1 |
| pca increased | #1 |
| reversal antiparkinson drugs | #1 |
| xlinked inherited defect | #1 |
| propanolamines putamen | #1 |
| alf proinflammatory | #1 |
| progressive volume increase | #1 |
| thiamine deficiency brains | #1 |
| pse complication | #1 |
| glutamine synthetase protein | #1 |
| normalisation enzyme activities | #1 |
| precise nature | #1 |
| hepatic encephalopathy integrity | #1 |
| acute chronic hyperammonemia | #1 |
| ammonialowering agents | #1 |
| nacl mm nacl | #1 |
| neuropathologic damage | #1 |
| excess bloodborne ammonia | #1 |
| fco cau | #1 |
| lcarnitine energy metabolites | #1 |
| previous portacaval anastomoses | #1 |
| thalamus symptomatic rats | #1 |
| relation deterioration | #1 |
| densities 3hpk11195 | #1 |
| hepatic encephalopathy | #1 |
| flumazenil cirrhotic patients | #1 |
| l3hnoarg | #1 |
| blood ammonia md | #1 |
| region selective | #1 |
| ammonia liver failure | #1 |
| model human disorder | #1 |
| thiamine deficiency activities | #1 |
| alpha1 isoform ec50 | #1 |
| neurological syndrome nature | #1 |
| histamine receptor sites | #1 |
| reduction brain ammonia | #1 |
| rats portacaval | #1 |
| pyrithiamine rats | #1 |
| astrocytic proteins | #1 |
| edema glutamine | #1 |
| brain edema complications | #1 |
| minocyclinetreated alf rats | #1 |
| neurosteroids hepatic encephalopathy | #1 |
| betaep brain | #1 |
| free neurological | #1 |
| maternal thiamine deficiency | #1 |
| pharmaceutical benzodiazepines | #1 |
| ptbr ligand 3hpk11195 | #1 |
| portalsystemic encephalopathy | #1 |
| acute hyperammonemic syndromes | #1 |
| etanercept aom | #1 |
| benzoate spf | #1 |
| protective pathogenesis | #1 |
| subjects transport defect | #1 |
| encephalopathy zidovudine | #1 |
| continues rely | #1 |
| glur3 subunits opca | #1 |
| pathogenesis hepatic encephalopathy | #1 |
| aspartate pons | #1 |
| oatreated rats alf | #1 |
| relation energy metabolism | #1 |
| “ peripheral | #1 |
| familial hyperbilirubinemia | #1 |
| role endogenous benzodiazepines | #1 |
| indwelling cisterna | #1 |
| kidney portacaval anastomosis | #1 |
| severe pse | #1 |
| astrocytic glycine | #1 |
| maximal binding absence | #1 |
| thiamine deficiency expression | #1 |
| dehydrogenase complex friedreichs | #1 |
| components brain glutamate | #1 |
| pca rat | #1 |
| alf nmda receptor | #1 |
| pse portalsystemic shunting | #1 |
| symptomatic stages encephalopathy | #1 |
| preference pca | #1 |
| 57 caudate putamen | #1 |
| pathogenesis portalsystemic encephalopathy | #1 |
| brain glutamine | #1 |
| hyperglycemic focal | #1 |
| animal pyridinium | #1 |
| degree shunting hyperammonemia | #1 |
| nh4cl glutamate release | #1 |
| psychometric testing risk | #1 |
| key astroglial proteins | #1 |
| thalamus vulnerable region | #1 |
| autopsy brain choline | #1 |
| encephalopathy brain | #1 |
| ptbr mrna thalamus | #1 |
| immunohistochemistry cox2 immunoreactivity | #1 |
| sustained hyperammonemia pca | #1 |
| csf ammonia control | #1 |
| blood manganese etiology | #1 |
| thalamus wernicke encephalopathy | #1 |
| 3hpk binding | #1 |
| acute male pregnenolone | #1 |
| glutamine resonance | #1 |
| concentrations serotonin precursor | #1 |
| acquired hyperammonemia | #1 |
| copper pallidum | #1 |
| increase brain extracts | #1 |
| reduction cognitive dysfunction | #1 |
| pca astrocytic | #1 |
| induced stereotyped behavior | #1 |
| acute male muscle | #1 |
| congenital hyperammonemia lcarnitine | #1 |
| mutant spf | #1 |
| local brain production | #1 |
| tissue cirrhotic | #1 |
| normal conditions kidney | #1 |
| increased expression ptbribp | #1 |
| noradrenaline transporter sites | #1 |
| ammonia exposure brain | #1 |
| disorder portalsystemic encephalopathy | #1 |
| thiaminedeficient encephalopathy implications | #1 |
| pathogenesis neuronal loss | #1 |
| selective loss | #1 |
| increased extracellular brain | #1 |
| ptbrs portacaval anastomosis | #1 |
| glutamateper | #1 |
| region‐selective | #1 |
| findings reported increase | #1 |
| 071−084 | #1 |
| alf aom | #1 |
| novo synthesis gaba | #1 |
| 2 7fold increases | #1 |
| thiamine deficiency appearance | #1 |
| brain ammonia removal | #1 |
| ligand 3hpk11195 | #1 |
| measured homogenates | #1 |
| portacaval | #1 |
| tdwt mice | #1 |
| dha administration mnsod | #1 |
| hepatocerebral disorders | #1 |
| encephalopathy animals | #1 |
| acquired hyperammonemic | #1 |
| pathogenesis reversible symptoms | #1 |
| relation sustained hyperammonemia | #1 |
| alzheimertype astrocytosis | #1 |
| combined metabolic stresses | #1 |
| pathogenesis brain | #1 |
| ucds liver failure | #1 |
| caudate nucleus cau | #1 |
| nac animal hepatic | #1 |
| pca rats patients | #1 |
| interferongamma brains | #1 |
| improvements hepatic microcirculation | #1 |
| surgical probenecid rats | #1 |
| ohe prevention prophylaxis | #1 |
| pyrithiamine treatment | #1 |
| enzyme perivenous hepatocytes | #1 |
| manganese distribution brain | #1 |
| thiamine deficiency result | #1 |
| progression encephalopathy | #1 |
| caveolin1 pathway | #1 |
| propanolamines putamen rats | #1 |
| methylspiperone pet | #1 |
| portacaval‐shunted rat | #1 |
| reduced thiamine intake | #1 |
| bioaccumulation neuropathology | #1 |
| ammonia removal brain | #1 |
| alf amino | #1 |
| atrophy brain glutamate | #1 |
| ammonia metabolism disorders | #1 |
| deficiency densities | #1 |
| brain osmolytes | #1 |
| astrocytic cox2 | #1 |
| alf37 degrees | #1 |
| glast medial thalamus | #1 |
| reduced astrocytic uptake | #1 |
| ptbr increased expression | #1 |
| cns complications alf | #1 |
| brain astrocytes alterations | #1 |
| 213caspartate | #1 |
| alterations expression result | #1 |
| transketolase tk activities | #1 |
| brain pse | #1 |
| otc deficiency activities | #1 |
| loss righting reflexes | #1 |
| encephalopathy sham | #1 |
| cerebral energy deficit | #1 |
| mild hypothermia reduction | #1 |
| hyperammonemic spf | #1 |
| activities thalamus | #1 |
| peripheral inflammation etanercept | #1 |
| muscle ammonia removal | #1 |
| sites ptbr | #1 |
| phenols fig 1structure | #1 |
| sparsefur spf mouse | #1 |
| direct evidence rats | #1 |
| hypoglycaemia cerebral cortex | #1 |
| deficiency tritium | #1 |
| hepatic encephalopathy cirrhosis | #1 |
| exp assessment | #1 |
| normal limits findings | #1 |
| albumin dialysis systems | #1 |
| leigh disease forms | #1 |
| alterations neurological alterations | #1 |
| brain cirrhotic patients | #1 |
| ro15 10 microm | #1 |
| astrocytic integrity | #1 |
| regionselective increases | #1 |
| 15–1788 plasma levels | #1 |
| bbb animal hepatic | #1 |
| monoaminergic synaptic function | #1 |
| cau cirrhotic patients | #1 |
| effective approach onset | #1 |
| pca cns | #1 |
| alterations 3h8ohdpat | #1 |
| etanercept biological plausibility | #1 |
| result toxins | #1 |
| decreased pdhc | #1 |
| catecholaminelike trace amines | #1 |
| brain glutamate synthesis | #1 |
| dose dependent swelling | #1 |
| 25mm nh4cl p005 | #1 |
| gaba 11 | #1 |
| activities alpha kgdh | #1 |
| wistar receptors pca | #1 |
| thalamus thiamine deficiency | #1 |
| appearance neurological symptoms | #1 |
| complications alf | #1 |
| proinflammatory cytokines strategies | #1 |
| bergmann glial pathology | #2 |
| 5ht turnover brain | #2 |
| methyhistamine | #2 |
| reduced brain levels | #2 |
| computed wernicke encephalopathy | #2 |
| cholinergic neuronal loss | #2 |
| reduction dopamine turnover | #2 |
| fold allopregnanolone | #2 |
| cirrhotic patients modulation | #2 |
| brain organic myoinositol | #2 |
| alanine frontal cortex | #2 |
| hypokinesia produced | #2 |
| encephalopathy aids | #2 |
| ohe encephalopathy humans | #2 |
| pallidal manganese | #2 |
| degree gfap immunoreactivity | #2 |
| human brain contrast | #2 |
| precoma stages p001 | #2 |
| mice congenital | #2 |
| phosphate sulfate mixture | #2 |
| decreased gfap immunoreactivity | #2 |
| autopsy delay intervals | #2 |
| cortical astrocytes ammonia | #2 |
| aged muscimol | #2 |
| 150 dose increase | #2 |
| rat brain relation | #2 |
| intracranial hypertension alf | #2 |
| cisterna magna catheter | #2 |
| csf ammonia | #2 |
| thiamine dependent | #2 |
| reduced concentrations dheas | #2 |
| mrna expression gfap | #2 |
| 4week portacaval | #2 |
| aqp4 cerebral cortex | #2 |
| portacaval shunting | #2 |
| neuroinhibitory steroids | #2 |
| hyperammonemic brain | #2 |
| increasing dheas currents | #2 |
| membranes tomography | #2 |
| early precoma stages | #2 |
| 970±079 | #2 |
| model wernicke | #2 |
| portacaval anastomosis pca | #2 |
| neurons nmr | #2 |
| concentrations dheas | #2 |
| shunted | #2 |
| 3hpk11195 brain regions | #2 |
| liver cirrhosis activation | #2 |
| reflex stage | #2 |
| death thiamine | #2 |
| glutamine hepatic | #2 |
| bckdh bckdh activity | #2 |
| glutamate glur2 | #2 |
| mouse astrocytes effects | #2 |
| alf control | #2 |
| ammonia octanoic acid | #2 |
| inbred strains glutamine | #2 |
| cerebellum cirrhotic patients | #2 |
| mri neurological evaluation | #2 |
| neurosteroid pregnenolone fold | #2 |
| failure alf | #2 |
| 2 brain samples | #2 |
| isomorphic model | #2 |
| hyperammonaemia hepatic encephalopathy | #2 |
| electrified grid | #2 |
| responsible neurological | #2 |
| implicated pathogenesis | #2 |
| concentrations gammaguanidinobutyric acid | #2 |
| ammoniainduced alterations | #2 |
| selective increase | #2 |
| gabaa encephalopathy humans | #2 |
| disorder loss | #2 |
| wks enzyme activities | #2 |
| ammonia gabaergic neurotransmission | #2 |
| congenital hyperammonemias | #2 |
| impaired gaba function | #2 |
| ouabain upregulation | #2 |
| dheas reduced | #2 |
| liver spf | #2 |
| 2 flumazenil | #2 |
| improvement mental state | #2 |
| densities binding | #2 |
| gammagba nalphaacetylarginine nalphaaa | #2 |
| cirrhotic patients pathology | #2 |
| bath concentration ammonia | #2 |
| thiamine‐dependent | #2 |
| deficient encephalopathy | #2 |
| haloperiodol | #2 |
| pca brain regions | #2 |
| cerebral edema loss | #2 |
| thiamine deprivation | #2 |
| brain dehydroepiandrosterone dhea | #2 |
| thiamine deficiency wks | #2 |
| plasma levels 3alpha5alphathp | #2 |
| wernickes encephalopathy patients | #2 |
| body fatigue rats | #2 |
| animal hepatic encephalopathy | #2 |
| concentrations ammonium chloride | #2 |
| sgc brain | #2 |
| fold thdoc | #2 |
| thiamine‐dependent enzyme | #2 |
| thiaminedeficient mice | #2 |
| progression ohe | #2 |
| encephalopathy portacaval | #2 |
| taurine platelets | #2 |
| wernickes encephalopathy | #2 |
| defect membrane transport | #2 |
| modulation brain | #2 |
| thirtytwo cirrhotic patients | #2 |
| failure altered | #2 |
| diseases manganese | #2 |
| alf drug | #2 |
| activities choline acetyltransferase | #2 |
| cerebral complications alf | #2 |
| encephalopathy onset | #2 |
| vesicular dysfunction | #2 |
| mental state trials | #2 |
| ligand 3hpk | #2 |
| disorder mystery | #2 |
| brain edema concentrations | #2 |
| activities maoa | #2 |
| hyperammonemia increased | #2 |
| pdh activity platelets | #2 |
| cns consequences | #2 |
| encephalopathy acute | #2 |
| thiamine phosphorylation | #2 |
| controls 3alpha5alphathp | #2 |
| brains 36 patients | #2 |
| mice alf | #2 |
| ammonia detoxification glutamine | #2 |
| ammonia animal hepatic | #2 |
| pyrithiamine rats rats | #2 |
| brain lactate increase | #2 |
| thiaminedeficiency | #2 |
| brain taurine concentrations | #2 |
| 26 153 | #2 |
| nash addition | #2 |
| glt1 increased | #2 |
| mice acetaminophen toxicity | #2 |
| precoma coma | #2 |
| gaba ammonia | #2 |
| thiamine deficiency patients | #2 |
| brain levels neurosteroids | #2 |
| isomorphic models | #2 |
| gammagba | #2 |
| experimental alf | #2 |
| ornithine aminotransferase administration | #2 |
| allopregnanolone fold | #2 |
| pathophysiologic mechanisms | #2 |
| densities binding sites | #2 |
| 67 coma stages | #2 |
| ataxia animals | #2 |
| encephalopathy glutamine concentrations | #2 |
| hepatic cerebral | #2 |
| increase coma | #2 |
| neuropsychiatric complication | #2 |
| deficiency include | #2 |
| ammonia central role | #2 |
| form ataxia | #2 |
| activities muscle | #2 |
| ammoniainduced neurotoxicity | #2 |
| liver failure studies | #2 |
| lactate coma stages | #2 |
| alf mrna expression | #2 |
| encephalopathy major | #2 |
| reduced brain dheas | #2 |
| hepatic encephalopathy ohe | #2 |
| liver thiamine | #2 |
| moderate grade iii | #2 |
| alpha1 sites | #2 |
| brain samples alcoholics | #2 |
| pathogenesis portal | #2 |
| vulnerable brain structures | #2 |
| rats portacaval anastomosis | #2 |
| sites increased | #2 |
| 3alpha5betathp patients | #2 |
| swelling cortical astrocytes | #2 |
| alpha kgdh | #2 |
| extracellular brain | #2 |
| 3beta5alphathp | #2 |
| 3000 microg m3 | #2 |
| brain portacaval shunting | #2 |
| glutamate syndrome | #2 |
| increased brain turnover | #2 |
| increased levels pregnenolone | #2 |
| millimolar concentrations brain | #2 |
| encephalopathy histamine | #2 |
| lornithinelaspartate | #2 |
| dheas body fatigue | #2 |
| tyrosine tyr levels | #2 |
| treatment cns complications | #2 |
| loss eaat2 expression | #2 |
| densities bmax | #2 |
| kidney ammonia | #2 |
| systemic encephalopathy | #2 |
| 3alpha5alphathp 3alpha5betathp | #2 |
| rats thiamine | #2 |
| gfap immunoreactivity degree | #2 |
| increase coma stages | #2 |
| increased manganese | #2 |
| kinetics taurine | #2 |
| hepatic encephalopathy controls | #2 |
| brain lactate synthesis | #2 |
| nmda receptor pca | #2 |
| thp metabolites fatigue | #2 |
| cisterna magna catheters | #2 |
| sustained deficiency arginine | #2 |
| symptomatic rats | #2 |
| coma stages p001 | #2 |
| brain shunted rats | #2 |
| chronic thiamine | #2 |
| neurons glutamine synthesis | #2 |
| thiamine turnover | #2 |
| induced liver failure | #2 |
| pyrithiamine treated | #2 |
| pathogenesis friedreichs ataxia | #2 |
| edematous cerebral cortex | #2 |
| loss eaat2 protein | #2 |
| dheas bdl rats | #2 |
| development ethanol preference | #2 |
| edema hepatic | #2 |
| treatment asparagine | #2 |
| increased novo synthesis | #2 |
| hyperammonemia synaptosomes | #2 |
| 3acetyl pyridine | #2 |
| thiamine deprivation loss | #2 |
| animals hepatic | #2 |
| thiaminedependent enzymes | #2 |
| sustained hyperammonemia | #2 |
| increased activities | #2 |
| symptoms thiamine | #2 |
| binding 3hpk11195 | #2 |
| gabaa receptor indomethacin | #2 |
| rats cortex male | #2 |
| edema alf | #2 |
| decreased reuptake | #2 |
| immunohistochemistry liver failure | #2 |
| l‐ornithine‐l‐aspartate | #2 |
| nitric oxide brain | #2 |
| pyrithiamine induced | #2 |
| hepatic encephalopathy gabaa | #2 |
| glutamine intracranial | #2 |
| plasma proinflammatory cytokines | #2 |
| central neuroinflammatory | #2 |
| indomethacin locomotor deficit | #2 |
| encephalopathy wernicke | #2 |
| novo synthesis lactate | #2 |
| ataxic animals | #2 |
| thdoc fold | #2 |
| spf mutant mice | #2 |
| dheas hepatic | #2 |
| carboxamide binding | #2 |
| cuznsod mrna cuznsod | #2 |
| computerized autotrack | #2 |
| osmotic effects glutamine | #2 |
| hepatic encephalopathy complication | #2 |
| restricted transfer | #2 |
| protein levels glast | #2 |
| hydrolases aged | #2 |
| neuronal loss alterations | #2 |
| precoma stages increase | #2 |
| shunted pcs | #2 |
| wks decreased activities | #2 |
| brain glutamine synthesis | #2 |
| modulation sgc | #2 |
| neuropathic pain etanercept | #2 |
| pallidum cirrhotic patients | #2 |
| male portacaval shunt | #2 |
| astrocytic benzodiazepine | #2 |
| serum lad | #2 |
| enzyme deficits | #2 |
| tdp dependent enzymes | #2 |
| ammonia metabolism astrocytes | #2 |
| thiamine bloodbrain barrier | #2 |
| alcoholics absence | #2 |
| cerebellum output | #2 |
| lower levels arginine | #2 |
| liver failure gfap | #2 |
| pca rats allopregnanolone | #2 |
| iggimmunoreactivity | #2 |
| lcarnitine atp | #3 |
| deletion delays | #3 |
| doubt25 ammonia | #3 |
| mhe lola | #3 |
| adequate substrates | #3 |
| glutamate transporter cells | #3 |
| cholinergic m1 | #3 |
| akinesia corneal reflex | #3 |
| addition astrocyte morphology | #3 |
| rats pyrithiamine | #3 |
| animals profiles | #3 |
| encephalopathy aged | #3 |
| glutamine brain edema | #3 |
| ammoniainduced impairment | #3 |
| βendorphin apomorphine basal | #3 |
| turnover study rats | #3 |
| neuroglial proteins | #3 |
| protein hepatic | #3 |
| encephalopathy inflammation | #3 |
| altered glial | #3 |
| pca odn immunolabeling | #3 |
| selective brain lesions | #3 |
| drug situ nickend | #3 |
| central cholinergic deficit | #3 |
| globus pallidus putamen | #3 |
| transporter snat5 | #3 |
| medium 5 mm | #3 |
| activities brains | #3 |
| cerebral cortex pons | #3 |
| kornetsky | #3 |
| increases il1beta | #3 |
| portocaval anastomosis pca | #3 |
| acids relation | #3 |
| decreased concentrations striatum | #3 |
| ammonia swelling | #3 |
| pcs rat brain | #3 |
| αmt midbrain | #3 |
| βendorphin decreased concentrations | #3 |
| administration ammonium | #3 |
| acute ammonia exposure | #3 |
| 5fmorn | #3 |
| carnitine ammonia | #3 |
| mk‐801‐sensitive nitration | #3 |
| concentrations αmt | #3 |
| ammoniatreated cells | #3 |
| midbrain turnover study | #3 |
| decreased aspartate | #3 |
| doubt25 | #3 |
| genial expression | #3 |
| il6 levels brain | #3 |
| muscle glutamine synthetase | #3 |
| rats pse | #3 |
| alcoholics wks | #3 |
| singlesite model | #3 |
| severity reviews see1–4 | #3 |
| reflex serotonin βendorphin | #3 |
| decreased concentrations αmt | #3 |
| bckdh activity rats | #3 |
| repetitive removal | #3 |
| 13 consecutive weeks | #3 |
| humans neurotransmitter | #3 |
| edema intracranial | #3 |
| male portacaval | #3 |
| animals coma | #3 |
| rats αmt | #3 |
| strains thiamine | #3 |
| type ” | #3 |
| autotrack | #3 |
| late symptomatic stages | #3 |
| deficiency thiamine | #3 |
| congenital hyperammonemia | #3 |
| cholestasis‐associated fatigue | #3 |
| total brain glutamine | #3 |
| ishen guidelines | #3 |
| ammonia energy metabolism | #3 |
| corneal reflex apomorphine | #3 |
| odn immunolabeling | #3 |
| liver–brain axis | #3 |
| precoma stages | #3 |
| hepatic neurological | #3 |
| ammonia glutamate | #3 |
| models thiamine | #3 |
| predictions disorder | #3 |
| brain portocaval anastomosis | #3 |
| hyperammonemia acute | #3 |
| homologous models | #3 |
| potent neuroactive properties | #3 |
| protective glutamine | #3 |
| cellspecific pathways | #3 |
| cirrhosis agents | #3 |
| akinesia βendorphin | #3 |
| hepatic encephalopathy humans | #3 |
| thiamine deficient | #3 |
| binding sites heart | #3 |
| blood transketolase | #3 |
| deficiency acidosis | #3 |
| thiamine deficiency wernicke | #3 |
| homogenates frontal cortex | #3 |
| basal ganglia βendorphin | #3 |
| pdhc acetyl coa | #3 |
| platelets 10 patients | #3 |
| astrocyte glutamine | #3 |
| synthesis aspartate | #3 |
| major neurotransmitter systems | #3 |
| brain edema alf | #3 |
| brain concentrations rats | #3 |
| cirrhosis iii | #3 |
| portacavalshunted rats | #3 |
| acrylamide pyrithiamine | #3 |
| treatment portalsystemic encephalopathy | #3 |
| brain densities | #3 |
| abstract hepatic encephalopathy | #3 |
| selective down‐regulation | #3 |
| coma stage | #3 |
| skeletal portacaval shunt | #3 |
| cogent explanation | #3 |
| pdh friedreich | #3 |
| decreased densities | #3 |
| portacaval anastomosis rats | #3 |
| activities reduced | #3 |
| peripheral‐type | #3 |
| abstract mild hypothermia | #3 |
| signs mild personality | #3 |
| effects ldeprenyl | #3 |
| αketoglutarate dehydrogenase | #3 |
| cerebellum activities | #3 |
| gfap mrna gfap | #3 |
| glutamates hippocampus rats | #3 |
| ammonia‐induced brain edema | #3 |
| statistical significance regions | #3 |
| neurobiological characterization | #3 |
| encephalopathy hepatic | #3 |
| αmt βendorphin | #3 |
| lobe hepatic | #3 |
| electrically stimulated release | #3 |
| 320350 degrees | #3 |
| controls emax | #3 |
| prevents cerebral | #3 |
| effects ro15 | #3 |
| intraneuronal release | #3 |
| 38 alcoholic patients | #3 |
| pallidal signals | #3 |
| tissue ornithine concentrations | #3 |
| rats pathogenesis | #3 |
| mrna ammonia | #3 |
| brain improvement | #3 |
| alf animals | #3 |
| astrocytic cell swelling | #3 |
| amphetamine amphetamine animals | #3 |
| endogenous agonists role | #3 |
| transketolase activities | #3 |
| ganglia structures | #3 |
| regions cns | #3 |
| operated controls | #3 |
| cerebellar amino | #3 |
| increased uptake capacity | #3 |
| pallidus hepatic | #3 |
| ammonia brain edema | #3 |
| 3hdaspartate uptake | #3 |
| rats glutamates hippocampus | #3 |
| hepatobiliary route | #3 |
| onset neurological signs | #3 |
| pathogenesis central | #3 |
| neurotransmission failure | #3 |
| tetrahydrodesoxycorticosterone | #3 |
| testis preparations | #3 |
| βendorphin akinesia | #3 |
| hypothermia brain edema | #3 |
| increased ptbr | #3 |
| pbgd study | #3 |
| vitro binding technique | #3 |
| coma equal | #3 |
| hepatic devascularized rat | #3 |
| increase brain lactate | #3 |
| glial cells ammonia | #3 |
| thiamine phosphate | #3 |
| 5fmorn treatment | #3 |
| ammonia hepatic | #3 |
| nmda subclass | #3 |
| acids cerebrospinal | #3 |
| xlinked deficiency | #4 |
| inos mnsod | #4 |
| liver central | #4 |
| lornithine laspartate | #4 |
| transketolase wernicke | #4 |
| cases alcohol abuse | #4 |
| encephalopathy coma | #4 |
| benzodiazepines increase | #4 |
| decreased activities | #4 |
| albumin dialysis alf | #4 |
| peripheral‐type benzodiazepine | #4 |
| degree alzheimer type | #4 |
| 13 moles | #4 |
| amino acids areas | #4 |
| thp metabolites | #4 |
| acute liver failure | #4 |
| onset severe encephalopathy | #4 |
| ammonia levels blood | #4 |
| alcohol thiamine deficiency | #4 |
| mhe mildest form | #4 |
| effects mild hypothermia | #4 |
| arterial ammonia mmars | #4 |
| 5 mm nh4cl | #4 |
| brain neuroinflammation | #4 |
| taurine friedreichs ataxia | #4 |
| activities glutamine synthetase | #4 |
| rat brain pca | #4 |
| calcium microsomes | #4 |
| rats βendorphin | #4 |
| guanylate cyclase patients | #4 |
| activities brain | #4 |
| glt1 transcript | #4 |
| plasma clearance groups | #4 |
| subclinical seizure activity | #4 |
| brain pregnenolone content | #4 |
| postmortem delay interval | #4 |
| brain dopamine receptor | #4 |
| synaptic membrane preparations | #4 |
| izuru matsumoto | #4 |
| tspo sites | #4 |
| locomotor evaluation | #4 |
| increased concentrations prostaglandins | #4 |
| extrapyramidal symptoms patients | #4 |
| brain glutamic | #4 |
| tdpase | #4 |
| thiamine diphosphatase | #4 |
| carnitine energy | #4 |
| mmars time | #4 |
| otcdeficient mice | #4 |
| patients wernicke | #4 |
| edema gene | #4 |
| loss glt1 | #4 |
| inbred strains ammonia | #4 |
| liver brain | #4 |
| increased brain glutamine | #4 |
| regional amino | #4 |
| ouabainlike compounds | #4 |
| p001 hypothermia | #4 |
| shunted rats | #4 |
| newly synthesized glutamine | #4 |
| condition development | #4 |
| opioid pca | #4 |
| tdinduced cell death | #4 |
| acute ammonia treatment | #4 |
| gaba friedreich | #4 |
| brain 5ht release | #4 |
| ouabain ec50 | #4 |
| arterial ammonia alf | #4 |
| ischemic liver failure | #4 |
| cerebral amino acids | #4 |
| brain thiamine | #4 |
| pse increased | #4 |
| thiamine‐deficient rat brain | #4 |
| normal coupling | #4 |
| mmars increased icp | #4 |
| alcoholism thiamine | #4 |
| thiamine thiamine pyrophosphate | #4 |
| mmars brain water | #4 |
| neurotransmitter dysfunction | #4 |
| anastomosis rat | #4 |
| astrocytic metabolic | #4 |
| surgical rna rats | #4 |
| maoa isoform | #4 |
| brain hepatic encephalopathy | #4 |
| cerebral cortex kidney | #4 |
| administration central | #4 |
| protein expression brain | #4 |
| severe neuronal dysfunction | #4 |
| rats asparagine | #4 |
| expression alf | #4 |
| aged pyruvate | #4 |
| shamoperated controls | #4 |
| time mmars | #4 |
| wernickekorsakoff syndrome | #4 |
| thiamine deficiency rats | #4 |
| amino acids regions | #4 |
| affinities densities | #4 |
| early microglial response | #4 |
| alf | #4 |
| ions synaptic | #4 |
| hepatocytes ascorbate | #4 |
| animals liver failure | #4 |
| brain edema increase | #4 |
| icp arterial ammonia | #4 |
| treatment hepatic encephalopathy | #4 |
| rats portacaval shunting | #4 |
| thiamine antagonist | #4 |
| cbf inflammatory mediators | #4 |
| alf expression | #4 |
| total shunting | #4 |
| deoxyglucose endothelium | #4 |
| 6 hrs alf | #4 |
| inflammation mediators icp | #4 |
| astrocytic genes | #4 |
| vitro techniques ketoglutarate | #4 |
| increased icp alf | #4 |
| brain energy failure | #4 |
| activities prefrontal cortex | #4 |
| elevated ammonia levels | #4 |
| alf brain | #4 |
| thiamine deficient animals | #4 |
| histaminergic histamine | #4 |
| postsynaptic action | #4 |
| thiochrome derivatives | #4 |
| ornithine aspartate | #4 |
| locomotor deficit | #4 |
| sham mmars | #4 |
| alterations glutamatergic | #5 |
| saturation binding isotherms | #5 |
| treatment malnutrition | #5 |
| monoamines metabolites | #5 |
| hepatic encephalopathy gaba | #5 |
| alf ammonia | #5 |
| studied brain | #5 |
| vulnerable regions | #5 |
| extracellular quin | #5 |
| glur2 glur3 subunits | #5 |
| wernicke | #5 |
| content modulation | #5 |
| maoa function | #5 |
| acetyl pyridine | #5 |
| manganese astrocytes | #5 |
| transporter sites | #5 |
| reserpinelike | #5 |
| exposure cultured astrocytes | #5 |
| pet scan study | #5 |
| cytokines ammonia | #5 |
| vulnerable brain | #5 |
| reduction glutamate | #5 |
| tpp cofactor | #5 |
| brain ammonia | #5 |
| result altered | #5 |
| cns ammonia | #5 |
| thiamine status | #5 |
| ammonia metabolism | #5 |
| glutamate symporters | #5 |
| tissue autopsy | #5 |
| hexyl1h | #5 |
| sites peripheral | #5 |
| astrocytic | #5 |
| amino acids pathogenesis | #5 |
| chronic exposure manganese | #5 |
| brain glutamate concentrations | #5 |
| acute magnetic | #5 |
| activities gad | #5 |
| hand densities | #5 |
| 45 cirrhotic patients | #5 |
| neurotransmitter pool | #5 |
| complication acute | #5 |
| brain histamine receptors | #5 |
| homologous model | #5 |
| activities cerebellum | #5 |
| encephalopathy cerebral | #5 |
| cerebral hepatic | #5 |
| maoa activities | #5 |
| pse encephalopathy humans | #5 |
| mmars | #5 |
| neurological status | #5 |
| ammonia muscle | #5 |
| patients hepatic | #5 |
| acute rats rats | #5 |
| mild personality | #5 |
| responsible brain | #5 |
| spf mice controls | #5 |
| brain acute | #5 |
| glutamine hypothesis | #5 |
| medial thalamus | #5 |
| allopregnanolone gabaa | #5 |
| congenital urea | #5 |
| age matched subjects | #5 |
| rats fatigue | #5 |
| surgical receptors | #5 |
| methioninesulfoximine | #5 |
| anterolateral hypothalamus | #5 |
| prevention prophylaxis | #5 |
| aspartate lola | #5 |
| liver disease rats | #5 |
| amino acid regions | #5 |
| activities choline | #5 |
| liver assist devices | #5 |
| pregnenolone content | #5 |
| publication animals rats | #5 |
| onset coma | #5 |
| laspartate lola | #5 |
| topic rifaximin | #5 |
| intracranial hypertension rats | #5 |
| hyperammonemia liver | #5 |
| ammonia removal | #5 |
| genetics astrocytes blotting | #5 |
| kstimulated ca2dependent release | #5 |
| spectroscopy tomography emissioncomputed | #5 |
| rats portacaval shunts | #5 |
| ammonia lowering | #5 |
| alcoholic receptors | #5 |
| branchedchain analysis | #5 |
| adequate experimental models | #5 |
| convulsions onset | #5 |
| thiaminedeficient diet | #5 |
| kgdh | #5 |
| latenight snack | #5 |
| tk activities | #5 |
| allopregnanolone thdoc | #5 |
| sustained deficiency | #5 |
| gait animals | #5 |
| currents concentrations | #5 |
| increases ammonia | #5 |
| kinetics pharmacology | #5 |
| thiamine phosphate esters | #6 |
| encephalopathy humans | #6 |
| activities liver | #6 |
| brain benzodiazepine | #6 |
| blood‐brain barrier integrity | #6 |
| basal ganglia structures | #6 |
| fur mice | #6 |
| 3nmol | #6 |
| inflammatory mediators groups | #6 |
| platelets 11 patients | #6 |
| 14c taurine | #6 |
| expression astrocytic genes | #6 |
| endstage liver failure | #6 |
| mice nacetylcysteine | #6 |
| relationship neurological symptoms | #6 |
| induced thiamine | #6 |
| humans hyperammonemia | #6 |
| models alf | #6 |
| dehydrogenase pdhc | #6 |
| nencki | #6 |
| benzodiazepine intake | #6 |
| lola improvement | #6 |
| increased expression aqp4 | #6 |
| alf nac | #6 |
| glast transporter | #6 |
| central proinflammatory | #6 |
| perispinal etanercept | #6 |
| liver failure | #6 |
| fmorn | #6 |
| increased glut1 expression | #6 |
| alphaketoglutarate dehydrogenase | #6 |
| glt1 brain | #6 |
| pca sham | #6 |
| glt1 glast protein | #6 |
| ascorbate protects | #6 |
| dha administration | #6 |
| enzymes pyruvate | #6 |
| hyperammonemic | #6 |
| enzymes brains | #6 |
| 3htryptamine binding sites | #6 |
| controls arginine | #6 |
| capacity removal | #6 |
| output cerebellum | #6 |
| nac alf | #6 |
| implications pathogenesis | #6 |
| righting reflexes | #6 |
| hepatic encephalopathy effects | #6 |
| mars alf | #6 |
| receptors hepatic | #6 |
| hypothermia alf | #6 |
| ammonia glutamine | #6 |
| term fluorescence | #6 |
| astrocyte cell volume | #6 |
| dogs hepatic encephalopathy | #6 |
| cerebellum caudate nucleus | #6 |
| concomitant 24fold increase | #6 |
| arginine brain | #6 |
| gabaergic tone | #6 |
| tmpase | #6 |
| thiamine esters | #6 |
| frontal cortex rats | #6 |
| deterioration neurological | #6 |
| plasma frontal cortex | #6 |
| disease ammonia | #6 |
| 3htryptamine binding | #6 |
| direct neurotoxic | #6 |
| cerebral cortex activities | #6 |
| unaltered distribution | #6 |
| cerebral amino | #6 |
| acetyl lcarnitine | #6 |
| brain cirrhotic | #6 |
| mediators liver | #7 |
| liver hepatic encephalopathy | #7 |
| central neuroinflammation | #7 |
| ammonia kidney | #7 |
| encephalopathy findings | #7 |
| surgical rats | #7 |
| acute minocycline | #7 |
| wernicke‐korsakoff syndrome | #7 |
| pregnant rats offspring | #7 |
| pca pss | #7 |
| frontal cortex controls | #7 |
| failure acute | #7 |
| chronic deprivation | #7 |
| hiaa increased | #7 |
| rats ammonium acetate | #7 |
| size portacaval | #7 |
| columbia rating scale | #7 |
| cyclase hepatic | #7 |
| kcl medium | #7 |
| ischemia hyperglycemic | #7 |
| gdh activities | #7 |
| neuropsychiatric abnormalities patients | #7 |
| tdp ttp | #7 |
| chemistry disease | #7 |
| neuronal cell loss | #7 |
| flumazenil 10 microm | #7 |
| 70 mm kcl | #7 |
| astrocytic transporters | #7 |
| glutamate acute | #7 |
| vpmt | #7 |
| edema plasma | #7 |
| 3htryptamine | #7 |
| uremic coma | #7 |
| animal hepatic | #7 |
| central benzodiazepine receptors | #7 |
| metallic phosphate | #7 |
| fatigue severity patients | #7 |
| typical friedreichs ataxia | #7 |
| severe thiamine deficiency | #7 |
| glutamine synthesis ammonia | #7 |
| cerebral alterations alf | #7 |
| icp alf | #7 |
| thiamine dependent enzymes | #7 |
| igg immunohistochemistry | #7 |
| fulminant liver failure | #7 |
| l3harginine uptake | #7 |
| transporter deficit | #7 |
| brain glutamate | #7 |
| neuroinhibitory | #7 |
| thiamine absorption | #7 |
| tppdependent enzymes | #7 |
| perineuronal astrocytes | #7 |
| glutamine increased | #7 |
| notion activation | #7 |
| nutritional management patients | #7 |
| concentrations allopregnanolone | #7 |
| flumazenil patients | #7 |
| loss transporter | #7 |
| inhibitor src | #7 |
| edema extracellular | #7 |
| hepatic encephalopathy studies | #7 |
| alcoholic brain damage | #7 |
| increased cerebellum | #7 |
| neurological symptoms | #7 |
| skeletal muscle adapts | #7 |
| alf arterial ammonia | #7 |
| alf sham | #7 |
| transketolase animals | #7 |
| swelling astrocytes | #7 |
| thalamus cerebellum | #8 |
| autopsied human | #8 |
| alcohol brain damage | #8 |
| gaba reverse | #8 |
| tests ataxia | #8 |
| receptors mitochondrial | #8 |
| direct toxic actions | #8 |
| normal metabolic balance | #8 |
| izuru | #8 |
| brain ammonia levels | #8 |
| activities glutamine | #8 |
| voluntary ethanol consumption | #8 |
| peter dodd | #8 |
| spraguedawley temporal lobe | #8 |
| lactate synthesis | #8 |
| prefrontal nmda | #8 |
| cerebellum activation | #8 |
| brain increased expression | #8 |
| proinflammatory mediators expression | #8 |
| ammonia metabolites | #8 |
| arterial ammonia concentrations | #8 |
| concentrations thdoc | #8 |
| alterations modulation | #8 |
| sourkes | #8 |
| dependent enzymes | #8 |
| expression glyt1 | #8 |
| synthesis lactate | #8 |
| rindi | #8 |
| content frontal cortex | #8 |
| hyperglycemic cerebral ischemia | #8 |
| intracranial pressure increase | #8 |
| complications liver disease | #8 |
| portocaval anastomosis | #8 |
| cells ammonia | #8 |
| portalsystemic shunting | #8 |
| disease gad | #8 |
| affinity glutamate uptake | #8 |
| active pyruvate dehydrogenase | #8 |
| chronic brain dysfunction | #8 |
| clive harper | #8 |
| probenecid 5 | #8 |
| neuropathologic consequences | #8 |
| nmda sites | #8 |
| antisense elements genetics | #8 |
| ammonia hyperammonemia | #8 |
| strains ornithine | #8 |
| study binding sites | #8 |
| neurobehavioral damage | #8 |
| alf administration | #8 |
| result decreased | #8 |
| induced akinesia | #8 |
| loss congenital | #8 |
| falls cirrhosis | #8 |
| regional alterations | #8 |
| neuroprotective steroids | #8 |
| ultraviolet uv spectrum | #8 |
| measurement cell volume | #8 |
| tellez | #8 |
| elfar adalsteinsson | #8 |
| ammonium ions | #8 |
| assessment bioaccumulation | #8 |
| synthesis thiamine | #8 |
| alcohol thiamine | #8 |
| hyperglycemic cerebral | #8 |
| 3alpha5betathp | #8 |
| taurine ca2 | #8 |
| cirrhotic patients | #8 |
| central noradrenergic function | #8 |
| pallidal signal | #9 |
| central gabaa receptor | #9 |
| hepatic encephalopathy ammonia | #9 |
| 37 decrease | #9 |
| acute rats | #9 |
| perispinal administration | #9 |
| activities skeletal muscle | #9 |
| binding sites brain | #9 |
| hyperammonemia liver cirrhosis | #9 |
| sham alf | #9 |
| portacaval rat | #9 |
| manganese dust | #9 |
| acute hyperammonemia | #9 |
| glutamate glt1 | #9 |
| cerebral ammonia toxicity | #9 |
| kinetics distribution | #9 |
| mechanisms responsible | #9 |
| male cirrhotic patients | #9 |
| hepatocerebral | #9 |
| acid hepatic | #9 |
| rats phosphate | #9 |
| hepatic coma | #9 |
| joanne lewohl | #9 |
| sites frontal | #9 |
| disease thiamine | #9 |
| neurotoxic substance | #9 |
| cerebellum medulla oblongata | #9 |
| order address | #9 |
| nonneuronal elements | #9 |
| mild hypothermia | #9 |
| observed frontal | #9 |
| portal hypertension result | #9 |
| acute nitric oxide | #9 |
| arterial ammonia concentration | #9 |
| autopsied brain | #9 |
| adolf pfefferbaum | #9 |
| ammonia neurotoxicity | #9 |
| thiamine monophosphatase | #9 |
| glutamate receptor ligands | #9 |
| edema rats | #9 |
| brain herniation | #9 |
| animals acute | #9 |
| prevention complications | #9 |
| taurine calcium | #9 |
| 11 cirrhotic patients | #9 |
| gaba reference | #9 |
| ammonia key role | #9 |
| edith sullivan | #9 |
| transcarbamylase otc | #9 |
| binding sites nmda | #9 |
| vulnerable brain regions | #9 |
| ammonia binding | #9 |
| gabaa tissue distribution | #9 |
| taurine binding | #9 |
| neuroinhibition | #9 |
| glucose hypothermia | #9 |
| glyt1 transporter | #9 |
| pcs rats | #9 |
| brain postsynaptic | #9 |
| ammonia induced | #9 |
| glial tca cycle | #9 |
| rat brain density | #9 |
| protein glut1 | #9 |
| 5fluoromethylornithine | #9 |
| complication chronic | #10 |
| mechanisms include | #10 |
| flumazenil hepatic | #10 |
| 200 appearance | #10 |
| progression hepatic encephalopathy | #10 |
| mnsod cuznsod | #10 |
| nh4ac | #10 |
| 3hketanserin binding sites | #10 |
| rats daily injections | #10 |
| swelling ammonia | #10 |
| 3hpk | #10 |
| cerebral consequences | #10 |
| rat leads | #10 |
| neuroactive amino acids | #10 |
| cerebellum pons | #10 |
| model alf | #10 |
| rats nimesulide | #10 |
| neurological symptomatology | #10 |
| decreased glutamate | #10 |
| encephalopathy grade | #10 |
| 10 mm concentration | #10 |
| anastomosis hepatic | #10 |
| brain edema | #10 |
| activation pathogenesis | #10 |
| mechanisms tnfalpha | #10 |
| selective brain regions | #10 |
| loss reflex | #10 |
| stress thiamine | #10 |
| cord taurine | #10 |
| massive brain edema | #10 |
| nh4 forms | #10 |
| 3omethylglucose animals animals | #10 |
| urea cycle enzymopathies | #10 |
| dissected material | #10 |
| identification alterations | #10 |
| neuropsychiatric disorder | #10 |
| fur mouse | #10 |
| disorders include | #10 |
| ammonia study | #10 |
| expression superoxide | #10 |
| labeling glutamine | #10 |
| glutathione levels expression | #10 |
| hrqol mhe | #10 |
| thalamic structures | #10 |
| thiamine transketolase | #10 |
| rats stereotyped behavior | #10 |
| glutamine synthesis astrocytes | #10 |
| bdl surgery | #10 |
| thiamine replenishment | #10 |
| affinities binding sites | #10 |
| deficiency congenital | #10 |
| encephalopathy cirrhotic | #10 |
| mechanisms free radicals | #10 |
| brain pca | #10 |
| subsequent gc analysis | #10 |
| gabaergic tonic currents | #11 |
| isoforms mrna | #11 |
| pca p005 | #11 |
| fluoromethylornithine | #11 |
| hypothermia liver | #11 |
| 1h‐13c | #11 |
| capacity ammonia | #11 |
| cerebral vulnerability | #11 |
| ammonia pathogenesis | #11 |
| oxidative nitrosative stress | #11 |
| studies convincing evidence | #11 |
| amino acids rats | #11 |
| dehydrogenase alpha | #11 |
| ammonia amino acids | #11 |
| alterations brain | #11 |
| brain liver | #11 |
| impaired locomotor activity | #11 |
| placebo benzodiazepines | #11 |
| increased expression brain | #11 |
| benzodiazepine bdz receptors | #11 |
| impaired oxidation | #11 |
| pca brain | #11 |
| cirrhotic patients relationship | #11 |
| deficiency brain | #11 |
| portal systemic | #11 |
| experimental design limitations | #11 |
| brain increased | #11 |
| time icp | #11 |
| hyperammonemias | #11 |
| brain alf | #11 |
| dawley thalamus | #11 |
| ammonia animals rats | #11 |
| biosynthetic purposes | #11 |
| reduced activities | #11 |
| rats nh4cl | #11 |
| benzodiazepinelike compounds | #11 |
| signal hyperintensity | #11 |
| manganese blood | #11 |
| glutamate gammaaminobutyric acid | #11 |
| ammonia astrocytes | #11 |
| benzodiazepines neurosteroids | #11 |
| brain h1 | #11 |
| patients gabaa | #11 |
| halflife age | #11 |
| pdh alpha | #11 |
| clinical hepatic encephalopathy | #12 |
| igg extravasation | #12 |
| humans hepatic | #12 |
| improvement neurological symptoms | #12 |
| brains rats | #12 |
| deficiency amino | #12 |
| binding sites ligands | #12 |
| thiamin triphosphate | #12 |
| neuroactive amino | #12 |
| prevention hepatic encephalopathy | #12 |
| increased ammonia | #12 |
| ammonia animals | #12 |
| brain chronic | #12 |
| shunt surgical | #12 |
| cerebellar tissue | #12 |
| subclinical encephalopathy | #12 |
| selective inactivator | #12 |
| ammonia | #12 |
| brain slices synaptosomes | #12 |
| contribute pathogenesis | #12 |
| selective radioligands | #12 |
| anaplerotic activity | #12 |
| hyperammonemia liver failure | #12 |
| ammonia amino | #12 |
| p005 pca | #12 |
| diphosphate form | #12 |
| selective loss expression | #12 |
| loss righting | #12 |
| aqp4 brain edema | #12 |
| acetyltransferase disease | #12 |
| humans ketoglutarate | #12 |
| total glutamine | #12 |
| binding medium | #12 |
| thalamus cerebral cortex | #12 |
| microglial activation brain | #12 |
| blood manganese concentrations | #12 |
| ammonia salts | #12 |
| perispinal | #12 |
| pairfed control mice | #12 |
| thiamine deficient diet | #12 |
| rats glut1 | #12 |
| mm nh4cl | #12 |
| patients frontal cortex | #12 |
| mild hypothermia patients | #12 |
| thiamine intake | #13 |
| loss gfap | #13 |
| greatest vulnerability | #13 |
| treatment liver failure | #13 |
| role selective vulnerability | #13 |
| increased csf concentrations | #13 |
| levels octopamine | #13 |
| tissuespecific alterations | #13 |
| hyperglycemic ischemia | #13 |
| survival liver injury | #13 |
| evidence central | #13 |
| liver toxins | #13 |
| neuroprotection pretreatment | #13 |
| hand activities | #13 |
| hyperammonemic conditions | #13 |
| veratramine | #13 |
| patients flumazenil | #13 |
| peripheral nerve conduction | #13 |
| ampa receptor glur2 | #13 |
| ammonia manganese | #13 |
| butyrylglycine | #13 |
| ammonia cytokines | #13 |
| expression ammonia | #13 |
| regions rat brain | #13 |
| cytokines hepatic | #13 |
| presence hippocampal sclerosis | #13 |
| frontal cortex administration | #13 |
| ishen | #13 |
| neurosteroids gabaa | #13 |
| acute ammonia | #13 |
| amino acids lactate | #13 |
| hepatic encephalopathy patients | #13 |
| gfap protein | #13 |
| growing body evidence | #13 |
| neurosteroids pregnenolone | #13 |
| endogenous neuropeptide ligands | #13 |
| transcarbamylase deficiency | #13 |
| complex ketone | #13 |
| cerebral edema icp | #13 |
| body fatigue | #13 |
| hyperammonemia ammonia | #13 |
| increased brain lactate | #13 |
| blood csf concentrations | #13 |
| brain water accumulation | #13 |
| pallidal dopamine | #13 |
| development severe encephalopathy | #13 |
| loss chat | #13 |
| increased copper content | #13 |
| sites brain | #13 |
| postsynaptic gaba | #13 |
| antibiotic minocycline | #14 |
| manganese distribution | #14 |
| pathogenesis | #14 |
| ataxia neurological signs | #14 |
| mammillary body atrophy | #14 |
| sparse fur | #14 |
| 8024 | #14 |
| αmt | #14 |
| striatum concentrations | #14 |
| portacaval rats | #14 |
| gfap aqp4 | #14 |
| brain energy metabolites | #14 |
| hypothermia reduction | #14 |
| systemic shunting | #14 |
| models hepatic | #14 |
| clinical neurological signs | #14 |
| cerebellum cerebellar cortex | #14 |
| aged biogenic | #14 |
| glutamine concentrations | #14 |
| portocaval shunts | #15 |
| microglial activation neuroinflammation | #15 |
| gabaa reference values | #15 |
| apaptreated mice | #15 |
| 3hquisqualate | #15 |
| alcoholic brain | #15 |
| cirrhosis systematic review | #15 |
| acute liver | #15 |
| manganese phosphate | #15 |
| hyperintensity patients | #15 |
| ataxics | #15 |
| activity pdhc | #15 |
| thiamin metabolism | #15 |
| vulnerable region | #15 |
| 3hpk 11195 | #15 |
| fulminant liver | #15 |
| glur3 subunits | #15 |
| moderate drinkers | #15 |
| failure encephalopathy | #15 |
| purkinje cell terminals | #15 |
| white matter cbf | #15 |
| cerebral complications | #15 |
| astrocytic volume | #15 |
| treatment measurement | #15 |
| role thiamine | #15 |
| socalled type | #16 |
| distribution tritium | #16 |
| hypothermia 35 | #16 |
| cirrhosis ammonia | #16 |
| isoform gene | #16 |
| endothelial glucose | #16 |
| benzodiazepine gaba | #16 |
| proteins implicated | #16 |
| hypothesises | #16 |
| encephalopathy chronic | #16 |
| glutamine increase | #16 |
| nonvulnerable | #16 |
| agonal status | #16 |
| wks | #16 |
| pathophysiologic cascade | #16 |
| animal modelling | #16 |
| encephalopathy liver | #16 |
| pcs sham | #16 |
| gabaa receptor complex | #16 |
| new prospects | #16 |
| benzodiazepine ligands | #16 |
| hepatic metabolic pathways | #16 |
| new mechanistic basis | #16 |
| addition degree | #16 |
| encephalopathy loss | #16 |
| brain modulation | #16 |
| taurine brain | #16 |
| brain proinflammatory | #16 |
| acids ammonia | #17 |
| cox2 expression immunohistochemistry | #17 |
| cerebellum enzyme | #17 |
| isoquinoline carboxamide | #17 |
| benzoate therapy | #17 |
| antibiotic rifaximin | #17 |
| cortical astrocyte | #17 |
| glutamine phenylalanine | #17 |
| vulnerable structures | #17 |
| acid thiamine | #17 |
| early microglial | #17 |
| surgical construction | #17 |
| liver disease mice | #17 |
| dependent enzyme | #17 |
| activation sgc | #17 |
| platelets dopamine | #17 |
| neuroinflammatory mechanisms | #17 |
| pregnenolone allopregnanolone | #17 |
| upregulation aqp4 | #17 |
| complications malnutrition | #17 |
| absence ammonia | #17 |
| day heavy drinking | #17 |
| pathogenesis complications | #17 |
| glutamate enzyme | #17 |
| endogenous benzodiazepines | #17 |
| patient malnutrition | #17 |
| onset convulsions | #17 |
| encephalopathy rats | #17 |
| loss liver | #17 |
| reprint | #17 |
| excess ammonia | #17 |
| early glial | #17 |
| 4fold increases | #17 |
| ammonia induces | #17 |
| synthetase activities | #17 |
| result molecules | #18 |
| concentrations kcl | #18 |
| binding sites hippocampus | #18 |
| wernicke korsakoff | #18 |
| doserelated reduction | #18 |
| administration aom | #18 |
| reversible coma | #18 |
| brain regions rat | #18 |
| alcoholic cirrhotic patients | #18 |
| neuropathological damage | #18 |
| neurological psychiatric | #18 |
| type benzodiazepine | #18 |
| neuropathologic evaluation | #18 |
| portocaval shunting | #18 |
| compared pair | #18 |
| 13c isotopomer analysis | #18 |
| active pyruvate | #18 |
| autopsied | #18 |
| wernicke korsakoff syndrome | #18 |
| coa levels | #18 |
| astrocytic glutamine synthetase | #18 |
| prevention progression | #18 |
| beta endorphin betaep | #18 |
| encephalopathy patients | #18 |
| patients therapeutic options | #18 |
| astrocytes blotting | #18 |
| condition evidence | #18 |
| selective neuronal | #18 |
| generalized reduction | #18 |
| 11195 binding | #18 |
| bbb igg | #18 |
| activities alpha | #18 |
| csf concentrations 5hiaa | #19 |
| treatment mhe | #19 |
| outcome prevention | #19 |
| 125iiodopindolol | #19 |
| energy metabolism brain | #19 |
| serum ammonia levels | #19 |
| rats stages | #19 |
| distribution binding | #19 |
| acids glutamate | #19 |
| exposure cultured | #19 |
| brain lactate | #19 |
| endogenous benzodiazepine | #19 |
| equal age | #19 |
| severe encephalopathy | #19 |
| disease frontal | #19 |
| lola patients | #19 |
| control groups animals | #19 |
| agents hepatic | #19 |
| response neurodegeneration | #19 |
| synthetase protein | #19 |
| increase brain water | #19 |
| astrocytic neuronal | #19 |
| ornithine transcarbamylase | #19 |
| blood manganese | #19 |
| free coa | #19 |
| cholinergic cell loss | #19 |
| complications acute | #19 |
| pathophysiology hepatic encephalopathy | #19 |
| brain peripheral | #19 |
| cirrhotic patients controls | #19 |
| errors mice | #19 |
| expression result | #19 |
| glutamates glutamine | #19 |
| brain autopsy samples | #20 |
| glutamate nmda receptors | #20 |
| syndrome wks | #20 |
| rats patients | #20 |
| regions rat | #20 |
| brain organic osmolytes | #20 |
| adequate dietary protein | #20 |
| benzodiazepine medication | #20 |
| acute ammonia toxicity | #20 |
| expression oxidative stress | #20 |
| lola | #20 |
| l3harginine | #20 |
| animals tests | #20 |
| animal frontal | #20 |
| coma brain | #20 |
| effects neurosteroids | #20 |
| biochemical lesion | #20 |
| volume plasmapheresis | #20 |
| glutamate increased | #20 |
| alf mars | #20 |
| aids patients patients | #20 |
| bbb alterations | #20 |
| pallidal hyperintensity | #20 |
| diencephalic | #20 |
| blood–brain barrier permeability | #21 |
| symptomatic stages | #21 |
| nakatpase activities | #21 |
| alanine increased | #21 |
| failure skeletal | #21 |
| hyperammonemia rats | #21 |
| endorphin induced | #21 |
| glast protein | #21 |
| vivo cerebral | #21 |
| transport ammonia | #21 |
| mild hypothermia survival | #21 |
| deficiency synthesis | #21 |
| cisterna magna csf | #21 |
| protective hypothermia | #21 |
| selective loss neurons | #21 |
| 5 p0001 | #21 |
| 8094 | #21 |
| direct neurotoxic effects | #21 |
| plasma ammonia concentrations | #21 |
| tetrahydrodeoxycorticosterone | #21 |
| metabolic trafficking | #21 |
| mhe encephalopathy humans | #21 |
| sgc nitric oxide | #21 |
| 3alpha5alphathp | #21 |
| distribution amino acids | #22 |
| gabaa receptors humans | #22 |
| alf infection | #22 |
| cerebral cortex brainstem | #22 |
| acute hepatic encephalopathy | #22 |
| effects glutamate | #22 |
| sites cerebral | #22 |
| characterized model | #22 |
| deficiency alterations | #22 |
| zieve | #22 |
| concentrations glycine | #22 |
| sites measured | #22 |
| 3alpha5beta | #22 |
| stereotyped behavior rats | #22 |
| inbred strains cns | #22 |
| exposed manganese | #22 |
| 3hafdx | #22 |
| antiparkinson drugs | #22 |
| temporal cortex cerebellum | #22 |
| hepatic carnitine | #22 |
| normal circumstances | #22 |
| brain experimental | #22 |
| brain alanine | #22 |
| partial inverse agonists | #22 |
| gaba regions | #22 |
| sham operation rats | #22 |
| dewhurst | #23 |
| mm ammonia | #23 |
| gabaa steroids | #23 |
| deficiency animals | #23 |
| glutamine neurons | #23 |
| thiamine homeostasis | #23 |
| diphosphate dependent | #23 |
| hippocampus thalamus | #23 |
| glutamine taurine | #23 |
| brain neurosteroid | #23 |
| marrero | #23 |
| ammonia lactate | #23 |
| treatment sarcopenia | #23 |
| portal systemic encephalopathy | #23 |
| neuropathological evaluation | #23 |
| cortex male rats | #23 |
| bckdh activity | #23 |
| astrocytic protein | #23 |
| glutamine accumulation | #23 |
| brain cell function | #23 |
| amino acids model | #23 |
| aspartate alanine | #23 |
| impaired absorption | #23 |
| ammonia liver | #23 |
| increased sites | #23 |
| oxidative stress nac | #23 |
| proinflammatory cytokines mice | #23 |
| cerebral gaba | #23 |
| encephalopathy ammonia | #24 |
| ” ligands | #24 |
| activites | #24 |
| p005 activities | #24 |
| neuropathologic studies | #24 |
| brain coenzyme | #24 |
| pathophysiological levels | #24 |
| sites ligands | #24 |
| external warming | #24 |
| controls cirrhotic | #24 |
| serotonin 5ht metabolism | #24 |
| extracellular glutamine | #25 |
| severe muscle damage | #25 |
| copper zinc concentrations | #25 |
| sites glutamate | #25 |
| malnutrition chronic | #25 |
| nmdareceptor | #25 |
| ammonia reduction | #25 |
| glutamine liver | #25 |
| katpase src | #25 |
| chronic hepatic | #25 |
| glutamine synthesis | #25 |
| transketolase tk | #25 |
| damage dysfunction | #25 |
| deficiency regulation | #25 |
| mousseau | #25 |
| inhalation exposure rats | #25 |
| synthase activities | #25 |
| uptake 14c | #25 |
| cns complication | #25 |
| cytotoxic brain edema | #25 |
| 11195 | #25 |
| human experimental | #25 |
| treatment hepatic | #26 |
| aqp4 levels | #26 |
| adult patterns | #26 |
| failure increased | #26 |
| concentrations ammonia | #26 |
| isoquinolines ligands | #26 |
| ketoglutarate dehydrogenase | #26 |
| pathophysiological significance | #26 |
| pathogenesis cerebral | #26 |
| 60p | #26 |
| flumazenil placebo | #26 |
| anastomosis rats | #26 |
| fluid amino | #26 |
| synthesis amino acids | #26 |
| oxidative stress processes | #26 |
| alanine concentrations | #26 |
| arterial ammonia levels | #26 |
| 17 39 | #26 |
| glucose loading | #27 |
| accumulation glutamine | #27 |
| liver fasting | #27 |
| beta sites | #27 |
| regional densities | #27 |
| cerebellum brain | #27 |
| fgin1 | #27 |
| manganese ammonia | #27 |
| deficient brain | #27 |
| binding site densities | #27 |
| binding 3hmuscimol | #27 |
| onset encephalopathy | #27 |
| support potential | #27 |
| asparagine glutamine | #27 |
| increased concentrations | #27 |
| treatment cirrhosis | #27 |
| noradrenaline transport | #27 |
| alf induced | #27 |
| rifaximin mhe | #27 |
| brain serotonin metabolism | #27 |
| oxidative stress evidence | #27 |
| ornithine transcarbamylase otc | #27 |
| eaat3 expression | #28 |
| type hepatic | #28 |
| selective neuronal loss | #28 |
| baldessarini | #28 |
| astrocytic metabolism | #28 |
| effects thiamine | #28 |
| allosteric modulatory | #28 |
| astrocytes loss | #28 |
| glutamate transporter activity | #28 |
| ataxic gait | #28 |
| metabolism relation | #28 |
| chronic liver failure | #28 |
| devascularized | #28 |
| wernicke encephalopathy | #28 |
| experimental acute | #28 |
| activities decreased | #28 |
| striatum contrast | #29 |
| induction mild hypothermia | #29 |
| frontal temporal cortex | #29 |
| subchronic inhalation exposure | #29 |
| flumazenil flunitrazepam | #29 |
| dopamine metabolism striatum | #29 |
| 3hro5 | #29 |
| putamen frontal cortex | #29 |
| increased glutamine | #29 |
| superoxide scavenger | #29 |
| effective adjunct therapy | #29 |
| travelled distance | #29 |
| re‐evaluation | #29 |
| serotonin turnover | #29 |
| glutamine content | #29 |
| rats probenecid | #29 |
| shamoperated control animals | #29 |
| optimal supply | #29 |
| dust rats | #29 |
| cerebral cortex thalamus | #29 |
| diverse etiology | #29 |
| isopregnanolone | #29 |
| oxide brain | #29 |
| cerebral energy failure | #29 |
| cytoplasmic nuclear signal | #29 |
| pairfed controls | #29 |
| chronic hyperammonemia | #30 |
| 3dsrt | #30 |
| presymptomatic animals | #30 |
| west criteria | #30 |
| glycine glutamine | #30 |
| aspartate glutamine | #30 |
| glutamate content | #30 |
| chat activities | #30 |
| glutamate cgmp | #30 |
| inflammatory cascades | #30 |
| flumazenil gaba | #30 |
| hyperglycemic stroke | #30 |
| neurotransmitter amino acids | #30 |
| frontal cortex samples | #30 |
| blood ammonia concentration | #30 |
| quantitative receptor | #30 |
| progression liver injury | #30 |
| nonabsorbable disaccharides | #30 |
| gaba receptor complex | #30 |
| studies experimental | #30 |
| mediated excitotoxicity | #30 |
| neuronal cell counts | #30 |
| stroke neurological | #30 |
| encephalopathy portal | #30 |
| increased nmda | #30 |
| cuznsod protein | #31 |
| stupor | #31 |
| shunted animals | #31 |
| dogs hepatic | #31 |
| brain monoamine oxidase | #31 |
| brain decreased | #31 |
| antisense elements | #31 |
| glutamate nmda | #31 |
| leading increased | #31 |
| expression tight junction | #31 |
| pannecrosis | #31 |
| peripheral type | #31 |
| clinical prospects | #31 |
| cerebral glutamate | #31 |
| study ammonia | #31 |
| neuroinflammation pathogenesis | #31 |
| production microglial | #31 |
| binding gaba | #32 |
| 2 alteration | #32 |
| uptake ammonia | #32 |
| akinesia | #32 |
| friedreichs ataxia | #32 |
| effects mild | #32 |
| temporal cortex patients | #32 |
| fixed intervals | #32 |
| astrocytes ammonia | #32 |
| detoxification unit | #32 |
| increased nitric | #32 |
| minimal mhe | #32 |
| gabaa receptor ligands | #32 |
| deficiencies vitamins | #32 |
| hepatic symptoms | #32 |
| binding sites presence | #32 |
| acute hyperglycemic | #32 |
| intracellular osmolarity | #32 |
| cerebral ammonia | #32 |
| telemethylhistamine | #32 |
| indian national association | #32 |
| hepatoprotective properties | #32 |
| reversible alterations | #33 |
| cns complications | #33 |
| failing liver | #33 |
| binding microsomes | #33 |
| hand addition | #33 |
| brain gaba levels | #33 |
| gaba aspartate | #33 |
| selective decreases | #33 |
| rats ammonia | #33 |
| otc deficiency | #33 |
| neuronal cell survival | #33 |
| ohe patients | #33 |
| snat5 | #33 |
| monoamines brain | #33 |
| regions brains | #33 |
| cns concentrations | #33 |
| species rats | #33 |
| proinflammatory cytokines brain | #33 |
| glycine aspartate | #33 |
| et495 | #33 |
| nash treatment | #33 |
| clinical laboratory findings | #33 |
| 11 agematched controls | #34 |
| gad activities | #34 |
| severe neurological symptoms | #34 |
| nh4oac | #34 |
| severe neurological dysfunction | #34 |
| metabolite 5 | #34 |
| inadequate dietary intake | #34 |
| cytotoxic brain | #34 |
| relation brain | #34 |
| nonepileptic controls | #34 |
| groups cirrhotic patients | #34 |
| acetylcholinesterase activities | #34 |
| stupor coma | #34 |
| nac reduction | #34 |
| encephalopathy hippocampus | #34 |
| hepatic artery ligation | #34 |
| ammonium tartrate | #34 |
| total thiamine | #35 |
| ammonia concentrations | #35 |
| space glutamic | #35 |
| fatigue rats | #35 |
| manganese tricarbonyl | #35 |
| neuropsychiatric abnormalities | #35 |
| chronic hepatic encephalopathy | #35 |
| overt encephalopathy | #35 |
| type gaba | #35 |
| neurotransmitter amino | #35 |
| fluid ammonia | #35 |
| activation proinflammatory | #35 |
| dawley reverse | #35 |
| octadecaneuropeptide | #35 |
| astrocytic glutamate | #35 |
| effects manganese | #35 |
| severe compromise | #35 |
| free hepatic | #35 |
| chapter 29 | #35 |
| cerebral cortical astrocytes | #36 |
| numerous etiologies | #36 |
| uptake glutamate | #36 |
| astrocytic glutamine | #36 |
| synthesis glutamate | #36 |
| detoxification product | #36 |
| thioacetamide treatment | #36 |
| electricalfield stimulation | #36 |
| aom treatment | #36 |
| acid brain | #36 |
| cycle glucose | #36 |
| arterial ammonia | #36 |
| astrocyte glutamate | #36 |
| muscarinic sites | #36 |
| brain regions studies | #36 |
| protein glutamate | #37 |
| acute receptors | #37 |
| excitotoxic mechanism | #37 |
| csf cisterna magna | #37 |
| blood manganese levels | #37 |
| mild hypothermia therapy | #37 |
| increased blood glucose | #37 |
| increased voluntary | #37 |
| 3beta5alpha | #37 |
| alf mice | #37 |
| mice ammonia | #37 |
| perivenous hepatocytes | #37 |
| astrocytic marker | #38 |
| ammonium acetate | #38 |
| glutamate ammonia | #38 |
| corneal reflex | #38 |
| gfap immunohistochemistry | #38 |
| brain amino acids | #38 |
| hypothermia attenuates | #38 |
| brain rats | #38 |
| failure male | #38 |
| increase glutamine | #38 |
| glutamatergic function | #38 |
| pdhc | #39 |
| brain regional distribution | #39 |
| loss gene expression | #39 |
| glutamine formation | #39 |
| pca surgery | #39 |
| chronic alcoholism | #39 |
| clive | #39 |
| thiamine administration | #39 |
| benzodiazepine antagonist | #39 |
| severe liver dysfunction | #39 |
| findings increased | #39 |
| hyperammonaemic | #39 |
| concomitant decreases | #39 |
| posterior columns | #39 |
| acetylcoa levels | #40 |
| regiondependent manner | #40 |
| nitroarginine rats rats | #40 |
| glutamine glycine | #40 |
| seizures mental retardation | #40 |
| quin levels | #40 |
| ammonia homeostasis | #40 |
| concentrations catecholamines | #40 |
| argininic acid | #40 |
| neurological alterations | #40 |
| dheas | #40 |
| liver inasl | #40 |
| increased density | #40 |
| etiology severity | #40 |
| nmdamediated excitotoxicity | #40 |
| arginine uptake | #40 |
| regionally selective | #40 |
| concentration areas | #40 |
| regions concentrations | #41 |
| vulnerable area | #41 |
| detoxification ammonia | #41 |
| regulation caveolin1 | #41 |
| thiamine metabolism | #41 |
| increased glutamate release | #41 |
| brain extracts | #41 |
| brain benzodiazepine receptors | #41 |
| lateral vestibular nucleus | #41 |
| sgc activation | #41 |
| brain taurine | #41 |
| cellcell signalling | #41 |
| activation nmda receptor | #41 |
| acid neurotransmitter | #41 |
| complications chronic | #41 |
| deficiency disease | #41 |
| thdoc | #42 |
| benzodiazepine sites | #42 |
| complex pdhc | #42 |
| illness terminology topic | #42 |
| trace amines | #42 |
| cerebral alterations | #42 |
| cerebral glutamine | #42 |
| pk11195 binding | #42 |
| increased neuronal | #43 |
| carbamoyltransferase deficiency | #43 |
| metabolism acute | #43 |
| nonalcoholic patients | #43 |
| glutamine insulin | #43 |
| gabaa tritium | #43 |
| liver assist | #43 |
| transcarbamylase | #43 |
| acute ammonia intoxication | #43 |
| western brain dna | #44 |
| reduction brain | #44 |
| increased serotonin | #44 |
| ohe mhe | #44 |
| acid glutamine | #44 |
| sarcopenia cirrhosis | #44 |
| toxic liver | #44 |
| severe hyperammonemia | #44 |
| treament | #44 |
| ammonia increases | #44 |
| ataxia humans | #44 |
| behavioral excitation | #44 |
| aged portacaval | #44 |
| cerebral levels | #44 |
| mechanisms disorder | #44 |
| aspartate gaba | #45 |
| model congenital | #45 |
| mice etanercept | #45 |
| ventral white matter | #45 |
| welldefined areas | #45 |
| glutamate transporter | #45 |
| mild encephalopathy | #45 |
| cholinergic neuronal | #45 |
| isoquinolines kinetics | #45 |
| cortex dose | #45 |
| thiamin deficiency | #45 |
| small meals | #45 |
| fatigue controls | #46 |
| brain gamma | #46 |
| exposed ammonia | #46 |
| 11cnmethylspiperone | #46 |
| normoglycemic rats | #46 |
| treatment downregulation | #46 |
| brain oxidative metabolism | #46 |
| cortex glutamate | #46 |
| microsomes isolated | #47 |
| human rat brain | #47 |
| anaplerotic flux | #47 |
| alcoholic cirrhotics | #47 |
| rtpcr experiments | #47 |
| glutamate removal | #47 |
| distinctive pattern | #47 |
| brain amino | #47 |
| neurosteroid | #47 |
| metabolism astrocytes | #47 |
| pathophysiologically | #47 |
| glutamate aspartate | #47 |
| benzodiazepine receptors | #47 |
| hyperammonemia | #48 |
| thalamus pons | #48 |
| tnf brain | #48 |
| allopregnanolone concentrations | #48 |
| maob | #48 |
| age injection | #48 |
| mitochondrial benzodiazepine | #48 |
| 113cglucose | #48 |
| cerebellum medulla | #48 |
| concomitant increases | #48 |
| central nervous function | #48 |
| 3hmuscimol | #48 |
| neurotoxic agents | #48 |
| sites nmda | #48 |
| amino acid synthesis | #48 |
| cerebral dysfunction | #48 |
| neurotoxic actions | #49 |
| nmda binding | #49 |
| cerebellum patients | #49 |
| rcts low risk | #49 |
| ammonia detoxification | #49 |
| glycerol phenylbutyrate | #49 |
| voluntary ethanol | #49 |
| central benzodiazepine | #49 |
| pallidal | #49 |
| brain tryptophan | #49 |
| alcoholic dementia | #50 |
| hepatic encephalopathy study | #50 |
| rational explanation | #50 |
| increased extracellular | #50 |
| tyrosine ammonia | #50 |
| effects body temperature | #50 |
| hepatic congestion | #50 |
| manganese middle | #50 |
| expression glt1 | #50 |
| extracellular glycine | #50 |
| levels brain | #50 |
| brain banks | #50 |
| acids measured | #51 |
| glutamate receptors nmda | #51 |
| righting | #51 |
| inflamed brain | #51 |
| electromyographic evaluation | #51 |
| management hepatic | #51 |
| lcarnitine treatment | #51 |
| early microglial activation | #51 |
| false neurotransmitters | #51 |
| friedreichs ataxia patients | #52 |
| brain concentrations | #52 |
| 12 rats | #52 |
| vivo microdialysis | #52 |
| severe stages | #52 |
| pse | #52 |
| synthesis glutamine | #52 |
| early losses | #52 |
| alcoholic cirrhotic | #52 |
| nitroarginine rats | #52 |
| neurobehavioral disturbances | #52 |
| complex rats | #52 |
| cognitive motor dysfunction | #52 |
| altered permeability | #52 |
| mice carnitine | #52 |
| 3hkainate | #53 |
| treatment alf | #53 |
| rats portacaval shunt | #53 |
| pathophysiologic | #53 |
| 3hmuscimol binding | #53 |
| neurosteroid pregnenolone | #53 |
| neurosteroid synthesis | #53 |
| central histaminergic | #53 |
| mildest form | #54 |
| portacaval shunt pcs | #54 |
| cerebral inflammation | #54 |
| mechanisms proposed | #54 |
| portacaval shunts | #54 |
| substitutive therapy | #54 |
| neuropsychiatric syndrome | #54 |
| liver atrophy | #54 |
| stroke penumbra | #54 |
| subsequent alteration | #54 |
| activation guanylate cyclase | #54 |
| gene expression liver | #54 |
| kidney testis | #54 |
| ischemic liver | #54 |
| activation glutamate receptors | #55 |
| hyperglycemic | #55 |
| encephalopathy hyperammonemia | #55 |
| neurotransmitter agents | #55 |
| glutathione plasma | #55 |
| concomitant reductions | #55 |
| occludin levels | #55 |
| messenger spraguedawley receptors | #55 |
| human disorder | #55 |
| heterogenity | #55 |
| severe cognitive dysfunction | #56 |
| awaits | #56 |
| deficiency decreased | #56 |
| delays onset | #56 |
| ca2dependent release | #56 |
| regions rats | #56 |
| levels allopregnanolone | #56 |
| oxidative nitrosative | #56 |
| type mitochondrial | #57 |
| current therapeutic options | #57 |
| failure muscle | #57 |
| ammonia exposure | #57 |
| tetrahydroprogesterone | #57 |
| mechanisms implicated | #57 |
| h1 receptors | #57 |
| brain glutamate levels | #57 |
| rats ouabain | #57 |
| resonance signal | #57 |
| increased intracellular ca2 | #57 |
| coma patients | #57 |
| astrocytes glutamate | #58 |
| brain histamine | #58 |
| activation glutamate | #58 |
| dansyl derivatives | #58 |
| lowering strategies | #58 |
| pdhc activity | #58 |
| probenecid treatment | #58 |
| manganese copper | #58 |
| swelling brain | #58 |
| levels ammonia | #58 |
| severity encephalopathy | #58 |
| levels amino acids | #58 |
| portacaval shunt | #58 |
| nervous complications | #58 |
| mechanism protective | #59 |
| 13c enrichments | #59 |
| uptake arginine | #59 |
| gfap gfap mrna | #59 |
| neuropharmacological studies | #59 |
| bilirubin metabolism | #59 |
| saline treated controls | #59 |
| hyperammonaemia | #59 |
| patients thiamine | #59 |
| acetaminophen toxicity | #59 |
| required cofactor | #60 |
| energy metabolites | #60 |
| cirrhotic patients patients | #60 |
| ammonia intoxication | #60 |
| brain production | #60 |
| alcoholics patients | #60 |
| lazabemide | #60 |
| purposing | #60 |
| alcoholic patients | #60 |
| cirrhosis middle | #60 |
| ammonia toxicity | #60 |
| spontaneous synaptic activity | #60 |
| subjects free | #61 |
| concentrations glutamate | #61 |
| maob maoa | #61 |
| threefold increase | #61 |
| opioid penicillamine | #61 |
| stem cerebral | #61 |
| excitotoxic brain injury | #61 |
| il1beta mrna expression | #61 |
| comparable magnitude | #61 |
| affinity gaba | #61 |
| 015 mmol | #61 |
| acid distribution | #61 |
| bz receptors | #61 |
| sham operated | #61 |
| ataxia friedreich | #61 |
| hypertension brain | #62 |
| receptors pathogenesis | #62 |
| brain1 | #62 |
| increased expression mrna | #62 |
| βendorphin | #62 |
| forebrain cholinergic neurons | #62 |
| elevated uptake | #62 |
| taurine synthesis | #62 |
| ultimate test | #62 |
| suggested role | #62 |
| metabolism glutamine | #63 |
| failure evidence | #63 |
| regions contrast | #63 |
| role glutamate | #63 |
| manganese intoxication | #63 |
| focal increases | #63 |
| spectroscopy tomography | #63 |
| manganese treatment | #63 |
| heavy drinking day | #63 |
| portocaval | #63 |
| rtpcr gene expression | #63 |
| gaba glutamic acid | #63 |
| thiamine | #63 |
| subclinical hepatic | #63 |
| fatigue pbc | #64 |
| sodium phenylacetate | #64 |
| disease activities | #64 |
| parietal lobe rats | #64 |
| thalamus gamma | #64 |
| neurosteroid allopregnanolone | #64 |
| brain | #64 |
| transketolase activity | #64 |
| attenuates oxidative | #64 |
| neurotoxic substances | #64 |
| kcl nacl | #65 |
| deficiency induced | #65 |
| manganese deposits | #65 |
| hypokinesia | #65 |
| symptoms addition | #65 |
| butyrylcholinesterases | #65 |
| glutamine ammonia | #65 |
| brain cell death | #65 |
| frontal parietal cortex | #65 |
| methylhistamine | #65 |
| female flumazenil | #65 |
| 2454 | #65 |
| sodium benzoate | #65 |
| brain chemistry | #65 |
| ataxia patients | #66 |
| isethionic | #66 |
| putative endogenous ligands | #66 |
| increases brain | #66 |
| mice sodium | #66 |
| gaba animals | #66 |
| 13cnmr | #66 |
| brain water | #66 |
| uptake cultured | #66 |
| αmethylptyrosine | #67 |
| cerebral energy metabolism | #67 |
| humans korsakoff | #67 |
| lactate increase | #67 |
| brain patients | #67 |
| ascorbate synthesis | #67 |
| tyrosine content | #67 |
| erythrocyte transketolase | #67 |
| brain 24 | #67 |
| serotonin transport | #68 |
| reduction ammonia | #68 |
| indian national | #68 |
| decreased concentrations | #68 |
| glutamate transporter glast | #68 |
| benzodiazepine receptor ligands | #68 |
| selective reductions | #68 |
| attenuation effects | #69 |
| processing product | #69 |
| unleaded gasoline | #69 |
| drug repositioning humans | #69 |
| active removal | #69 |
| osmotic effects | #69 |
| decreased removal | #69 |
| hepatoprotection | #69 |
| substance rats | #69 |
| rats sham operation | #69 |
| electronic manual searches | #70 |
| cortex caudate | #70 |
| bergmann glial | #70 |
| glutamic acid hippocampus | #70 |
| reduces brain | #70 |
| m1 sites | #70 |
| glutamates glutamic | #71 |
| medium concentrations | #71 |
| failure animals | #71 |
| animals benzodiazepines | #71 |
| alloxan diabetes | #71 |
| carbamoyltransferase | #71 |
| shunting | #71 |
| organic aciduria | #72 |
| cortex increased | #72 |
| hyperammonemia male | #72 |
| agematched control subjects | #72 |
| gabaa tomography | #72 |
| common inborn error | #72 |
| glutamine brain | #72 |
| concentration norepinephrine | #72 |
| brain allopregnanolone | #72 |
| thiamine treatment | #73 |
| homologous structures | #73 |
| astrocyte swelling | #73 |
| ro15 | #73 |
| glutamine glutamate | #73 |
| pse patients | #73 |
| hippocampal ca1 subfield | #73 |
| alterations mitochondrial function | #73 |
| sites observed | #73 |
| cerebroprotective effects | #73 |
| onset neurological | #73 |
| mechanisms involving | #74 |
| decrease brain | #74 |
| glutamic | #74 |
| brain content | #74 |
| bath concentration | #74 |
| cortex chromatography | #74 |
| astrocytes brain | #74 |
| gaba steroids | #74 |
| nature distribution | #75 |
| severe neurological impairment | #75 |
| thiamine transport | #75 |
| expression glial | #75 |
| normal limits | #75 |
| fully elucidated | #75 |
| cerebral cortex patients | #75 |
| acids hepatic | #75 |
| superfused slices | #75 |
| cirrhosis brain | #76 |
| transporter eaat3 | #76 |
| receptors gaba | #76 |
| receptors studied | #76 |
| glutamate binding | #76 |
| gaba glutamine | #76 |
| direct toxic effects | #76 |
| larginine uptake | #76 |
| glutamate concentration | #77 |
| brain skeletal muscle | #77 |
| metabolite acetaldehyde | #77 |
| glycine concentrations | #77 |
| muscle acute | #77 |
| alcoholic patients cirrhosis | #77 |
| millimolar range | #77 |
| nnos protein | #78 |
| benzodiazepines binding | #78 |
| brain glucose metabolism | #78 |
| oxide liver | #78 |
| muscle glutamine | #78 |
| interatomic bonds | #78 |
| lnitroarginine methyl ester | #78 |
| function hepatic | #78 |
| semiquantitative rtpcr | #79 |
| metabolism brain | #79 |
| excited ground states | #79 |
| previous reports | #79 |
| l‐carnitine | #79 |
| deep coma | #79 |
| thiamine triphosphate | #79 |
| cns function | #79 |
| methylcyclopentadienyl | #79 |
| taming | #79 |
| hepatic energy | #79 |
| neuronally | #79 |
| failure nitric | #80 |
| expression glutamate | #80 |
| quantitative autoradiographic | #80 |
| emerging therapeutic target | #80 |
| gaba benzodiazepine | #80 |
| cresyl violet staining | #80 |
| medullapons | #80 |
| pathogenesis animals | #80 |
| neurosteroid biosynthesis | #80 |
| encephalopathy treatment | #80 |
| maximal binding | #80 |
| molecular neurobiology | #81 |
| muscle ammonia | #81 |
| glutamine astrocytes | #81 |
| 85 mmol | #81 |
| controls increased | #81 |
| astrocyte morphology | #81 |
| study sections | #81 |
| chaired | #82 |
| brain extracellular | #82 |
| agents receptors | #82 |
| receptor regions | #82 |
| shortchain acylcoa dehydrogenase | #82 |
| glutamate nitric | #82 |
| lcarnitine administration | #82 |
| treatment thiamine | #83 |
| ethanol preference | #83 |
| proposed explain | #83 |
| tca cycle flux | #83 |
| glutamate brain | #83 |
| 3hro15 | #83 |
| water channel protein | #84 |
| measured brain | #84 |
| elevated ammonia | #84 |
| aom induced | #84 |
| 3hflumazenil | #84 |
| cerebral cortex striatum | #84 |
| pathophysiologic basis | #84 |
| devascularization | #84 |
| pbgd | #84 |
| patients decreases | #84 |
| role glutamine | #85 |
| arga | #85 |
| 3hgammaaminobutyric acid | #85 |
| urea cycle enzymes | #85 |
| 5ht turnover | #85 |
| maoa maob | #85 |
| ammonia patients | #85 |
| decreased ca2 | #85 |
| increase brain | #85 |
| concomitant decrease | #85 |
| central muscarinic | #86 |
| glutamate amino | #86 |
| release synaptic | #86 |
| wilsonian | #87 |
| spraguedawley statistics | #87 |
| rats sacrificed | #87 |
| tissue brain | #88 |
| benzodiazepines brain | #88 |
| csf lactate | #88 |
| selective vulnerability | #88 |
| 52 mmol | #88 |
| brain binding | #88 |
| complication cirrhosis | #88 |
| concomitantly | #88 |
| undoubtedly | #89 |
| exposure ammonia | #89 |
| alpha ketoglutarate | #89 |
| caudate nuclei | #89 |
| prior onset | #89 |
| role human diseases | #89 |
| sham operations | #89 |
| edema cerebral | #89 |
| brain regions rats | #89 |
| olivopontocerebellar atrophy opca | #89 |
| lactate increased | #90 |
| patients alf | #90 |
| receptor ligand | #90 |
| encephalopathy ohe | #90 |
| rats species | #90 |
| glutamatemediated excitotoxicity | #90 |
| gaba modulators | #91 |
| reduced brain | #91 |
| monoamine neurotransmitters | #91 |
| bcaa concentrations | #91 |
| amino acids brain | #92 |
| enzymopathies | #92 |
| leucine concentrations | #92 |
| bckdh | #92 |
| altered protein expression | #92 |
| neuroinflammatory response | #92 |
| induced alf | #93 |
| congenital deficiencies | #93 |
| widespread damage | #93 |
| acid liver | #93 |
| brain compared | #94 |
| increases extracellular | #94 |
| brain kidney | #94 |
| neuronal loss | #94 |
| thiamin diphosphate | #94 |
| mri intensity | #94 |
| manganese poisoning | #94 |
| inhibitory neurotransmission | #95 |
| benzodiazepines treatment | #95 |
| induced stereotyped | #95 |
| patients liver failure | #95 |
| acetate administration | #95 |
| ammonia accumulation | #95 |
| glutamine synthetase expression | #95 |
| astrocytic function | #96 |
| 16 mmol | #96 |
| ornithine phenylacetate | #96 |
| skeletal muscle brain | #96 |
| discrete areas | #96 |
| βlipotropin | #96 |
| covert hepatic encephalopathy | #97 |
| astrocytes neurons | #97 |
| ammonia release | #97 |
| brain vivo | #97 |
| molecules brain | #97 |
| brain cytokine | #97 |
| acrylamides animals | #98 |
| receptors increased | #98 |
| dehydroascorbic acid | #98 |
| carbamoyltransferase ornithine | #98 |
| glutamate glutamine | #98 |
| glycine transporters | #98 |
| hepatocerebral degeneration | #98 |
| thiamine diphosphate | #98 |
| dorsal tegmental nucleus | #98 |
| stress ammonia | #99 |
| examination role | #99 |
| 3045 | #99 |
| walking gait | #99 |
| fatigue impact scale | #100 |
| commonly encountered | #100 |
| symptomatic stage | #100 |
| aspartate levels | #100 |
| increases levels | #101 |
| animal hypothermia | #101 |
| temporal cortex | #101 |
| proinflammatory | #101 |
| pressure liver | #101 |
| inhibitory amino acids | #101 |
| treatment complications | #102 |
| microdialysis rats | #102 |
| neurological symptoms patients | #102 |
| brain barrier breakdown | #102 |
| tk activity | #102 |
| synergistic mechanisms | #102 |
| lcarnitine | #102 |
| cerebral cortex cerebellum | #102 |
| levels dheas | #102 |
| brain extracellular space | #103 |
| controls cirrhotic patients | #103 |
| collisional deactivation | #103 |
| removal ammonia | #103 |
| brain levels | #103 |
| benzodiazepine receptor | #103 |
| label incorporation | #104 |
| methylspiperone | #104 |
| cerebral oxidative metabolism | #104 |
| regional distribution | #104 |
| experimental animal models | #104 |
| thiamine monophosphate | #104 |
| 90 loss | #104 |
| receptors brain | #105 |
| experimental models | #105 |
| loss cholinergic | #105 |
| fatigue severity | #105 |
| olivopontocerebellar atrophy | #105 |
| neurological consequences | #105 |
| m3 exposure | #105 |
| transporter glt1 | #105 |
| complication liver | #106 |
| toxic liver injury | #106 |
| receptors rats | #107 |
| concentrations serotonin | #107 |
| 3h8ohdpat | #107 |
| sham operated controls | #108 |
| current theories | #108 |
| characteristic alterations | #108 |
| monoamines | #108 |
| gaba content | #108 |
| dopaminergic dysfunction | #108 |
| t1weighted magnetic resonance | #109 |
| ldeprenyl | #109 |
| disease hepatic | #109 |
| glutamate plasma | #109 |
| symptomatic animals | #109 |
| extrapyramidal symptoms | #110 |
| rats hepatic | #110 |
| 3hnisoxetine | #110 |
| azoxymethane aom | #110 |
| deficiency humans | #110 |
| glutamates humans | #110 |
| reye syndrome | #111 |
| glt1 glast | #111 |
| enzymes brain | #111 |
| 3alpha5alpha | #112 |
| evidence role | #112 |
| lymphocytes rats | #113 |
| activities | #113 |
| hypertension liver | #113 |
| expression testis | #113 |
| metabolic block | #113 |
| glutamate synaptic | #113 |
| brain preparations | #113 |
| midbrain striatum | #113 |
| ligated rats | #113 |
| nutritional management | #114 |
| rat astrocytes | #114 |
| 57 reduction | #114 |
| radioenzymatic assay | #114 |
| fco | #114 |
| nmda receptor expression | #115 |
| experimental animals | #115 |
| brain dogs | #115 |
| decreased synthesis | #116 |
| 3hmepyramine | #116 |
| gabaa gabaergic | #116 |
| mammillary body | #116 |
| pallidum putamen | #116 |
| opioid brain | #117 |
| friedreich ataxia patients | #117 |
| growing body | #117 |
| controls plasma levels | #117 |
| cholinergic deficit | #117 |
| cortex alzheimer | #117 |
| tips procedure | #117 |
| cirrhotic | #118 |
| albumin dialysis | #118 |
| arginine deficiency | #118 |
| mechanism ammonia | #118 |
| amine levels | #118 |
| myelin synthesis | #118 |
| brain dopamine | #118 |
| allopregnanolone | #118 |
| apapinduced | #119 |
| cerebral energy | #119 |
| pathologic manifestations | #119 |
| patients fatty liver | #119 |
| nervous dysfunction | #119 |
| site densities | #119 |
| hydroxylating | #119 |
| opioid beta | #119 |
| genes coding | #120 |
| balb cbyj mice | #120 |
| frontal cortex | #120 |
| glutamates | #120 |
| ouabain induced | #120 |
| pugh score | #121 |
| monoamine oxidaseb | #121 |
| 3hketanserin | #121 |
| copper manganese | #121 |
| mechanisms pathogenesis | #121 |
| unleaded | #122 |
| bergmann glia | #122 |
| nuclear signal | #122 |
| brain evidence | #122 |
| complex activities | #122 |
| brain enzyme | #122 |
| rat brain synaptosomes | #122 |
| beneficial patients | #123 |
| implicated | #123 |
| selective damage | #123 |
| normal human brains | #123 |
| newborn astrocytes cells | #124 |
| gene expression brain | #124 |
| modulatory site | #124 |
| asterixis | #124 |
| striatum cerebellum | #125 |
| ammonia control | #125 |
| neurological signs | #125 |
| icp cbf | #125 |
| ol20 | #126 |
| synthase nitroarginine | #126 |
| brain male | #126 |
| ornithine aminotransferase | #126 |
| 11cpk11195 | #126 |
| glt1 | #126 |
| ala2mephe4met0ol | #126 |
| role ammonia | #126 |
| high‐affinity | #127 |
| cytokines brain | #128 |
| neuronal cell | #128 |
| taurine uptake | #128 |
| proteins nitric | #128 |
| cox2 immunoreactivity | #129 |
| neurochemical mechanisms | #129 |
| glutamate concentrations | #129 |
| chronic alcoholic patients | #129 |
| patients friedreichs ataxia | #129 |
| agonist action | #130 |
| unanesthetized dogs | #130 |
| spontaneous activities | #130 |
| cox2 levels | #130 |
| blood ethanol levels | #130 |
| primary deficit | #131 |
| llactate dehydrogenase | #131 |
| observed brain | #131 |
| ammonia levels | #131 |
| carnitine administration | #132 |
| animals azoxymethane | #132 |
| hepatic abnormalities | #132 |
| continuous supply | #132 |
| taurine release | #132 |
| blood ammonia | #132 |
| ischemia rat | #133 |
| lipoamide dehydrogenase | #133 |
| manganese neurotoxicity | #133 |
| friedreich | #133 |
| nacetyl cysteine | #133 |
| factor pathogenesis | #133 |
| α ketoglutarate | #133 |
| site human | #133 |
| lactate accumulation | #134 |
| brain glial | #134 |
| kidney skeletal muscle | #135 |
| endogenous amino acids | #135 |
| exposure manganese | #135 |
| models acute | #135 |
| concentrations gaba | #135 |
| impact treatments | #136 |
| acid ammonia | #137 |
| 3hcitalopram | #137 |
| manganese toxicity | #137 |
| psychometric testing | #137 |
| increased intracranial pressure | #137 |
| release glutamate | #137 |
| function addition | #137 |
| pregnenolone rats | #137 |
| neuropsychiatric complications | #138 |
| spinocerebellar degeneration | #138 |
| inherited ataxias | #138 |
| tracer doses | #139 |
| chatpositive neurons | #139 |
| cycle enzyme | #139 |
| disorder animals | #139 |
| lornithine | #139 |
| glutamine alanine | #139 |
| nanomolar affinity | #139 |
| cerebral herniation | #139 |
| −70°c | #139 |
| nutritional recommendations | #140 |
| patients friedreich | #140 |
| nonbenzodiazepine | #141 |
| dehydrogenase pdh | #141 |
| cortex male | #141 |
| aminobutyric acid | #141 |
| concentrations nacl | #141 |
| development hepatic | #142 |
| cbyj | #142 |
| huntingtons chorea | #142 |
| humans isoquinolines | #142 |
| alcoholic nonalcoholic | #142 |
| gaba synaptic | #142 |
| cerebellar ataxias | #142 |
| diminished activity | #143 |
| monoamine oxidasea | #143 |
| brain glucose uptake | #143 |
| hypothermia induced | #143 |
| alternative site | #143 |
| serotonin precursor | #143 |
| lactate alanine | #143 |
| ornithine carbamoyltransferase | #144 |
| glutamateglutamine | #144 |
| allosteric agonists | #144 |
| dopamine metabolism | #144 |
| delayed myelination | #144 |
| brain gaba | #144 |
| taurine content | #144 |
| insulin hypoglycaemia | #144 |
| selective brain | #144 |
| cerebral microdialysis | #145 |
| hyperglycemic rats | #145 |
| brain tissue | #145 |
| inferior olivary nucleus | #145 |
| receptormediated responses | #146 |
| glucose load | #146 |
| brain peripheral tissues | #146 |
| brain hypothermia | #146 |
| relation degree | #146 |
| lateral vestibular | #147 |
| comparable degree | #147 |
| rapid filtration | #147 |
| increase presence | #147 |
| animals brain | #148 |
| energy failure | #148 |
| lactate brain | #148 |
| neurosteroids | #149 |
| coa acetyl | #149 |
| ohe | #149 |
| cirrhosis hepatic | #149 |
| diazepam binding inhibitor | #149 |
| western cells rats | #149 |
| acetyllcarnitine | #149 |
| glutamate neurons | #149 |
| consumption ethanol | #150 |
| failure studies | #150 |
| metabolic impairments | #150 |
| probenecid rats | #150 |
| zo2 | #151 |
| protein tyrosine nitration | #151 |
| patient tissue | #151 |
| progesterone metabolites | #151 |
| fatigue scores | #151 |
| animals astrocytes | #151 |
| female friedreich | #151 |
| selective neuronal death | #152 |
| patients hepatic encephalopathy | #152 |
| beta actin | #152 |
| inhibition binding | #153 |
| increased synthesis | #153 |
| concentrations amino | #153 |
| testis brain | #153 |
| alcoholism brain | #154 |
| tight junction proteins | #154 |
| impaired brain | #154 |
| transporter protein | #154 |
| increased cerebral | #155 |
| 15 1788 | #155 |
| brain cerebrospinal | #156 |
| experimental male rats | #156 |
| ammonia ligase | #156 |
| protein acute | #157 |
| 1788 | #157 |
| radioenzymatic | #157 |
| neuroactive | #157 |
| affinity uptake | #157 |
| ethanol day | #158 |
| korsakoff syndrome | #158 |
| dimethadione | #158 |
| prominent increase | #159 |
| nitrosative | #159 |
| glt1 expression | #159 |
| water brain | #159 |
| increased 5 | #159 |
| gfap expression | #159 |
| 3methoxytyramine | #160 |
| groups responses | #160 |
| glutamate ampa | #160 |
| brain dysfunction | #160 |
| astrocytosis | #160 |
| expression hepatic | #161 |
| neuropathologically | #161 |
| reaction ammonia | #161 |
| gfap mrna | #161 |
| diphosphatase | #161 |
| homogenates | #162 |
| perivenous | #162 |
| increased stimulation | #162 |
| mercaptans | #162 |
| synaptosomal uptake | #162 |
| neurological evaluation | #163 |
| affinity transport | #163 |
| vicious cycle | #163 |
| rats nitric | #163 |
| transketolase | #164 |
| mice acetaminophen | #164 |
| increased degradation | #164 |
| glutamine production | #164 |
| manganese concentrations | #164 |
| victor | #165 |
| human alcoholics | #165 |
| regions levels | #166 |
| brain energy metabolism | #166 |
| glast | #166 |
| bergmann glial cells | #166 |
| extracellular concentrations | #166 |
| dansyl chloride | #167 |
| severe signs | #167 |
| increased csf | #167 |
| neurotransmitter | #167 |
| male manganese | #167 |
| aids aidsrelated complex | #167 |
| benzodiazepine | #167 |
| increased cerebrospinal | #167 |
| surgical models | #168 |
| neurotoxic compounds | #168 |
| deficiency liver | #168 |
| precise role | #169 |
| malateaspartate shuttle | #169 |
| strains spectrometry | #170 |
| monophosphatase | #170 |
| increase pge2 | #171 |
| acetaminophen acetylcysteine | #171 |
| complications liver | #171 |
| elevated activities | #171 |
| medial geniculate nucleus | #171 |
| transport brain | #172 |
| expression alpha1 | #172 |
| ketoglutarate | #172 |
| apap administration | #172 |
| early increases | #172 |
| terms relationship | #172 |
| rats protective | #173 |
| complex pyruvate | #174 |
| protein gfap | #174 |
| stereotyped behavior | #175 |
| brain energy | #175 |
| chain amino | #175 |
| binding calcium | #175 |
| synergistic actions | #175 |
| dehydroascorbic | #175 |
| taurine concentrations | #175 |
| gfap immunoreactivity | #176 |
| guanidino compounds | #177 |
| neurological dysfunction | #178 |
| eaat4 | #178 |
| neurological complications | #178 |
| patients plasma levels | #179 |
| fine motor function | #179 |
| brain monoamine | #180 |
| rats csf | #180 |
| symptoms including | #180 |
| serotonin 5hydroxytryptamine | #180 |
| 3hflunitrazepam | #181 |
| experimental hepatic | #181 |
| brain concentration | #181 |
| autoradiography binding | #181 |
| dheas dhea | #182 |
| accumulation brain | #182 |
| dehydroepiandrosterone sulphate | #182 |
| biochemical consequences | #182 |
| patients mhe | #183 |
| competitive brain | #183 |
| neuropsychiatric | #183 |
| nutritional consequences | #184 |
| nnos mrna | #184 |
| animals antimetabolites | #184 |
| glast glt1 | #185 |
| neurological disorder | #185 |
| fluorescence analysis | #185 |
| amphetamine apomorphine | #185 |
| branchedchain amino acids | #185 |
| mm kcl | #186 |
| sequellae | #187 |
| controls regions | #187 |
| expression occludin | #187 |
| stress pathogenesis | #187 |
| spraguedawley serotonin | #187 |
| otc | #188 |
| pcr ratio | #188 |
| dehydrogenase complex | #188 |
| compared sham | #188 |
| cb154 | #188 |
| dawley serotonin | #188 |
| alcar | #188 |
| vasogenic brain edema | #189 |
| highaffinity uptake | #189 |
| rat cerebellum | #189 |
| agonist properties | #190 |
| aminobutyric | #190 |
| dopamine turnover | #191 |
| pregnanolone | #192 |
| specific ligand | #192 |
| aged ammonia | #192 |
| studies alterations | #193 |
| gilles tourettes syndrome | #194 |
| patient material | #194 |
| righting reflex | #194 |
| pavlov | #194 |
| of3h | #195 |
| limited therapeutic | #195 |
| gamma aminobutyric | #195 |
| patients immunohistochemistry | #195 |
| intracellular receptors | #196 |
| mice acute | #197 |
| tissue patients | #197 |
| expression tight | #197 |
| unaltered | #198 |
| manganese compounds | #198 |
| guanidino | #198 |
| concomitant loss | #198 |
| astrocyte function | #198 |
| mrna protein expression | #198 |
| thalamus hippocampus | #199 |
| glutamatergic synaptic | #200 |
| experimental chronic | #200 |
| mitochondria neurons | #200 |
| noradrenaline transporter | #200 |
| 35 degrees | #200 |
| substitutive | #200 |
| etiology patients | #200 |
| csf concentrations | #201 |
| highest density | #201 |
| brainstem structures | #201 |
| synthetase expression | #201 |
| severity liver disease | #202 |
| cerebral glucose utilization | #202 |
| translation clinic | #202 |
| activation brain | #202 |
| equal | #202 |
| activities increased | #203 |
| therapeutic interventions | #203 |
| vitro receptor | #203 |
| benzodiazepine binding | #204 |
| chronic alcohol abuse | #204 |
| ketone oxidoreductases | #205 |
| cns dysfunction | #205 |
| grc | #206 |
| poor nutrition | #206 |
| manganism | #206 |
| trials low risk | #206 |
| cuznsod | #206 |
| ldh1 | #207 |
| ldh5 | #207 |
| central noradrenergic | #207 |
| immunohistochemistry messenger receptors | #209 |
| astrocytic response | #209 |
| laboratory rat | #209 |
| neuropathological studies | #209 |
| concomitant increase | #210 |
| ethanol increased | #210 |
| overt hepatic | #210 |
| uptake pattern | #210 |
| bergmann | #210 |
| millimolar concentrations | #211 |
| laspartate | #212 |
| histopathological studies | #212 |
| cns gaba | #212 |
| patients liver dysfunction | #212 |
| brain structures | #212 |
| isoquinolines male | #212 |
| cerebellum striatum | #213 |
| plasma ammonia | #214 |
| address issue | #214 |
| gabaa receptor agonist | #214 |
| patients died | #214 |
| 3h8 | #215 |
| role pathogenesis | #215 |
| animals liver | #216 |
| nitrite nitrate levels | #216 |
| glutamine cycle | #216 |
| key factor | #216 |
| failure mice | #216 |
| bbb breakdown | #217 |
| noradrenergic function | #217 |
| glutamine synthetase activity | #217 |
| cultured rat astrocytes | #218 |
| taurine animals | #219 |
| thiamine vitamin | #219 |
| 3hro | #219 |
| inbred strains spectrometry | #220 |
| agonal | #221 |
| glutamate exposure | #221 |
| excitatory neurotransmitters | #221 |
| new therapeutic opportunities | #221 |
| 3 post | #222 |
| level severity | #222 |
| terry | #223 |
| deficient animals | #224 |
| death mechanisms | #224 |
| cyclase sgc | #225 |
| vulnerable period | #226 |
| 2 quality | #226 |
| gaba receptor | #227 |
| il1beta mrna | #228 |
| exposure inhalation | #228 |
| gaba cns | #228 |
| hepatic microcirculation | #228 |
| excitatory transmitter | #229 |
| cortical synaptosomes | #229 |
| animals effects | #229 |
| acute chronic exposure | #229 |
| muscarinic cholinergic | #230 |
| mk801 treatment | #230 |
| opca | #230 |
| shunt | #230 |
| cholestatic rats | #230 |
| glutamate excitotoxicity | #231 |
| hippocrates | #231 |
| receptor ligands | #231 |
| previous report | #231 |
| extracellular glutamate | #232 |
| rats weeks | #233 |
| spraguedawley reference values | #234 |
| glutamate transport | #234 |
| increased intracranial | #234 |
| increasing evidence | #234 |
| brain deposition | #235 |
| phosphate esters | #235 |
| cau | #235 |
| pair fed | #236 |
| liver injury mice | #236 |
| resonance study | #236 |
| serotonin tryptophan | #237 |
| 3hglutamate | #237 |
| pdh complex | #238 |
| glial proliferation | #238 |
| lc3 lipidation | #238 |
| encephalopathy mhe | #239 |
| animals rats | #239 |
| multiple systematic reviews | #240 |
| reduced glutathione levels | #240 |
| concentrations elevated | #240 |
| levels glutamate | #240 |
| binding brain | #240 |
| end‐stage liver disease | #240 |
| nacl kcl | #241 |
| caudate putamen | #241 |
| minimal hepatic | #241 |
| psychoactive medications | #241 |
| presynaptic neuron | #241 |
| brain samples | #242 |
| cycle disorders | #242 |
| 13cacetate | #242 |
| neurobehavioral | #243 |
| treatment central | #243 |
| glur2 | #243 |
| sgc | #243 |
| neuronal membrane | #244 |
| manganese concentration | #244 |
| alf patients | #244 |
| normal processes | #244 |
| cerebral cortex hippocampus | #244 |
| neuronal localization | #244 |
| aged monoamine | #245 |
| hypothalamus hypothalamus | #245 |
| neurologic assessment | #246 |
| tritium animals | #246 |
| unchanged | #246 |
| glutamine concentration | #246 |
| bloodbrain barrier breakdown | #246 |
| acids animals | #246 |
| nonpregnant rats | #247 |
| synaptosomal preparations | #247 |
| soluble guanylate | #247 |
| plasma brain | #247 |
| neuroactive steroids | #248 |
| histaminergic | #248 |
| 5 hydroxyindoleacetic | #248 |
| hippocampal sclerosis | #248 |
| minimal hepatic encephalopathy | #248 |
| deficient rats | #249 |
| allosteric coupling | #249 |
| betaep | #249 |
| glutamate transporter glt1 | #250 |
| synaptic transmission | #250 |
| increased expression | #250 |
| findings activation | #251 |
| reactive nitrogen intermediates | #251 |
| glutamate gaba | #251 |
| fatigue chronic | #252 |
| gaba uptake | #252 |
| symptoms brain | #253 |
| animals aspartic | #253 |
| reduced cerebral | #253 |
| focal loss | #254 |
| rats taurine | #255 |
| watersoluble vitamins | #256 |
| rat cerebellar | #256 |
| brain caudate | #256 |
| brain disorder | #257 |
| 4513 | #257 |
| alterations expression | #257 |
| soluble guanylate cyclase | #257 |
| therapeutic measures | #257 |
| norepinephrine turnover | #257 |
| mhe | #258 |
| pallidum | #258 |
| animals ataxia | #258 |
| receptor autoradiography | #259 |
| – brain | #259 |
| ed1 | #259 |
| transporters amino | #259 |
| rats time factors | #259 |
| choline acetyltransferase | #259 |
| phenylalanine levels | #260 |
| agents rats | #260 |
| glutamine synthetase | #260 |
| precipitating factors | #260 |
| liver liver failure | #261 |
| gene expression alterations | #261 |
| treatment neurological disorders | #262 |
| endogenous ligands | #262 |
| binding ligands | #262 |
| liver skeletal muscle | #262 |
| neurological impairment | #263 |
| acetyl carnitine | #263 |
| gamma tumor | #264 |
| liver testis | #264 |
| muscle rigidity | #264 |
| concentrations brain | #264 |
| alcoholic male | #264 |
| spf | #264 |
| rats compared | #265 |
| gabaergic neurotransmission | #265 |
| calleja | #265 |
| cisterna | #265 |
| cerebellar pathology | #266 |
| male c57bl6 mice | #267 |
| reactive gliosis | #267 |
| dopamine noradrenaline | #267 |
| dopamine spiperone | #267 |
| electrically stimulated | #268 |
| isoquinolines | #268 |
| protein gene expression | #268 |
| cell volume regulation | #268 |
| contributory | #269 |
| expression nitric | #270 |
| sleep abnormalities | #271 |
| hepatic | #271 |
| female hepatic | #271 |
| displaceable | #272 |
| microdialysates | #272 |
| hydroxyindoleacetic acid | #272 |
| octanoic acid | #272 |
| pharmacological manipulation | #272 |
| brain human | #272 |
| neurotransmitter systems | #274 |
| brains | #274 |
| greenwood | #276 |
| expression brain | #277 |
| quin | #277 |
| normal conditions | #277 |
| neuronal cell death | #278 |
| glutamate uptake | #279 |
| neurotoxic action | #280 |
| tryptamine | #280 |
| national association | #280 |
| gamma liver | #280 |
| striatum cerebral cortex | #281 |
| 14c2 | #281 |
| microassay | #281 |
| metal toxicity | #281 |
| gaba levels | #282 |
| intracranial hypertension | #282 |
| guanylate cyclase | #282 |
| maoa | #283 |
| glur3 | #283 |
| severe neurological | #284 |
| behavioural impairment | #284 |
| 3mt | #284 |
| cortical astrocytes | #284 |
| nitrated proteins | #285 |
| ucds | #285 |
| concentrations dopamine | #285 |
| ht release | #285 |
| barrier breakdown | #285 |
| acute hepatic failure | #287 |
| glomerular filtrate | #287 |
| deficiency disorders | #288 |
| excitatory amino acids | #289 |
| acid astrocytes | #289 |
| adult values | #290 |
| reduction oxidative stress | #290 |
| apap hepatotoxicity | #290 |
| azoxymethane | #291 |
| brain cerebellum | #292 |
| mice cerebral | #292 |
| human liver disease | #292 |
| patients fatigue | #292 |
| ligands male | #292 |
| failure rats | #293 |
| effects hypothermia | #293 |
| reduced capacity | #293 |
| autoradiographic studies | #293 |
| concentrations zinc | #293 |
| glutamine | #293 |
| brain regional | #293 |
| odn | #294 |
| blood – | #294 |
| induced swelling | #294 |
| altered expression | #294 |
| substantial increases | #295 |
| synthase expression | #296 |
| betaactin | #297 |
| rats increased | #297 |
| rats western cells | #300 |
| overt hepatic encephalopathy | #300 |
| groups sham | #304 |
| dawley receptors opioid | #304 |
| actin mrna | #304 |
| brain choline | #304 |
| rifamycins rifaximin | #305 |
| severe alterations | #306 |
| damaged liver | #306 |
| cytotoxic mechanism | #306 |
| lnoarg | #306 |
| gamma aminobutyric acid | #306 |
| powerful antioxidant | #307 |
| glutamate | #307 |
| selection model | #307 |
| 3hsch | #307 |
| cerebral function | #308 |
| dihydrolipoamide | #308 |
| bioaccumulation | #308 |
| tight junction protein | #310 |
| molecular biological techniques | #310 |
| serotonin metabolism | #311 |
| agonists gaba | #312 |
| 4864 | #312 |
| gaba taurine | #312 |
| brain genes | #312 |
| treatment rats | #313 |
| rats messenger | #313 |
| male osmolar | #314 |
| secondary biliary cirrhosis | #315 |
| chloride animals | #316 |
| receptors glutamate | #316 |
| brain serotonin | #316 |
| mice mutant | #318 |
| adjacent sections | #318 |
| nitrogen metabolism | #318 |
| basal ganglia patients | #319 |
| mitochondrial proliferation | #319 |
| humans manganese | #319 |
| quantitative autoradiography | #319 |
| cultured hippocampal neurons | #320 |
| rats brain | #320 |
| cell death mechanisms | #320 |
| tailpipe | #321 |
| dehydrogenase activity | #321 |
| eaat3 | #322 |
| 235triphenyltetrazolium chloride | #322 |
| isethionate | #323 |
| aqp4 expression | #324 |
| thalamus | #325 |
| acid 5 | #325 |
| neurochemical studies | #327 |
| decreased brain | #327 |
| nervous function | #327 |
| complications outcome | #327 |
| olivopontocerebellar | #328 |
| 5 hiaa | #328 |
| pathol | #329 |
| uptake increased | #329 |
| flumazenil | #330 |
| cerebellar astrocytes | #330 |
| sites human | #331 |
| β endorphin | #331 |
| uptake brain | #333 |
| proinflammatory cytokines | #333 |
| aaas | #333 |
| locomotor | #333 |
| experimental rat | #334 |
| hydroxyindoleacetic | #335 |
| neurotransmitter uptake | #335 |
| 13cglucose | #335 |
| increased binding | #335 |
| 8 rats | #336 |
| brain accumulation | #336 |
| nitrotyrosine | #337 |
| inhalation exposure | #338 |
| responsible | #339 |
| cortex brain | #339 |
| transport defect | #340 |
| positive synergistic | #340 |
| pdh activity | #341 |
| human hepatic | #341 |
| biological plausibility | #341 |
| cerebral cortical | #342 |
| mutant rats | #342 |
| reyes syndrome | #343 |
| benzodiazepine site | #344 |
| brain 5 | #344 |
| altered mental status | #344 |
| placebo improvement | #345 |
| dehydrogenase humans | #345 |
| dansyl | #346 |
| activation nmda | #346 |
| vulnerable | #347 |
| acid gaba | #347 |
| intraventricularly | #347 |
| control values | #347 |
| marked decreases | #349 |
| bdl rats | #349 |
| pigs groups | #350 |
| glutamate levels | #350 |
| increased immunoreactivity | #350 |
| alanine amino | #351 |
| nonalcoholics | #351 |
| patients dying | #351 |
| cortex cerebellum | #352 |
| consequent increase | #352 |
| manganese | #353 |
| series studies | #354 |
| apapinduced liver injury | #354 |
| western brain | #354 |
| consumption rats | #354 |
| proinflammatory cytokine release | #354 |
| expression increased | #355 |
| complex male | #356 |
| thiamine supplementation | #356 |
| duct ligated | #356 |
| brain excitability | #356 |
| deterioration | #357 |
| receptor sites | #357 |
| 5hiaa | #358 |
| postmortem brain tissue | #358 |
| wellestablished model | #358 |
| onset brain | #359 |
| proposed role | #359 |
| convulsions | #359 |
| increase extracellular | #361 |
| glutamate homeostasis | #361 |
| mammalian brain | #361 |
| autoradiography brain | #362 |
| neuroinflammatory | #363 |
| metabolic events | #363 |
| reduced plasma | #363 |
| histamine h1 | #363 |
| rats cns | #364 |
| 9998 | #365 |
| expression pglycoprotein | #365 |
| white matter structures | #366 |
| acids branched | #366 |
| neuroglia | #367 |
| posttranslational rats rats | #367 |
| folic acid antagonists | #368 |
| methoxytyramine | #369 |
| 56 mm | #370 |
| sulfate dheas | #370 |
| cerebral oedema | #370 |
| nacetylcysteine nac | #371 |
| sites binding | #371 |
| glutamate synthesis | #372 |
| perineuronal | #372 |
| metabolic impairment | #372 |
| induction cox2 | #373 |
| chemical forms | #373 |
| acid rats | #373 |
| affinities | #373 |
| encountered | #373 |
| accompanied | #375 |
| astrocytes microglia | #375 |
| 3hmk801 | #375 |
| highaffinity | #376 |
| ca1 subfield | #376 |
| anaplerotic | #376 |
| antioxidant nacetylcysteine | #377 |
| nh3 nh4 | #377 |
| acetyltransferase chat | #378 |
| cirrhosis alcoholic | #378 |
| ngnitro | #378 |
| novo synthesis | #379 |
| positive allosteric | #380 |
| cell swelling | #380 |
| basal ganglia thalamus | #380 |
| epileptic patients | #382 |
| pons | #382 |
| acute chronic | #382 |
| pregnenolone | #383 |
| overwhelming evidence | #383 |
| densities | #385 |
| exposure brain | #386 |
| dihydrolipoamide dehydrogenase | #386 |
| transporter glut1 | #386 |
| phenylalanine tyrosine | #388 |
| hyperglycemic conditions | #390 |
| pbz | #390 |
| acetylcholine synthesis | #390 |
| focal cerebral ischemia | #390 |
| cerebral edema | #390 |
| effects administration | #390 |
| pet assessment | #392 |
| mice enos | #393 |
| phthalaldehyde | #394 |
| thioacetamide induced | #394 |
| glycine transporter | #394 |
| phenylacetate | #395 |
| scatchard plot | #395 |
| model acute | #396 |
| failure induced | #396 |
| positive allosteric modulator | #397 |
| carnitine levels | #397 |
| omega 3 | #398 |
| pathophysiological mechanism | #399 |
| bbb permeability | #399 |
| methylhistamines | #399 |
| patients platelets | #400 |
| vestibular nucleus | #400 |
| korsakoff | #400 |
| acetyl coa | #400 |
| insulin metabolism | #401 |
| frontal | #401 |
| inferior olive | #402 |
| falls patients | #402 |
| radioligands | #403 |
| rats purpose | #405 |
| concerted effort | #407 |
| liver gut | #407 |
| marker enzymes | #408 |
| methionine sulfoximine | #408 |
| neuropathologic | #408 |
| releasable | #410 |
| adult activities | #412 |
| dopaminergic neurones | #414 |
| shunt surgery | #415 |
| patients ataxia | #416 |
| forebrain cholinergic | #416 |
| ketamine anesthesia | #417 |
| gabaa gammaaminobutyric acid | #418 |
| intellectual function | #419 |
| pk11195 | #419 |
| alcoholic liver | #421 |
| fibrillary | #421 |
| serotonin content | #422 |
| regions brain | #423 |
| rats animal | #423 |
| asparagine | #423 |
| housekeeping gene | #423 |
| sham operation | #423 |
| hypothermia | #424 |
| diazepam binding | #424 |
| salinetreated controls | #425 |
| tissues brain | #425 |
| aidsrelated complex | #426 |
| direct evidence | #426 |
| binding parameters | #426 |
| exsanguination | #427 |
| rats mutant | #428 |
| hepatocyte necrosis | #430 |
| protein utilization | #431 |
| glutamine levels | #431 |
| sacrificed | #432 |
| peripheral benzodiazepine | #434 |
| dawley tissue | #434 |
| hippocampus frontal cortex | #434 |
| onset severe | #434 |
| rats experimental | #435 |
| cytotoxic edema | #437 |
| patients pbc | #437 |
| 12 control subjects | #438 |
| benzoate | #438 |
| addition evidence | #439 |
| isoquinoline | #440 |
| ligand selectivity | #440 |
| central process | #441 |
| attenuates | #441 |
| acids brain | #442 |
| neurological syndrome | #442 |
| 13c enrichment | #443 |
| brain microglia | #443 |
| arginine transport | #443 |
| patients encephalopathy | #443 |
| brain glucose | #443 |
| cultured astrocytes | #444 |
| glyt1 | #444 |
| cultured cerebellar | #445 |
| operated | #445 |
| compounds rats | #446 |
| butterworth | #446 |
| brain water content | #447 |
| pyruvate dehydrogenase | #450 |
| topographic distribution | #450 |
| liver skeletal | #450 |
| agematched controls | #450 |
| brain tissue patients | #451 |
| acute mice mice | #451 |
| effects liver | #451 |
| t1weighted mri | #453 |
| severe liver | #454 |
| s100beta | #455 |
| immunohistochemistry liver | #455 |
| aged amino | #455 |
| central pontine myelinolysis | #455 |
| brain swelling | #456 |
| h1 receptor | #456 |
| body evidence | #456 |
| parachlorophenylalanine | #456 |
| impaired liver function | #457 |
| vitro binding assay | #457 |
| aspartic | #457 |
| brain monoamines | #458 |
| neurobiology | #460 |
| brain alterations | #460 |
| effects brain | #460 |
| increased release | #461 |
| neuropathology | #462 |
| substantial body | #463 |
| equivocal | #463 |
| 5ht levels | #463 |
| neurological | #465 |
| hepatic glutathione | #466 |
| dentate nuclei | #466 |
| neurobehavioural | #467 |
| studies reveal | #468 |
| central cholinergic | #469 |
| glutamic acid | #469 |
| reye | #470 |
| monoamine metabolism | #471 |
| amino acid levels | #471 |
| urea production | #472 |
| patients hippocampal | #473 |
| alcoholic liver disease | #473 |
| putamen patients | #474 |
| glutamate transporters | #475 |
| ox42 | #475 |
| gaba glycine | #475 |
| liver dysfunction | #475 |
| inherited defects | #476 |
| thiamin | #477 |
| alcohol brain | #477 |
| thiamine pyrophosphate | #479 |
| release proinflammatory cytokines | #479 |
| acid humans | #480 |
| amino acid transporters | #480 |
| parkinsons diseases | #481 |
| acute male | #482 |
| inferior colliculus | #482 |
| images brain | #482 |
| brain csf | #484 |
| chronic alcoholics | #484 |
| nitric oxide synthase | #487 |
| manganese levels | #488 |
| concentrations increased | #488 |
| triphosphate amino | #488 |
| acids rats | #490 |
| urea ammonia | #491 |
| multinuclear nmr spectroscopy | #491 |
| increased production | #492 |
| jadad | #492 |
| role brain | #492 |
| glial fibrillary | #492 |
| ischemic cortex | #493 |
| pet ligand | #494 |
| aspartate glutamate | #495 |
| pyruvates | #495 |
| ammonium ion | #495 |
| outer mitochondrial membrane | #495 |
| emitted radiation | #495 |
| hexanones | #496 |
| schaffer collaterals | #496 |
| rat hippocampal | #496 |
| ataxic | #499 |
| neurons nitric | #499 |
| brain diseases | #501 |
| beneficial | #502 |
| 3hd | #505 |
| brain synaptosomes | #505 |
| 5 hydroxytryptophan | #507 |
| ketoacid | #508 |
| acid metabolites | #509 |
| fatal complication | #510 |
| gene therapy treatment | #510 |
| histamine h1 receptors | #511 |
| increased icp | #511 |
| medulla oblongata | #511 |
| discrete brain regions | #511 |
| exposure rats | #515 |
| acids amino | #516 |
| abnormal metabolism | #517 |
| major feature | #517 |
| humans neurons | #518 |
| chain acyl | #518 |
| concentrations 5 | #521 |
| ltrp | #523 |
| neurochemistry | #523 |
| inflammation mediators | #525 |
| toxic agents | #526 |
| rat hippocampal slices | #530 |
| brain female | #530 |
| aom | #531 |
| dawley receptors | #533 |
| agents dopamine | #533 |
| receptor complex | #533 |
| ligation bdl | #534 |
| 100 µg | #534 |
| muscle loss | #534 |
| focal cerebral | #534 |
| neurotoxins | #534 |
| combined actions | #535 |
| cerebellum cerebral | #536 |
| bdz | #537 |
| divalent metals | #538 |
| carroll | #539 |
| selective | #539 |
| alcoholic cirrhosis | #539 |
| severe liver disease | #539 |
| tipss | #540 |
| tyrosine nitration | #541 |
| hydroxymethylbilane | #541 |
| moderate drinking | #542 |
| brain astrocytes | #542 |
| moderate increase | #543 |
| aspartate | #544 |
| portasystemic | #544 |
| pyruvate oxidation | #544 |
| organic osmolytes | #545 |
| liver enzyme | #545 |
| chronic liver | #545 |
| energy metabolism | #546 |
| model hepatic | #547 |
| dissected | #548 |
| unanesthetized rats | #548 |
| cumene | #548 |
| nitrosative stress | #548 |
| alpha1 alpha2 | #549 |
| unconjugated bilirubin | #549 |
| thalamic lesions | #550 |
| taurine levels | #551 |
| brain region | #551 |
| genes brain | #553 |
| fatigue patients | #553 |
| brain cytokines | #554 |
| glutamatergic neurotransmission | #554 |
| water ammonia | #555 |
| increased uptake | #555 |
| nmda receptor antagonist | #556 |
| disease liver | #557 |
| failure liver | #558 |
| rats bile | #558 |
| gabaergic gaba | #563 |
| microdialysate | #563 |
| levels hepatic | #563 |
| hydroxytryptophan | #564 |
| cortex female humans | #564 |
| microglial response | #566 |
| mhe patients | #567 |
| malnutrition patients | #567 |
| serum bilirubin levels | #567 |
| ischemia liver | #568 |
| established role | #568 |
| autoradiographic | #569 |
| lhistidine | #569 |
| transient increase | #569 |
| neurotransmitter glutamate | #571 |
| neurologic signs | #573 |
| gaba | #574 |
| pathway brain | #574 |
| decarboxylase gad | #576 |
| outcome liver | #577 |
| octopamine | #577 |
| apap induced | #578 |
| expression mrnas | #578 |
| il1beta expression | #578 |
| liver pathology | #580 |
| oxobutanoate | #580 |
| biogenic monoamines | #581 |
| octanoic | #582 |
| increases blood | #582 |
| pyridinium compounds | #582 |
| brain metabolism | #583 |
| histological lesions | #583 |
| 5hydroxytryptophan | #584 |
| neurobehavioral effects | #588 |
| edema formation | #589 |
| bloodbrain barrier | #589 |
| monoamine oxidases | #589 |
| human spinal | #590 |
| activity brain | #591 |
| 13c nuclear | #592 |
| accompanying | #593 |
| toxic levels | #593 |
| endogenous opioid | #594 |
| pathophysiological mechanisms | #594 |
| catalytic sites | #594 |
| t1weighted imaging | #597 |
| highenergy phosphates | #598 |
| aminobutyric acid gaba | #599 |
| extracellular fluid | #600 |
| neuronal nitric | #601 |
| leigh disease | #601 |
| include | #601 |
| neuroglial | #601 |
| taurine | #602 |
| 3hcholine | #602 |
| largest increases | #604 |
| methyltyrosines | #606 |
| male nitric | #606 |
| glutamine humans | #607 |
| vermis | #608 |
| extracellular compartment | #608 |
| molecular studies | #609 |
| cirrhosis | #609 |
| acetyl | #609 |
| male metabolism | #610 |
| cortical slices | #610 |
| ammonia concentration | #612 |
| ventricular enlargement | #612 |
| friedreich ataxia | #612 |
| animals autoradiography | #614 |
| spraguedawley receptors | #615 |
| neurovascular unit | #615 |
| axonopathy | #616 |
| selective accumulation | #616 |
| microglial | #616 |
| artery ligation | #618 |
| c57bl6 mice | #618 |
| tricarboxylic | #618 |
| normothermic | #619 |
| mammillary | #620 |
| increased expression genes | #620 |
| acidic protein | #621 |
| junction proteins | #624 |
| controls addition | #624 |
| hippocampal slices | #625 |
| new approaches | #625 |
| oxidase mao | #625 |
| amino acid concentrations | #626 |
| semi quantitative | #626 |
| edema brain | #627 |
| hepatic levels | #628 |
| experimental animal model | #628 |
| nimesulide | #628 |
| clf | #629 |
| dbi | #629 |
| free radical formation | #630 |
| blood borne | #631 |
| neurobehavior | #631 |
| dehydroepiandrosterone sulfate dheas | #633 |
| ataxia | #634 |
| contributory role | #635 |
| allosteric interactions | #635 |
| urea synthesis | #635 |
| dopamine striatum | #635 |
| encephalopathies | #636 |
| neurological damage | #637 |
| astrocyte cultures | #638 |
| neuroinflammation | #638 |
| harper | #638 |
| levels observed | #638 |
| cerebellum | #639 |
| deleterious effects | #640 |
| conduction velocities | #640 |
| rats glucose | #641 |
| acid hippocampus | #643 |
| receptor densities | #644 |
| neuronal excitability | #645 |
| excitatory inhibitory | #645 |
| early role | #646 |
| nntetraacetic acid | #647 |
| frontal temporal | #647 |
| chronic exposure | #647 |
| desoxycorticosterone | #652 |
| matsumoto | #652 |
| excitatory amino | #653 |
| branched chain | #653 |
| cytokines tnf | #654 |
| tricarbonyl | #655 |
| gabaa gaba | #656 |
| 1400w | #657 |
| mental state | #657 |
| acid transporter | #659 |
| enos gene | #659 |
| dawley sodium | #661 |
| potential toxic effects | #662 |
| cerebral cortex | #663 |
| uptake release | #664 |
| metabolic basis | #665 |
| 3hspiperone | #665 |
| fibrillary acidic | #666 |
| cycle enzymes | #668 |
| heterogeneous distribution | #669 |
| cogent | #670 |
| inhibitory properties | #673 |
| minocycline treatment | #673 |
| metabolism rats | #675 |
| potassium concentration | #675 |
| 7ni | #678 |
| 7nitroindazole | #679 |
| evoked release | #682 |
| reduction expression | #683 |
| neuropathological | #683 |
| ornithine | #684 |
| regional specificity | #684 |
| excitatory | #684 |
| ammonia treatment | #684 |
| millimolar | #684 |
| gammaaminobutyric acid | #685 |
| frontal cortex hippocampus | #686 |
| cerebral atrophy | #688 |
| spraguedawley | #688 |
| microg m3 | #688 |
| protein tspo | #691 |
| hepatic damage | #695 |
| ca1 pyramidal cells | #695 |
| brain regions | #695 |
| fulminant | #695 |
| daily administration | #697 |
| acetylcysteine animals | #697 |
| synthase nnos | #698 |
| extrapyramidal | #698 |
| enzyme complex | #699 |
| bcaas | #700 |
| brain disorders | #700 |
| blood‐brain barrier | #701 |
| immunolabeling | #701 |
| normoglycemic | #703 |
| ammonia production | #703 |
| autophagy markers | #704 |
| rats dawley receptors | #705 |
| quinolinic | #706 |
| ethanol ingestion | #706 |
| acetylcysteine nac | #709 |
| cornerstone | #711 |
| glut1 expression | #714 |
| cortex rats | #715 |
| reductions | #719 |
| phenylbutyrate | #723 |
| bmax values | #723 |
| 6 day | #724 |
| surgical samples | #724 |
| nutritional status patients | #725 |
| acute hepatic | #726 |
| ketoglutaric | #729 |
| serotoninergic | #730 |
| contribute | #730 |
| expression isoforms | #736 |
| intensive study | #737 |
| piribedil | #740 |
| fluorimetric detection | #741 |
| mm nacl | #742 |
| ligation liver | #744 |
| dopaminergic function | #745 |
| biochemical alterations | #746 |
| cerebellar granule | #746 |
| methylglucose | #747 |
| tight junction | #748 |
| male microdialysis | #749 |
| glucose oxidation | #749 |
| choline acetyltransferase chat | #752 |
| cytochrome oxidase activity | #753 |
| scatchard analysis | #754 |
| alterations | #754 |
| illness terminology | #756 |
| portasystemic shunt | #757 |
| glutamate glu | #757 |
| delta receptors opioid | #758 |
| alcoholism animals | #760 |
| ergic | #761 |
| varying degrees | #762 |
| ammonium chloride | #763 |
| substantial evidence | #763 |
| tryptamines | #764 |
| opioid delta receptors | #764 |
| neutron activation analysis | #765 |
| levels 5 | #768 |
| gdh | #769 |
| normal liver function | #769 |
| excitotoxic | #769 |
| barrier permeability | #770 |
| control genes | #773 |
| newborn astrocytes | #774 |
| peripheral organs | #775 |
| cellular energy metabolism | #776 |
| ethanol consumption | #777 |
| increased blood | #778 |
| brain gene | #780 |
| hepatic dysfunction | #783 |
| species reactive | #783 |
| receptor function | #784 |
| methods principal findings | #785 |
| mnsod | #785 |
| cortex thalamus | #785 |
| messenger rats | #786 |
| glut1 | #786 |
| nakatpase | #787 |
| globus pallidus | #787 |
| early alterations | #789 |
| brain function | #790 |
| probenecid | #791 |
| spraguedawley receptors messenger | #791 |
| major route | #791 |
| glyceraldehyde3 phosphate | #792 |
| 2 fold | #792 |
| hypothermia treatment | #793 |
| specific ligands | #793 |
| rat cerebral | #795 |
| selective effects | #796 |
| typical cases | #796 |
| plasma clearance | #797 |
| ethanol solution | #797 |
| neuronal integrity | #799 |
| severity liver | #799 |
| nitroarginine | #801 |
| pertinence | #805 |
| hiaa | #806 |
| nh4cl | #807 |
| ultimately | #807 |
| neurotoxic effects | #807 |
| pyruvate metabolism | #808 |
| mrna protein | #809 |
| chat | #811 |
| predilection | #812 |
| acute brain injury | #812 |
| role astrocytes | #812 |
| enos mice | #815 |
| coma | #816 |
| update | #816 |
| glycolytic activity | #819 |
| cerebellar granule cells | #820 |
| nmethyldaspartate | #822 |
| eaat1 | #823 |
| pbc patients | #823 |
| iii groups | #824 |
| complete disappearance | #825 |
| pathogenesis treatment | #825 |
| edema | #826 |
| age matched | #826 |
| atomic absorption spectrometry | #828 |
| alzheimer type | #828 |
| synthesis rates | #829 |
| nitrite nitrate | #829 |
| glial | #830 |
| neurons astrocytes | #831 |
| water homeostasis | #831 |
| diseases alcoholic | #832 |
| alcoholics | #832 |
| eaat2 | #833 |
| monoamine | #834 |
| decreases | #835 |
| manifested | #836 |
| operated rats | #837 |
| pathophysiological | #837 |
| explain | #838 |
| amino3 | #838 |
| oligonucleotide primers | #839 |
| animal cell | #839 |
| treatment improvement | #841 |
| metabolic disorder | #842 |
| expression ho1 | #843 |
| cell loss | #845 |
| hypothermia patients | #846 |
| isotopomer | #846 |
| cfos cjun | #848 |
| pharmacokinetic analyses | #849 |
| oblongata | #849 |
| chronic alcohol consumption | #851 |
| gaba receptors | #852 |
| receptor mediated | #853 |
| nmda receptor | #853 |
| matched age | #854 |
| daily injections | #854 |
| consequence | #856 |
| glutamatergic | #856 |
| compromised | #857 |
| bbb integrity | #858 |
| griess | #861 |
| aromatic amino acids | #861 |
| alcoholic | #862 |
| order role | #862 |
| hepatic disease | #862 |
| continues | #863 |
| antioxidant action | #863 |
| inflammatory mechanisms | #866 |
| thalamic nuclei | #866 |
| cerebellar ataxia | #867 |
| early induction | #867 |
| normalizes | #869 |
| manifest | #870 |
| chronic liver disease | #871 |
| oxide rats | #872 |
| fpc | #874 |
| succimer | #877 |
| low risk bias | #880 |
| nmda receptor antagonists | #881 |
| excitatory amino acid | #882 |
| cisterna magna | #882 |
| barrier bbb | #882 |
| greater susceptibility | #882 |
| stimulated release | #887 |
| dehydrogenase | #890 |
| western cells | #890 |
| comatose | #890 |
| shamoperated animals | #891 |
| multinuclear | #891 |
| cultured hippocampal | #892 |
| interfere | #893 |
| nutritional intervention | #893 |
| mutant mouse | #894 |
| lipoamide | #897 |
| neuropsychiatric symptoms | #898 |
| exp | #899 |
| acetaminophen apap | #900 |
| sulfoximine | #901 |
| dizocilpine maleate | #901 |
| common death | #901 |
| cirrhosis pbc | #902 |
| lowering | #904 |
| neurons rna | #904 |
| experimental animal | #905 |
| quinolinic acid | #905 |
| autopsy brain | #907 |
| pcs | #907 |
| brain activities | #908 |
| factor tumor | #912 |
| acid animals | #912 |
| pathophysiology | #913 |
| selective ligands | #913 |
| colliculus | #913 |
| publication acidosis | #919 |
| placebo intervention | #919 |
| microdialysis study | #920 |
| cerebellar degeneration | #920 |
| rat cortical | #922 |
| liver homogenates | #922 |
| delta receptors | #924 |
| survival mice | #926 |
| urea cycle | #929 |
| striatum hippocampus | #930 |
| pugh | #931 |
| nacetylcysteine | #931 |
| microglial activation | #932 |
| findings evidence | #932 |
| hydroxy2di | #933 |
| activities enzymes | #936 |
| reaction water | #942 |
| hepatic diseases | #942 |
| developing rat brain | #942 |
| tartrates | #942 |
| injured liver | #943 |
| agents oxidative | #943 |
| rats exposed | #943 |
| mammalian cns | #943 |
| study liver | #943 |
| rapid removal | #945 |
| marked | #945 |
| pca | #948 |
| maladies | #949 |
| cirrhosis magnetic | #950 |
| 25mm | #951 |
| concentrations observed | #954 |
| spontaneous release | #957 |
| altered | #962 |
| spraguedawley receptors rats | #963 |
| detailed review | #964 |
| putamen | #967 |
| assay rats | #967 |
| translocator protein | #969 |
| humans hypothermia | #969 |
| moderate hypothermia | #970 |
| cerebral glucose | #971 |
| acid transport | #971 |
| increased glycolysis | #971 |
| chronic liver diseases | #971 |
| intermediary metabolism | #971 |
| nm range | #973 |
| autoradiographic study | #974 |
| aspartic acid | #979 |
| kidney heart | #979 |
| post translational modifications | #980 |
| neurological disease | #983 |
| occludin | #984 |
| oxygenase1 ho1 | #988 |
| effective measures | #990 |
| pdh | #990 |
| 9 mice mice | #990 |
| cirrhosis experimental | #991 |
| aquaporin4 | #991 |
| brain oedema | #992 |
| rats ethanol | #992 |
| spared | #993 |
| increased plasma | #993 |
| propylaminotetralin | #998 |
| damage mechanisms | #999 |
| adaptive mechanisms | #1006 |
| role oxidative stress | #1006 |
| uptake kinetics | #1008 |
| flunitrazepam | #1008 |
| soluble guanylyl | #1008 |
| rifaximin | #1009 |
| cerebro | #1009 |
| metabolic consequences | #1010 |
| rat brain | #1012 |
| neurotoxic | #1013 |
| progressing | #1013 |
| presymptomatic | #1015 |
| modulatory | #1015 |
| electrified | #1016 |
| fulminant hepatic | #1016 |
| publication amino acids | #1017 |
| ligands receptors | #1019 |
| animal models | #1020 |
| abundant evidence | #1020 |
| unsuspected | #1020 |
| acids bcaa | #1023 |
| 1h | #1023 |
| pallidus humans | #1024 |
| antioxidant anti | #1029 |
| astrocyte | #1030 |
| metabolism inborn | #1031 |
| tele | #1032 |
| microsomes | #1032 |
| etanercept treatment | #1034 |
| 7 hours | #1036 |
| muscle expression | #1038 |
| catalepsy | #1039 |
| interleukin1beta | #1041 |
| nutritional assessment | #1043 |
| monoamine oxidase | #1045 |
| pharmacology | #1048 |
| gabaergic | #1050 |
| acid decarboxylase | #1050 |
| aqp4 | #1050 |
| caudate nucleus | #1053 |
| major factor | #1053 |
| endogenous | #1055 |
| aquaporin 4 | #1056 |
| hepatolenticular | #1057 |
| specific antagonist | #1057 |
| synthetase | #1058 |
| involved pathogenesis | #1058 |
| frontoparietal cortex | #1060 |
| adaptive mechanism | #1060 |
| oxygenase1 | #1064 |
| gabaa receptors | #1066 |
| progression liver | #1067 |
| 5ht neurons | #1067 |
| sodium acetate | #1072 |
| rat hepatocytes | #1075 |
| efficacy treatment | #1075 |
| membrane preparations | #1077 |
| reflex | #1077 |
| inflammation infection | #1078 |
| glucose blotting | #1080 |
| accompanies | #1081 |
| enzyme activities | #1083 |
| gilles | #1083 |
| 34dihydroxyphenylacetic acid | #1085 |
| nonneuronal | #1086 |
| content increased | #1090 |
| complex carbohydrates | #1092 |
| lactate concentrations | #1092 |
| major players | #1095 |
| muscle brain | #1097 |
| radioligand assay | #1098 |
| awaiting | #1099 |
| intense staining | #1099 |
| rat primary | #1101 |
| baptaam | #1102 |
| normal physiological conditions | #1106 |
| tpp | #1107 |
| cell culture studies | #1107 |
| junction protein | #1108 |
| medial septum | #1109 |
| hyperintensity | #1111 |
| 5 mm | #1111 |
| assay receptors | #1113 |
| human brain tissue | #1116 |
| inflammation role | #1117 |
| patients alzheimers disease | #1117 |
| cirrhotics | #1118 |
| atrophy brain | #1122 |
| severe malnutrition | #1122 |
| ischemic core | #1127 |
| sprague | #1128 |
| cirrhosis male | #1129 |
| findings role | #1129 |
| astrocytes | #1130 |
| transient elevation | #1131 |
| amino acids | #1134 |
| tetrabenazine | #1135 |
| weight brain | #1137 |
| age controls | #1138 |
| diagonal band | #1139 |
| haloperidol humans | #1142 |
| oxide synthase | #1143 |
| receptors histamine | #1145 |
| hepatobiliary | #1146 |
| pyruvate | #1148 |
| worsens | #1153 |
| nonepileptic | #1153 |
| lactic acidosis | #1153 |
| dehydroepiandrosterone sulfate | #1154 |
| control tissue | #1157 |
| altered brain | #1162 |
| biogenic amines | #1163 |
| cresyl | #1166 |
| portosystemic | #1167 |
| h1 | #1168 |
| benzilate | #1171 |
| combustion products | #1172 |
| emax | #1173 |
| enzymologic | #1174 |
| lactate | #1177 |
| etanercept | #1179 |
| rats subjected | #1180 |
| parkinsonian symptoms | #1181 |
| glutamate dehydrogenase | #1182 |
| peripheral tissues | #1182 |
| nerve conduction | #1183 |
| rats receptors | #1185 |
| nnos | #1185 |
| urine levels | #1186 |
| principally | #1189 |
| mechanisms involved | #1191 |
| synaptic cleft | #1192 |
| cardinal features | #1192 |
| hyperintensities | #1193 |
| delta opioid | #1196 |
| causal factor | #1197 |
| rapid onset | #1198 |
| gabaa receptor | #1199 |
| transcriptase polymerase | #1201 |
| venous blood | #1204 |
| dopamine uptake | #1205 |
| dawley | #1205 |
| death cells | #1207 |
| acetyl cysteine | #1207 |
| hepatolenticular degeneration | #1209 |
| development brain | #1211 |
| increasing body | #1214 |
| direct effects | #1216 |
| stereotypy | #1218 |
| brains mice | #1220 |
| binding inhibitor | #1220 |
| radiometric | #1220 |
| pig model | #1221 |
| 5htp | #1222 |
| nmethyld | #1223 |
| fold increase | #1224 |
| neuropsychological impairment | #1226 |
| skeletal rats rats | #1226 |
| mitochondrial swelling | #1228 |
| wilson disease | #1229 |
| transjugular | #1229 |
| deprenyl | #1229 |
| 100 iu | #1232 |
| circadian rhythmicity | #1234 |
| severity assessment | #1234 |
| cultured rat | #1234 |
| hippocampus vitro | #1236 |
| hyperexcitability | #1239 |
| nakatpase activity | #1239 |
| spraguedawley receptors opioid | #1239 |
| congenitally | #1241 |
| hypermetabolism | #1242 |
| glyceraldehyde3 | #1242 |
| brain axis | #1246 |
| partial recovery | #1251 |
| elucidation | #1252 |
| kinetics male | #1253 |
| receptors neurotransmitter | #1254 |
| sprague dawley | #1255 |
| convincing evidence | #1258 |
| methyl aspartate | #1259 |
| gabaa | #1260 |
| 5hydroxyindoleacetic acid | #1261 |
| albumen | #1261 |
| hippocampus striatum | #1262 |
| clinical entities | #1262 |
| acetylcysteine | #1262 |
| myoinositol | #1264 |
| overactivation | #1270 |
| astroglial | #1271 |
| 1h 13c | #1271 |
| olfactory bulbs | #1273 |
| maleate | #1276 |
| rats expression | #1276 |
| congenital | #1281 |
| vicious | #1281 |
| apoenzyme | #1281 |
| milligram | #1281 |
| variable degree | #1282 |
| glutamate decarboxylase | #1287 |
| loss expression | #1288 |
| patients tle | #1288 |
| induced inhibition | #1289 |
| brain inflammation | #1290 |
| acid cycle | #1291 |
| metabolite | #1291 |
| acid male | #1291 |
| cortex kidney | #1292 |
| quisqualate | #1294 |
| ischemia cerebral | #1295 |
| radioreceptor | #1296 |
| rifamycins | #1296 |
| protective | #1297 |
| dawley animals | #1297 |
| deficient | #1297 |
| zinc concentrations | #1300 |
| permeability blood | #1301 |
| synaptosomes | #1302 |
| potential therapeutic approach | #1305 |
| frontoparietal | #1306 |
| 7 males | #1308 |
| opioid delta | #1308 |
| caveolin1 | #1310 |
| neuronal dysfunction | #1310 |
| 5mm | #1314 |
| liver | #1314 |
| heme oxygenase1 | #1316 |
| greater magnitude | #1317 |
| adrenals | #1318 |
| 35°c | #1319 |
| threefold | #1320 |
| receptors methyl | #1321 |
| invariably | #1324 |
| neurotransmission | #1325 |
| nanomolar | #1328 |
| dopamine serotonin | #1328 |
| appearance | #1329 |
| guanylyl | #1329 |
| animal electrophoresis | #1334 |
| major complication | #1334 |
| signaling mechanisms | #1335 |
| acetyltransferase | #1337 |
| cerebellum hippocampus | #1344 |
| phosphate dehydrogenase | #1344 |
| astrocytes cells | #1346 |
| cgmp pathway | #1349 |
| heavy drinkers | #1350 |
| transporter proteins | #1352 |
| brain effects | #1358 |
| neuronal | #1361 |
| dopamine female | #1361 |
| female globus | #1364 |
| interleukin1 receptors | #1364 |
| shunt tips | #1368 |
| male rats rats | #1369 |
| hypoglycaemic | #1375 |
| small decrease | #1378 |
| fur | #1380 |
| electrolyte balance | #1381 |
| aromatic amino | #1383 |
| bile duct ligation | #1386 |
| synergism | #1387 |
| chelation therapy | #1387 |
| nitrated | #1388 |
| gaba agonists | #1389 |
| ca2independent | #1392 |
| preliminary studies | #1394 |
| neurological sequelae | #1395 |
| transamination | #1396 |
| occipital cortex | #1401 |
| intrauterine growth | #1402 |
| immediateearly genes | #1403 |
| guanylate | #1409 |
| pallidus | #1409 |
| larginine | #1412 |
| selectively | #1416 |
| cerebral | #1417 |
| patients findings | #1425 |
| paper details | #1426 |
| normo | #1427 |
| mutant strains | #1429 |
| acute brain | #1433 |
| motor nerve | #1441 |
| paralleled | #1444 |
| shamoperated | #1445 |
| childpugh score | #1450 |
| common approaches | #1450 |
| mitochondrial membranes | #1451 |
| risk falls | #1451 |
| peripheral | #1452 |
| longer wavelength | #1453 |
| hypoglycaemia | #1455 |
| effective prevention | #1456 |
| intraventricular injections | #1456 |
| benzodiazepinones | #1459 |
| clonazepam | #1460 |
| modulatory effects | #1462 |
| hydroxydopamines | #1465 |
| studies brain | #1471 |
| quinuclidinyl | #1472 |
| swelling | #1477 |
| brain tissues | #1479 |
| patients liver disease | #1481 |
| saturable | #1482 |
| 13c | #1485 |
| 23390 | #1485 |
| deficiency | #1486 |
| excitatory neurotransmission | #1488 |
| characteristic | #1488 |
| gfap | #1491 |
| dopamine agents | #1499 |
| messenger rats rats | #1504 |
| neuroprotective role | #1505 |
| histological studies | #1509 |
| bilirubin levels | #1509 |
| primary concern | #1509 |
| volume regulation | #1512 |
| increases | #1512 |
| cortex striatum | #1513 |
| primary biliary cirrhosis | #1514 |
| receptor subunits | #1515 |
| herniation | #1516 |
| rat cerebral cortex | #1519 |
| liver disease | #1519 |
| 1h magnetic | #1523 |
| integrity | #1525 |
| glutamic acid decarboxylase | #1525 |
| tyrosine residues | #1527 |
| branched | #1530 |
| tk | #1532 |
| temporal profile | #1539 |
| increased capacity | #1541 |
| transport animals | #1546 |
| brain homogenates | #1547 |
| apomorphine | #1548 |
| acetylcarnitine | #1548 |
| cholinergic | #1549 |
| vitamins minerals | #1550 |
| tricarboxylic acid | #1551 |
| wistar receptors rats | #1552 |
| lactulose | #1554 |
| regional differences | #1557 |
| pathological hallmark | #1557 |
| neurochemical | #1559 |
| lactate levels | #1561 |
| cirrhosis liver | #1564 |
| reflexes | #1566 |
| pathological mechanisms | #1567 |
| extracellular | #1568 |
| neurotransmitters | #1572 |
| poor diet | #1575 |
| major forms | #1579 |
| brain cerebral | #1580 |
| light energy | #1584 |
| scad | #1584 |
| biliary cirrhosis | #1584 |
| epilepsy tle | #1585 |
| tryptophan | #1585 |
| brain cell | #1586 |
| patients review | #1589 |
| ependymal cells | #1591 |
| ngnitrolarginine methyl ester | #1592 |
| new findings | #1594 |
| lesser extent | #1595 |
| pyruvate carboxylase | #1596 |
| aspartate nmda | #1598 |
| llysine | #1600 |
| pbc | #1601 |
| rat hippocampus | #1602 |
| mri signal | #1605 |
| brain slices | #1606 |
| specific therapies | #1606 |
| ouabain | #1615 |
| tdp | #1615 |
| travelled | #1618 |
| unanesthetized | #1623 |
| anastomosis | #1626 |
| acute mice | #1627 |
| neuroglia neurons | #1629 |
| deficient diet | #1631 |
| failure mechanisms | #1633 |
| receptor human | #1635 |
| prevents | #1637 |
| zinc copper | #1640 |
| cerebellar | #1641 |
| tritium | #1642 |
| dorsal raphe nucleus | #1646 |
| regulation animals | #1647 |
| male membrane glycoproteins | #1648 |
| died | #1650 |
| animals cerebral | #1651 |
| experimental treatment | #1651 |
| brain endothelial | #1652 |
| synthase nitric | #1653 |
| neuromodulatory | #1653 |
| amino acid transport | #1654 |
| distribution animals | #1657 |
| glutamate receptors | #1657 |
| fourfold | #1658 |
| extracellular space | #1660 |
| excitotoxicity | #1661 |
| bbb disruption | #1664 |
| rapid accumulation | #1664 |
| gapdh | #1667 |
| striking similarities | #1667 |
| supporting cells | #1669 |
| autoradiography | #1673 |
| previous findings | #1674 |
| synthetase activity | #1675 |
| messenger | #1677 |
| veratrum | #1688 |
| brain area | #1691 |
| dehydrogenase deficiency | #1694 |
| diseases metabolic | #1696 |
| glycogen metabolism | #1701 |
| brainstem | #1704 |
| postulated | #1708 |
| midbrain | #1708 |
| thp | #1710 |
| accumulate | #1716 |
| fulminant hepatic failure | #1723 |
| ibotenic | #1723 |
| dizocilpine | #1724 |
| inborn | #1724 |
| polyclonal antibody | #1725 |
| phenomenon | #1726 |
| benzodiazepines | #1726 |
| il1beta | #1733 |
| alternative mechanism | #1734 |
| animals arginine | #1735 |
| carnitine | #1735 |
| cumene hydroperoxide | #1737 |
| noninvasive techniques | #1737 |
| disorders nervous | #1739 |
| decarboxylase | #1750 |
| normalization | #1756 |
| liver disease patients | #1757 |
| alternative hypothesis | #1757 |
| magna | #1759 |
| consequent | #1760 |
| tricarboxylic acid cycle | #1761 |
| shunts | #1762 |
| c57bl6 | #1762 |
| spiperone | #1763 |
| metabolism glucose | #1769 |
| intrahepatic portosystemic | #1770 |
| allosteric | #1770 |
| critical appraisal | #1773 |
| betaamyloid | #1781 |
| granule neurons | #1785 |
| acetaminophen induced | #1788 |
| muscarinic | #1789 |
| cell damage | #1790 |
| brain damage | #1791 |
| rats spraguedawley receptors | #1791 |
| body temperature | #1794 |
| adult rat brain | #1794 |
| normothermia | #1794 |
| glucose utilization | #1797 |
| common complication | #1799 |
| nmr study | #1802 |
| ampa receptors | #1806 |
| superfusion | #1810 |
| preliminary investigation | #1812 |
| primary metabolism | #1813 |
| nutritional supplements | #1815 |
| major organs | #1815 |
| coa dehydrogenase | #1815 |
| endorphin | #1817 |
| oxazepam | #1822 |
| pyruvic | #1822 |
| rat | #1829 |
| hypertension intracranial | #1832 |
| dorsal raphe | #1833 |
| hippocampal ca1 | #1834 |
| hepatic failure | #1835 |
| vmax values | #1836 |
| major roles | #1837 |
| bdl | #1839 |
| mild | #1840 |
| reuptake | #1843 |
| neurological deterioration | #1844 |
| compared controls | #1845 |
| granule cells | #1846 |
| metalloproteinase9 | #1847 |
| γaminobutyric acid | #1849 |
| toxins | #1850 |
| regulatory processes | #1854 |
| capillary gas chromatography | #1856 |
| chronic alcohol | #1857 |
| ammonium compounds | #1857 |
| monoaminergic | #1862 |
| cirrhotic rats | #1863 |
| body water | #1865 |
| liver transplantation patients | #1865 |
| caudate | #1868 |
| cholinergic neurons | #1872 |
| stroke outcome | #1876 |
| lactate production | #1877 |
| immunoreactivities | #1877 |
| platelets patients | #1882 |
| disorder treatment | #1886 |
| glutamate release | #1886 |
| neurotoxicity syndromes | #1886 |
| beta endorphin | #1892 |
| acute | #1900 |
| locomotor activity | #1902 |
| hepatoprotective | #1903 |
| common feature | #1904 |
| induced liver | #1906 |
| atp adp | #1913 |
| induced rats | #1917 |
| cirrhosis biliary | #1919 |
| stereotyped | #1920 |
| penicillamine | #1920 |
| colorimetric assay | #1921 |
| rodent models | #1923 |
| patients cirrhosis | #1923 |
| grossly | #1925 |
| dipeptides | #1930 |
| behavioral abnormalities | #1932 |
| precipitated | #1934 |
| tspo | #1935 |
| nitration | #1937 |
| areas brain | #1941 |
| patients aids | #1944 |
| neurocognitive impairment | #1945 |
| major metabolite | #1952 |
| major site | #1957 |
| synthase | #1958 |
| dpat | #1961 |
| concomitant | #1962 |
| normal dogs | #1965 |
| cerebral metabolism | #1965 |
| acid transporters | #1966 |
| acid synthesis | #1966 |
| spectroscopy male | #1968 |
| manganese superoxide dismutase | #1970 |
| druginduced liver injury | #1977 |
| globus | #1977 |
| 5hydroxytryptamine | #1977 |
| nmethyldaspartate receptors | #1977 |
| 28 weeks | #1981 |
| mice compared | #1981 |
| degeneration humans | #1986 |
| potassium exchanging | #1987 |
| erk1 | #1990 |
| duct ligation | #1991 |
| neurologic symptoms | #1991 |
| cognitive dysfunction | #1991 |
| idazoxan | #1993 |
| ideal model | #1994 |
| oxotremorine | #1994 |
| 5 ht | #1996 |
| recirculating | #1997 |
| primary biliary | #2000 |
| radioligand | #2001 |
| 2fold increase | #2006 |
| mk801 | #2007 |
| ampa receptor | #2015 |
| heterogeneously | #2017 |
| cerebellar cortex | #2019 |
| overactivity | #2020 |
| injury mice | #2022 |
| arterio | #2023 |
| pet imaging | #2028 |
| glucose brain | #2034 |
| aminoacids | #2036 |
| sham rats | #2036 |
| microdialysis | #2036 |
| neurologic complications | #2036 |
| sham | #2040 |
| peroneal nerve | #2041 |
| osmolytes | #2041 |
| exchanging atpase | #2043 |
| resonance nmr | #2043 |
| cerebri | #2046 |
| cyclase | #2046 |
| pathogenetic mechanisms | #2047 |
| passive diffusion | #2050 |
| suggested | #2053 |
| groups iii | #2063 |
| tracings | #2064 |
| decreased activity | #2064 |
| 10 12 | #2068 |
| dawley rats | #2069 |
| convulsants | #2071 |
| stage liver | #2072 |
| vivo brain | #2074 |
| elucidated | #2077 |
| tumor necrosis factoralpha | #2079 |
| penumbra | #2080 |
| biochemical parameters | #2082 |
| deficit | #2084 |
| acetates | #2087 |
| transjugular intrahepatic | #2089 |
| trace amounts | #2090 |
| international society | #2094 |
| autopsy | #2098 |
| ensuing | #2103 |
| zo1 | #2106 |
| solely | #2108 |
| atrophies | #2109 |
| p0018 | #2111 |
| nitric oxide synthesis | #2117 |
| portal pressure | #2117 |
| parallel | #2121 |
| chp | #2121 |
| synthase type | #2125 |
| neurological manifestations | #2141 |
| ligase | #2142 |
| synergistically | #2143 |
| exception | #2143 |
| brain barrier | #2148 |
| subsequent degradation | #2149 |
| indicative | #2150 |
| rats spraguedawley | #2158 |
| bmax | #2158 |
| time onset | #2158 |
| intracranial pressure | #2167 |
| amnestic | #2169 |
| male rat | #2170 |
| muscimol | #2173 |
| acute effects | #2178 |
| human patients | #2179 |
| neural inhibition | #2180 |
| gaa | #2180 |
| reactive nitrogen | #2187 |
| subchronic | #2189 |
| apap | #2194 |
| blood csf | #2194 |
| increasing recognition | #2200 |
| cox2 | #2203 |
| overt | #2205 |
| parkinsonism | #2209 |
| methysergide | #2212 |
| pressure icp | #2217 |
| homovanillic acid | #2217 |
| vitamin supplements | #2220 |
| hypothermic | #2223 |
| nitroarginine methyl | #2223 |
| brain cells | #2225 |
| function brain | #2230 |
| antiparkinson | #2232 |
| liver enzymes | #2238 |
| minocycline | #2242 |
| pss | #2244 |
| chelators | #2245 |
| neurological disorders | #2248 |
| humans liver | #2249 |
| diminution | #2262 |
| symporters | #2265 |
| blood brain | #2265 |
| liver circulation | #2265 |
| doubt | #2267 |
| nutritional deficiencies | #2268 |
| messenger systems | #2271 |
| gliosis | #2279 |
| behavior rats | #2280 |
| additional factors | #2297 |
| synaptic vesicles | #2297 |
| rats liver | #2299 |
| phosphate | #2300 |
| eeg activity | #2302 |
| acrylamides | #2303 |
| patients minimal | #2304 |
| isoxazolepropionic | #2307 |
| immunoreactive neurons | #2308 |
| superoxide dismutase | #2314 |
| tle | #2315 |
| memantine | #2320 |
| multiorgan failure | #2322 |
| cortex hippocampus | #2325 |
| brain expression | #2326 |
| cultured cerebral | #2327 |
| primary cultures | #2328 |
| systemic inflammatory response | #2328 |
| male nerve | #2330 |
| blindly | #2333 |
| hrqol patients | #2334 |
| housekeeping | #2336 |
| relative increase | #2338 |
| acidosis | #2338 |
| convincing | #2340 |
| scatchard | #2349 |
| lactates | #2359 |
| ligands | #2360 |
| binding assays | #2360 |
| olivary | #2362 |
| benzoic | #2364 |
| inbred strains | #2366 |
| patients increased | #2373 |
| endstage liver disease | #2376 |
| synaptic dysfunction | #2377 |
| voluntary | #2377 |
| competitive inhibitor | #2380 |
| clinical condition | #2391 |
| deficiencies | #2392 |
| mental fatigue | #2392 |
| potential adverse effects | #2393 |
| exchanging | #2401 |
| brains patients | #2401 |
| neurotoxin | #2406 |
| homovanillic | #2416 |
| lnmma | #2430 |
| induced brain | #2432 |
| protein mrna | #2433 |
| transporter 2 | #2443 |
| calcium binding | #2449 |
| cerebral metabolic | #2467 |
| extracellular levels | #2471 |
| 01 mm | #2473 |
| histamine receptor | #2483 |
| fluorescence detection | #2489 |
| peripheral inflammation | #2490 |
| adult male rats | #2491 |
| bbb | #2498 |
| receptors ampa | #2502 |
| synaptic function | #2508 |
| pathogenic role | #2509 |
| count cell | #2510 |
| effects alcohol | #2511 |
| animal model | #2513 |
| pyridinium | #2513 |
| activation microglia | #2514 |
| noxious stimuli | #2518 |
| hypotonia | #2524 |
| vmax | #2529 |
| 5ht | #2530 |
| physical conditioning | #2532 |
| dopac | #2534 |
| nuclear magnetic | #2534 |
| metabolic acidosis | #2541 |
| expression endothelial | #2563 |
| alcohol induced | #2566 |
| male matrix | #2571 |
| fmol | #2572 |
| understanding pathophysiology | #2573 |
| humans ligands | #2573 |
| receptor density | #2577 |
| ataxias | #2577 |
| alpha1 | #2577 |
| vessel walls | #2581 |
| postmortem brain | #2588 |
| microglia neurons | #2591 |
| mao | #2594 |
| multiple mechanisms | #2597 |
| acetylcholinesterase | #2598 |
| cerebrospinal | #2601 |
| groups subjects | #2608 |
| il1β il6 | #2619 |
| possibility | #2621 |
| 10 microm | #2621 |
| cognitive motor | #2623 |
| 15–30 | #2625 |
| greater extent | #2626 |
| methylaspartate | #2630 |
| normalisation | #2632 |
| nitrosation | #2635 |
| biochemical evidence | #2639 |
| circulating concentrations | #2640 |
| deteriorating | #2640 |
| day treatment | #2647 |
| activity rats | #2661 |
| thalamic | #2663 |
| transcriptase | #2663 |
| nitric | #2665 |
| katpase | #2665 |
| chc | #2665 |
| binding competitive | #2668 |
| glutathione levels | #2669 |
| olfactory bulb | #2669 |
| osmolar | #2683 |
| patients alcoholic | #2684 |
| guanylyl cyclase | #2685 |
| glial cell | #2686 |
| serotonin 5 | #2689 |
| effects ethanol | #2695 |
| indwelling | #2704 |
| nerve terminals | #2705 |
| rats control | #2705 |
| laboratory findings | #2710 |
| groups animals | #2715 |
| lactic | #2723 |
| situ nickend | #2733 |
| publication animals behavior | #2737 |
| frontal lobe | #2742 |
| hemodiafiltration | #2755 |
| suggests | #2760 |
| glutaminase | #2764 |
| functional integrity | #2767 |
| regions | #2769 |
| 6hydroxydopamine | #2771 |
| neurons animals | #2774 |
| kindred | #2775 |
| turnover rate | #2779 |
| leucine | #2779 |
| 24h | #2786 |
| glutamate receptor | #2789 |
| systemic circulation | #2789 |
| animal rats | #2790 |
| rhythmicity | #2798 |
| amino acid | #2798 |
| severity patients | #2806 |
| osmolar concentration | #2813 |
| inbred strains mice | #2814 |
| pontine | #2817 |
| exposed | #2821 |
| mechanisms | #2824 |
| hydroxy5 | #2826 |
| microglial cells | #2827 |
| p38mapk | #2831 |
| gastrointestinal agents | #2833 |
| neurological deficit | #2834 |
| regulation enzymologic | #2834 |
| minneapolis | #2835 |
| blood brain barrier | #2841 |
| brain calcium | #2847 |
| marked decrease | #2867 |
| bilirubin | #2876 |
| twofold increase | #2877 |
| amino | #2882 |
| alcoholic fatty | #2882 |
| nerve cells | #2883 |
| alanine | #2885 |
| synaptic | #2888 |
| diabetic animals | #2890 |
| ca2dependent | #2893 |
| pet study | #2897 |
| mmt | #2898 |
| trafficking | #2901 |
| kainate | #2903 |
| slices | #2905 |
| rigidity | #2905 |
| standpoint | #2906 |
| ameliorating | #2910 |
| confirming | #2918 |
| clinical syndrome | #2931 |
| cell volume | #2936 |
| dying | #2938 |
| normal control | #2938 |
| normal animals | #2939 |
| subfield | #2943 |
| translocator | #2943 |
| 12 weeks treatment | #2944 |
| receptors opioid | #2962 |
| impaired | #2964 |
| 11c | #2965 |
| assist devices | #2970 |
| astrocytes cell | #2971 |
| brain uptake | #2974 |
| unaffected | #2982 |
| inflammation liver | #2982 |
| pyruvic acid | #3000 |
| excitatory synapses | #3000 |
| intermediary | #3008 |
| normal values | #3015 |
| aquaporin | #3036 |
| uptake | #3039 |
| kainic | #3043 |
| barrier brain | #3047 |
| incubation medium | #3051 |
| cox2 expression | #3051 |
| ca1 pyramidal | #3053 |
| biliary obstruction | #3054 |
| weighted magnetic | #3069 |
| concert | #3073 |
| tmp | #3076 |
| metabolite concentrations | #3078 |
| portosystemic shunt | #3078 |
| harmful effects | #3082 |
| attenuation | #3083 |
| selegiline | #3086 |
| activated microglia | #3088 |
| reserpine | #3093 |
| liver injury | #3095 |
| cd1 | #3099 |
| catecholaminergic | #3109 |
| atp levels | #3111 |
| adult rats | #3113 |
| renal vein | #3115 |
| valine | #3133 |
| short halflife | #3136 |
| toxic effects | #3137 |
| relative roles | #3149 |
| decreased | #3156 |
| myo inositol | #3161 |
| higher doses | #3168 |
| animals binding | #3169 |
| dhea | #3171 |
| nmda | #3172 |
| loss | #3180 |
| carboxamide | #3189 |
| endorphins | #3192 |
| failure | #3192 |
| relation | #3194 |
| abruptly | #3195 |
| radical scavengers | #3198 |
| inhalation | #3199 |
| bcaa | #3199 |
| mental retardation | #3201 |
| enzymologic genes | #3209 |
| clinical presentations | #3210 |
| ketanserin | #3214 |
| liver function | #3214 |
| heavy drinking | #3218 |
| coenzymes | #3220 |
| noradrenaline | #3224 |
| imidodiphosphate | #3226 |
| active transport | #3232 |
| portal | #3235 |
| shortchain fatty acids | #3238 |
| gad | #3238 |
| acidic | #3243 |
| synaptic membranes | #3244 |
| pyrophosphate | #3248 |
| induced hepatic | #3252 |
| treated rats | #3256 |
| nitrogen species | #3267 |
| systemic | #3276 |
| oxidative metabolism | #3281 |
| respects | #3285 |
| induced seizures | #3287 |
| synaptosomal | #3291 |
| drug repositioning | #3296 |
| behavioral symptoms | #3300 |
| water electrolyte | #3306 |
| kcl | #3307 |
| cell death | #3311 |
| metabolic alterations | #3324 |
| anterolateral | #3326 |
| reverse | #3327 |
| metabolized | #3331 |
| nanomolar concentrations | #3335 |
| sedatives | #3342 |
| general circulation | #3344 |
| nac | #3347 |
| dab | #3352 |
| rats received | #3359 |
| regionally | #3359 |
| benzoates | #3360 |
| membrane transport | #3361 |
| dosedependent fashion | #3364 |
| aspartate receptors | #3366 |
| rats inbred | #3368 |
| subsequent studies | #3371 |
| phenylalanine | #3384 |
| cerebral ischemia | #3388 |
| opioid | #3388 |
| inbred strains receptors | #3389 |
| cortex | #3391 |
| robust evidence | #3394 |
| hydroxytryptamine | #3402 |
| tyrphostins | #3403 |
| galactosamine | #3404 |
| brain disease | #3407 |
| brain lesions | #3412 |
| falls | #3421 |
| disturbances | #3421 |
| progressive increase | #3423 |
| histamine | #3423 |
| ldopa | #3426 |
| quaternary ammonium | #3427 |
| morphologic | #3428 |
| transaminases | #3432 |
| gln | #3436 |
| decreased levels | #3437 |
| modulation | #3439 |
| levels liver | #3443 |
| indole3 | #3446 |
| superior colliculus | #3451 |
| epilepsy temporal | #3453 |
| toxic | #3455 |
| strains mice | #3456 |
| biogenic | #3458 |
| accumulates | #3462 |
| timecourse | #3467 |
| phosphocreatine | #3473 |
| rats rats | #3474 |
| indomethacin | #3480 |
| striatum | #3482 |
| developing rat | #3485 |
| upregulation | #3491 |
| glycine | #3492 |
| brain stem | #3495 |
| subcortical structures | #3497 |
| liver male | #3497 |
| electrochemical detection | #3499 |
| new evidence | #3499 |
| basal ganglia | #3500 |
| rat models | #3503 |
| lobe epilepsy | #3503 |
| previous observations | #3507 |
| aids patients | #3511 |
| huntington | #3515 |
| dehydroepiandrosterone | #3537 |
| aging brain | #3542 |
| rats treatment | #3545 |
| neurons oxidative | #3545 |
| kidney liver | #3555 |
| tyramine | #3558 |
| fold | #3563 |
| cytokines disease | #3576 |
| nerve degeneration | #3584 |
| portal vein | #3600 |
| inferior vena cava | #3600 |
| tissue distribution | #3600 |
| brain structure | #3613 |
| truncated 250 | #3627 |
| antioxidant properties | #3627 |
| pathology | #3635 |
| cofactor | #3636 |
| prolonged exposure | #3636 |
| hypertonic saline | #3638 |
| disease states | #3648 |
| implication | #3650 |
| increased activity | #3655 |
| hydroxydopamine | #3657 |
| precipitating | #3664 |
| ache | #3664 |
| fatty liver | #3666 |
| investigator | #3675 |
| circadian rhythms | #3680 |
| scavengers | #3682 |
| lobe | #3694 |
| splanchnic | #3699 |
| regional variation | #3700 |
| arginine | #3718 |
| proinflammatory cytokine | #3722 |
| new model | #3723 |
| medial | #3735 |
| thioacetamide | #3741 |
| cassette transporters | #3742 |
| treated animals | #3746 |
| induced neurotoxicity | #3751 |
| stress rats | #3755 |
| normal mice | #3758 |
| consensus statement | #3765 |
| dopamine d1 | #3773 |
| 4 wk | #3786 |
| 1968 | #3791 |
| parietal lobe | #3793 |
| acetylcholinesterase ache | #3799 |
| dietary protein | #3801 |
| mitochondrion | #3807 |
| finding | #3814 |
| major | #3815 |
| diazepam | #3825 |
| neural cell | #3825 |
| control animals | #3825 |
| resemble | #3833 |
| western blot analyses | #3838 |
| systemically | #3846 |
| inborn errors | #3846 |
| prefrontal | #3857 |
| effects chronic | #3872 |
| nmr spectroscopy | #3879 |
| malabsorption | #3896 |
| type nitric | #3897 |
| dopamine d1 receptors | #3899 |
| dopa | #3907 |
| enhanced production | #3909 |
| metabolic pathway | #3911 |
| elucidate | #3914 |
| levels measured | #3915 |
| nitric oxide production | #3919 |
| new therapeutic approaches | #3919 |
| tone | #3924 |
| pindolol | #3929 |
| peripheral neuropathy | #3937 |
| ascorbate | #3942 |
| medulla | #3949 |
| csf | #3949 |
| reabsorption | #3949 |
| wet weight | #3951 |
| tourette | #3975 |
| neuropsychiatric disorders | #3978 |
| purkinje cells | #3983 |
| antiinflammatory | #3987 |
| fatigue | #3992 |
| complication | #3992 |
| tca cycle | #4003 |
| pseudotumor | #4006 |
| brain activation | #4009 |
| day 5 | #4011 |
| treatment prevention | #4021 |
| transporter | #4026 |
| nmda receptors | #4053 |
| elevated blood | #4053 |
| bz | #4054 |
| strains receptors | #4069 |
| neurotoxicity | #4070 |
| fischer | #4082 |
| cultured neurons | #4097 |
| remove | #4101 |
| gastrointestinal bleeding | #4103 |
| involve | #4104 |
| nonalcoholic | #4111 |
| intracranial | #4134 |
| coa | #4138 |
| visible spectrum | #4140 |
| induced mitochondrial | #4149 |
| exacerbate | #4165 |
| lower affinity | #4172 |
| future clinical trials | #4178 |
| motor activity | #4178 |
| reverse transcriptase | #4185 |
| nitroso | #4190 |
| nuclear magnetic resonance | #4193 |
| oxide production | #4198 |
| ampa | #4204 |
| endothelial nitric | #4205 |
| liver cirrhosis | #4232 |
| steadystate levels | #4244 |
| knockout receptors | #4249 |
| enkephalins | #4276 |
| tips | #4318 |
| isoenzymes | #4321 |
| pathogenetic | #4326 |
| contention | #4326 |
| 3h | #4342 |
| oxidase inhibitors | #4346 |
| female frontal | #4355 |
| alcohol abuse | #4357 |
| matched | #4358 |
| chelator | #4359 |
| vitro model | #4364 |
| groups rats | #4365 |
| chorea | #4373 |
| acids | #4373 |
| geniculate | #4374 |
| prevention | #4375 |
| ratelimiting enzyme | #4382 |
| neocortical | #4398 |
| rtpcr | #4402 |
| mrna expression | #4418 |
| enos | #4425 |
| hepatic artery | #4425 |
| immunohistochemical analysis | #4428 |
| peripherally | #4430 |
| postnatally | #4433 |
| 10 micrograms | #4438 |
| specific activities | #4449 |
| carbon isotopes | #4449 |
| acid amino | #4455 |
| inos | #4460 |
| tetrahydrobiopterin | #4480 |
| diencephalon | #4481 |
| citric | #4487 |
| agents steroidal | #4499 |
| isoleucine | #4507 |
| chemical drug | #4509 |
| incompletely | #4517 |
| hippocampal neurons | #4518 |
| endogenously | #4521 |
| potent inhibitor | #4528 |
| pglycoprotein | #4535 |
| tissue concentrations | #4552 |
| model chronic | #4561 |
| gssg | #4562 |
| animal studies | #4562 |
| mitochondrial dysfunction | #4575 |
| substantia nigra | #4577 |
| neurological function | #4585 |
| explanation | #4600 |
| acetaminophen | #4606 |
| transaminase | #4608 |
| 250 | #4627 |
| small increase | #4629 |
| liver diseases | #4637 |
| mrna | #4639 |
| narcotic | #4643 |
| models neurological | #4666 |
| enzymes | #4671 |
| myo | #4677 |
| dopamine | #4679 |
| choline | #4683 |
| nitrites | #4684 |
| worsening | #4685 |
| tremor | #4694 |
| relate | #4701 |
| ho1 | #4704 |
| diphosphate | #4705 |
| neuronal survival | #4712 |
| develops | #4714 |
| realtime quantitative pcr | #4719 |
| techniques male | #4729 |
| key enzymes | #4730 |
| debilitating | #4732 |
| skeletal muscle | #4736 |
| amines | #4737 |
| receptors tumor | #4740 |
| motor coordination | #4745 |
| neurovascular | #4749 |
| patients liver cirrhosis | #4749 |
| triphosphate | #4752 |
| receptors | #4761 |
| apoptotic cell death | #4774 |
| patients liver | #4775 |
| neuroprotective agents | #4778 |
| mn2 | #4792 |
| male rats | #4793 |
| ulnar | #4795 |
| opioid peptides | #4821 |
| ganglia | #4828 |
| failing | #4835 |
| membrane cells | #4837 |
| liver regeneration | #4853 |
| regional cerebral | #4875 |
| constellation | #4875 |
| nonselective | #4891 |
| opioid receptors | #4901 |
| modulator | #4905 |
| transporters | #4906 |
| tyrosine | #4906 |
| 001 | #4915 |
| animals antioxidants | #4919 |
| injections intraperitoneal | #4921 |
| neurons rats | #4927 |
| glucose humans | #4936 |
| epilepsy humans | #4940 |
| degree | #4943 |
| kainic acid | #4963 |
| evident | #4988 |
| rapid progression | #4996 |
| viral hepatitis | #4998 |
| indazoles | #5000 |
| methyl2 | #5002 |
| clinical conditions | #5004 |
| 25 mm | #5009 |
| ammonium | #5017 |
| acid metabolism | #5018 |
| neurological diseases | #5024 |
| raphe | #5043 |
| consequences | #5048 |
| immunostaining | #5051 |
| weighted mri | #5053 |
| offspring | #5054 |
| tight | #5055 |
| alcoholism | #5063 |
| cyclooxygenase2 | #5066 |
| malnutrition | #5080 |
| metabolism | #5084 |
| suggesting | #5106 |
| endoperoxide | #5129 |
| clinical criteria | #5130 |
| acid | #5133 |
| nitric oxide | #5140 |
| disorder | #5143 |
| sarcopenia | #5163 |
| anticonvulsant | #5164 |
| glial cells | #5213 |
| temporal lobe | #5226 |
| leads | #5232 |
| animals | #5236 |
| portal hypertension | #5238 |
| child pugh | #5266 |
| severe | #5277 |
| sustained | #5277 |
| normal rats | #5278 |
| cerebrum | #5280 |
| organ dysfunction | #5288 |
| cerebrospinal fluid | #5299 |
| animal brain | #5308 |
| restores | #5312 |
| reversal | #5325 |
| methylarginine | #5330 |
| intoxication | #5344 |
| major impact | #5349 |
| 4 groups | #5350 |
| animal humans | #5364 |
| biomarkers brain | #5401 |
| gastroenterology | #5403 |
| experimental model | #5414 |
| superoxide production | #5416 |
| publication animals | #5417 |
| presynaptic | #5426 |
| induced acute | #5434 |
| regional brain | #5435 |
| gastrointestinal diseases | #5444 |
| intracellular levels | #5450 |
| postsynaptic | #5452 |
| concentrations | #5459 |
| food deprivation | #5463 |
| blotting western | #5466 |
| focal | #5466 |
| thioredoxins | #5505 |
| halflife | #5506 |
| aquaporins | #5515 |
| involving | #5517 |
| cns | #5517 |
| effects exposure | #5523 |
| nash | #5525 |
| controls | #5541 |
| catecholamines | #5549 |
| isolated rat | #5552 |
| affinity | #5553 |
| tca | #5564 |
| glucose metabolism | #5569 |
| lack | #5572 |
| higher density | #5575 |
| sleep disturbances | #5580 |
| hyperbilirubinemia | #5586 |
| glucose transport | #5607 |
| n11 | #5608 |
| summarizes | #5611 |
| platelets | #5615 |
| endotoxemia | #5639 |
| major complications | #5645 |
| free radicals | #5647 |
| postnatal development | #5651 |
| magnetic resonance images | #5652 |
| cachexia | #5666 |
| acute ischemic | #5672 |
| drinkers | #5693 |
| antimetabolites | #5699 |
| tnf | #5709 |
| 73 patients | #5711 |
| transport systems | #5712 |
| receptor binding | #5730 |
| 24 hours | #5741 |
| icp | #5768 |
| evidence base | #5790 |
| precipitate | #5790 |
| nonalcoholic steatohepatitis | #5796 |
| dehydrogenases | #5796 |
| p005 | #5800 |
| brain animals | #5810 |
| depolarization | #5812 |
| aspartate receptor | #5824 |
| serotonin | #5840 |
| substances | #5848 |
| prefrontal cortex | #5859 |
| extravasation | #5862 |
| steroidal | #5865 |
| neuroprotective | #5883 |
| levels elevated | #5885 |
| ketone | #5892 |
| western blot analysis | #5897 |
| appropriately | #5900 |
| mounting evidence | #5926 |
| enkephalin | #5928 |
| potentiate | #5945 |
| detoxification | #5949 |
| acrylamide | #5950 |
| disaccharides | #5950 |
| acid antagonists | #5952 |
| 100 microm | #5954 |
| background objectives | #5954 |
| bulb | #5976 |
| muscle mass | #5993 |
| metabolites | #5993 |
| coenzyme | #5994 |
| etiologies | #5997 |
| anterior cingulate cortex | #6016 |
| antagonist | #6019 |
| butyric | #6023 |
| reversible | #6029 |
| aged rats | #6030 |
| sodium potassium | #6068 |
| additional evidence | #6080 |
| transporter 1 | #6103 |
| methyl4 | #6109 |
| zona | #6114 |
| chemistry | #6120 |
| occurs | #6122 |
| barrier | #6138 |
| trh | #6148 |
| cirrhosis patients | #6152 |
| postmortem | #6152 |
| cortical regions | #6162 |
| hippocampus | #6166 |
| hydroperoxide | #6169 |
| deoxyglucose | #6171 |
| risk bias | #6188 |
| inbred | #6199 |
| esters | #6202 |
| proteins rats | #6221 |
| reduction oxidative | #6231 |
| nervous cns | #6235 |
| disruptions | #6250 |
| vascular endothelium | #6265 |
| anti inflammatory | #6284 |
| mitochondrial function | #6287 |
| hematoxylin | #6290 |
| lactate dehydrogenase | #6298 |
| chain | #6315 |
| carboxylase | #6322 |
| alpha2 | #6323 |
| protein expression | #6343 |
| induced increases | #6360 |
| 20 cases | #6371 |
| rna messenger | #6388 |
| dha | #6392 |
| cbf | #6404 |
| gamma | #6412 |
| remained | #6413 |
| chelating agents | #6422 |
| olfactory | #6441 |
| prosencephalon | #6456 |
| snap | #6464 |
| rats animals | #6469 |
| roi | #6470 |
| antagonists | #6475 |
| peripheral nerve | #6478 |
| histidine | #6482 |
| acyltransferases | #6490 |
| patients chronic | #6498 |
| mesencephalon | #6508 |
| notion | #6511 |
| disease brain | #6514 |
| bromocriptine | #6531 |
| ingestion | #6548 |
| ligation | #6552 |
| dopaminergic | #6553 |
| humans kinetics | #6566 |
| control mice | #6572 |
| longterm treatment | #6575 |
| nomenclature | #6576 |
| disease aged | #6579 |
| physiological function | #6586 |
| humans mitochondria | #6594 |
| oxidase | #6596 |
| microg | #6596 |
| led | #6597 |
| accumulation | #6599 |
| fluid csf | #6600 |
| mmol | #6609 |
| animal dose | #6610 |
| glycolytic | #6625 |
| publication analysis | #6642 |
| inducible nitric | #6643 |
| resonance spectroscopy | #6660 |
| glu | #6665 |
| lowers | #6665 |
| animals bile | #6671 |
| slowing | #6682 |
| p001 | #6684 |
| patients placebo | #6688 |
| proceedings | #6700 |
| interferongamma | #6742 |
| differential effects | #6755 |
| poisoning | #6767 |
| granule | #6768 |
| dystonia | #6769 |
| psychometric | #6774 |
| lad | #6783 |
| rats wistar receptors | #6791 |
| biological transport | #6801 |
| transport proteins | #6806 |
| specific regions | #6806 |
| cortices | #6825 |
| nitrates | #6833 |
| n5 | #6849 |
| inflammatory processes | #6849 |
| protects | #6857 |
| receptors dopamine | #6859 |
| tomography emission | #6887 |
| acetaldehyde | #6894 |
| enter | #6908 |
| patients brain | #6909 |
| sleep disorders | #6915 |
| mitochondrial membrane | #6916 |
| nutritional | #6921 |
| hypothalamus | #6930 |
| humans intracranial | #6937 |
| nutrition | #6972 |
| rendered | #6975 |
| cerebral blood flow | #6981 |
| low affinity | #6986 |
| acid levels | #7005 |
| eosin | #7011 |
| vitamins | #7012 |
| ascites | #7020 |
| adenosine triphosphate | #7030 |
| patients alzheimer | #7040 |
| compensatory | #7089 |
| free radical | #7092 |
| rois | #7098 |
| common form | #7109 |
| general agreement | #7117 |
| expression | #7125 |
| prothrombin | #7133 |
| mice treated | #7139 |
| synthases | #7140 |
| 13c nmr | #7146 |
| methyl | #7151 |
| hippocampus male | #7165 |
| methyl ester | #7177 |
| tartrate | #7178 |
| levels blood | #7198 |
| central nervous cns | #7202 |
| protective agents | #7214 |
| catecholamine | #7216 |
| undertaken | #7226 |
| probiotics | #7244 |
| humans inflammation | #7253 |
| systemic inflammation | #7280 |
| antiinflammatory agents | #7284 |
| neurodegeneration | #7290 |
| male sprague | #7307 |
| bile duct | #7311 |
| additional studies | #7322 |
| animal doseresponse relationship | #7334 |
| nh4 | #7336 |
| glucose transporter | #7337 |
| cyclooxygenase 2 | #7344 |
| life hrqol | #7350 |
| administration | #7353 |
| preliminary evidence | #7358 |
| symptomatic | #7371 |
| neuroprotection | #7374 |
| histamine release | #7378 |
| regional | #7382 |
| urea | #7386 |
| hippocampal | #7389 |
| insult | #7392 |
| pyridines | #7404 |
| intravenous infusion | #7420 |
| competitive | #7424 |
| animal | #7433 |
| excitability | #7442 |
| molecular mechanisms | #7448 |
| restored | #7464 |
| spectrophotometric | #7474 |
| osmotic | #7475 |
| biochemical studies | #7481 |
| ht | #7485 |
| excreted | #7507 |
| urease | #7536 |
| organ specificity | #7540 |
| lipid peroxidation | #7550 |
| pathological conditions | #7553 |
| dismutase | #7553 |
| brain ischemia | #7557 |
| implicating | #7564 |
| onset | #7570 |
| cytoprotection | #7580 |
| neuropathic pain | #7583 |
| imaging magnetic | #7585 |
| chromatography mass | #7603 |
| microglia | #7605 |
| matrix metalloproteinase | #7621 |
| mental status | #7630 |
| blood platelets | #7640 |
| neuroprotective effects | #7659 |
| characterized | #7659 |
| deleterious | #7665 |
| neurologic examination | #7672 |
| cortical neurons | #7687 |
| diminished | #7696 |
| specific binding | #7700 |
| guanidines | #7737 |
| perturbations | #7769 |
| alpha tnf | #7777 |
| oxide | #7779 |
| immunoreactivity | #7801 |
| oedema | #7810 |
| il6 levels | #7833 |
| tissue proteins | #7854 |
| tnf α | #7864 |
| animals blotting | #7882 |
| albumins | #7888 |
| m3 | #7897 |
| ca1 | #7899 |
| parietal cortex | #7915 |
| brain development | #7915 |
| cells brain | #7932 |
| freely | #7932 |
| lname | #7950 |
| aspartate aminotransferases | #7961 |
| assayed | #7986 |
| metabolic | #7989 |
| aetiology | #8016 |
| mouse brain | #8023 |
| alzheimer | #8025 |
| liver transplantation | #8033 |
| ka | #8038 |
| computerized | #8040 |
| constitutes | #8040 |
| organometallic compounds | #8052 |
| established | #8056 |
| brain humans | #8073 |
| cerebrovascular circulation | #8079 |
| chelation | #8081 |
| inferior | #8097 |
| reproduces | #8103 |
| modulate | #8143 |
| confirm | #8153 |
| produces | #8156 |
| large variety | #8164 |
| intraperitoneally | #8167 |
| immunohistochemistry male | #8184 |
| maintained | #8185 |
| benzazepines | #8192 |
| organs | #8193 |
| fluorescence intensity | #8201 |
| reduced | #8207 |
| neurologic | #8214 |
| dopamine receptor | #8253 |
| abnormally | #8260 |
| norepinephrine | #8288 |
| inflammatory agents | #8301 |
| neuronal damage | #8302 |
| antioxidant | #8310 |
| condition | #8326 |
| dependent | #8332 |
| therapeutic implications | #8336 |
| epileptic | #8359 |
| chromatography pressure | #8383 |
| turn | #8404 |
| gray matter | #8407 |
| reflect | #8410 |
| and or | #8413 |
| wistar receptors | #8433 |
| receptor expression | #8442 |
| chain reaction | #8446 |
| hyponatremia | #8454 |
| plasma levels | #8470 |
| hyperglycemia | #8472 |
| citalopram | #8472 |
| stereotaxic | #8495 |
| systemic inflammatory | #8499 |
| polymerase chain | #8501 |
| purkinje | #8517 |
| immunocytochemical | #8519 |
| brain imaging | #8538 |
| chloride | #8546 |
| copper | #8549 |
| intracellular ca2 | #8583 |
| restoration | #8595 |
| hepatotoxicity | #8598 |
| ischemia | #8616 |
| activates | #8631 |
| hippocampus humans | #8641 |
| oxide nitric | #8664 |
| levodopa | #8665 |
| n10 | #8672 |
| inflammatory cytokines | #8690 |
| male middle aged | #8715 |
| organometallic | #8716 |
| pyramidal cells | #8724 |
| retardation | #8736 |
| gsh | #8742 |
| oxidative | #8742 |
| 37°c | #8758 |
| emission computed | #8767 |
| parietal | #8790 |
| potassium chloride | #8814 |
| hplc | #8824 |
| nmr | #8871 |
| superoxide | #8875 |
| tonic | #8879 |
| sulfates | #8892 |
| devoid | #8898 |
| egf receptor | #8905 |
| lactic acid | #8906 |
| minimal | #8910 |
| caveolin | #8912 |
| oxo | #8932 |
| biochemical | #8935 |
| consciousness | #8985 |
| reflected | #9011 |
| intravenous injection | #9019 |
| alanine transaminase | #9038 |
| encephalitis | #9077 |
| emission tomography | #9083 |
| methylmercury | #9099 |
| aminotransferases | #9108 |
| acetate | #9111 |
| syndromes | #9112 |
| brain cognition | #9130 |
| aimed | #9163 |
| awake | #9175 |
| 62 patients | #9176 |
| likewise | #9181 |
| treated mice | #9194 |
| normal | #9207 |
| dysfunction | #9218 |
| corpus striatum | #9247 |
| key factors | #9254 |
| elevated | #9263 |
| deprived | #9285 |
| neuropathy | #9344 |
| cerebrospinal fluid csf | #9364 |
| cerebral blood | #9391 |
| pressure liquid | #9396 |
| deoxy | #9420 |
| immunoblotting | #9445 |
| complications patients | #9489 |
| citric acid | #9505 |
| intrahepatic | #9572 |
| oxidative stress | #9585 |
| irreversible | #9607 |
| naloxone | #9609 |
| absence | #9615 |
| synthase inos | #9615 |
| occipital | #9621 |
| neurons | #9627 |
| seizures | #9631 |
| terminals | #9647 |
| nerve tissue | #9655 |
| postoperative day | #9682 |
| compensate | #9687 |
| micromol | #9692 |
| imaging studies | #9718 |
| ameliorated | #9722 |
| bw | #9727 |
| protective effects | #9749 |
| 2 mm | #9756 |
| 064 | #9783 |
| neuro | #9788 |
| tumor necrosis | #9791 |
| middle cerebral | #9809 |
| chelating | #9823 |
| dependently | #9825 |
| patch clamp | #9830 |
| succinate | #9834 |
| diseases liver | #9842 |
| prevented | #9863 |
| severely | #9864 |
| contributes | #9880 |
| receptor agonist | #9912 |
| microm | #9930 |
| necrosis factor | #9933 |
| quantitative | #9943 |
| tight junctions | #9963 |
| liver cells | #9987 |
| neurobiological | #10000 |
| binding cassette | #10002 |
| central nervous | #10003 |
| conflicting | #10023 |
| kinetic parameters | #10033 |
| cycle | #10052 |
| mediated | #10072 |
| cortical | #10128 |
| cava | #10136 |
| dopamine receptors | #10169 |
| liver damage | #10178 |
| negative impact | #10202 |
| minerals | #10211 |
| stores | #10215 |
| ros production | #10235 |
| attenuated | #10240 |
| expression activity | #10242 |
| cgmp | #10262 |
| glutathione gsh | #10266 |
| transport complex | #10286 |
| plasma concentrations | #10292 |
| plasma patients | #10296 |
| urinary excretion | #10301 |
| adversely | #10328 |
| vitamin deficiency | #10328 |
| forebrain | #10337 |
| cassette | #10370 |
| permeable | #10373 |
| specific activity | #10384 |
| electroencephalogram | #10395 |
| steatohepatitis | #10395 |
| areas | #10419 |
| subacute | #10435 |
| biliary | #10436 |
| protein levels | #10453 |
| hrqol | #10455 |
| liver transplant | #10455 |
| nigra | #10479 |
| cerebral artery | #10481 |
| positron emission tomography | #10525 |
| biosynthesis | #10531 |
| substantia | #10550 |
| nervous | #10616 |
| transmitter | #10626 |
| twofold | #10627 |
| management patients | #10657 |
| lipopolysaccharide | #10674 |
| alzheimers disease | #10694 |
| dose dependent | #10699 |
| normal range | #10730 |
| protein level | #10752 |
| nutritional status | #10752 |
| quaternary | #10765 |
| glutathione | #10772 |
| glucose | #10806 |
| water content | #10826 |
| monophosphate | #10827 |
| liver mice | #10852 |
| vena | #10853 |
| nervous diseases | #10861 |
| microgram | #10880 |
| performance liquid | #10883 |
| entity | #10889 |
| eventually | #10941 |
| intraventricular | #10958 |
| saline | #10968 |
| occur | #10968 |
| dietary proteins | #10978 |
| breakdown | #10983 |
| earlier studies | #10997 |
| etiology | #10998 |
| doses | #11003 |
| accumbens | #11004 |
| impair | #11006 |
| rats inbred strains | #11023 |
| radioimmunoassay | #11026 |
| behavior animal | #11026 |
| atrophy | #11041 |
| tnfalpha | #11044 |
| atp binding | #11055 |
| western | #11061 |
| tests male | #11061 |
| peroxidation | #11077 |
| riboflavin | #11140 |
| positron emission | #11153 |
| potentiated | #11172 |
| preparations | #11184 |
| precursor | #11188 |
| adult male | #11195 |
| broad spectrum | #11196 |
| superoxides | #11202 |
| nick | #11227 |
| steroids | #11232 |
| animals anti | #11234 |
| acyl | #11314 |
| enzyme activity | #11342 |
| drug induced | #11347 |
| early identification | #11376 |
| neuropathic | #11380 |
| necrotic | #11392 |
| neurodegenerative disease | #11395 |
| centrally | #11415 |
| depletion | #11434 |
| major component | #11447 |
| clinical signs | #11463 |
| 3 weeks | #11495 |
| receptor antagonist | #11502 |
| animals disease | #11503 |
| complications | #11504 |
| alteration | #11581 |
| il1β | #11649 |
| trp | #11651 |
| prostaglandins | #11656 |
| survival cells | #11657 |
| kd | #11671 |
| gut | #11676 |
| dogs | #11676 |
| alcohol | #11740 |
| wilson | #11741 |
| dentate | #11769 |
| disappearance | #11773 |
| receptor antagonists | #11774 |
| ibuprofen | #11820 |
| neuron | #11824 |
| radiopharmaceuticals | #11825 |
| appears | #11872 |
| pigs | #11917 |
| inherited | #11924 |
| organ size | #11944 |
| mild cognitive impairment | #11954 |
| pyramidal | #12051 |
| corpus callosum | #12054 |
| gasoline | #12095 |
| aged alzheimer | #12101 |
| circulating levels | #12111 |
| carrier proteins | #12112 |
| reactive | #12134 |
| severity | #12227 |
| receptor activation | #12230 |
| blotting | #12274 |
| huntington disease | #12346 |
| infusions | #12347 |
| electrophysiological | #12375 |
| elevation | #12412 |
| aphasia | #12425 |
| emerging evidence | #12434 |
| atpase | #12447 |
| subclinical | #12476 |
| nh3 | #12499 |
| aminotransferase | #12509 |
| peripheral nervous | #12515 |
| absorbed | #12546 |
| cyclooxygenase | #12569 |
| exerts | #12573 |
| scavenger | #12589 |
| bile ducts | #12634 |
| c57bl 6 | #12683 |
| publisher | #12687 |
| chlorides | #12701 |
| reversed | #12782 |
| subcellular fractions | #12790 |
| inositol | #12832 |
| neuronal death | #12840 |
| measured | #12864 |
| intraperitoneal | #12878 |
| disorders | #12899 |
| cultured cells | #12900 |
| tnf alpha | #12912 |
| mediate | #12984 |
| mars | #13100 |
| slowly | #13118 |
| vesicular | #13121 |
| lesser | #13134 |
| cerebral infarction | #13141 |
| pretreatment | #13141 |
| therapeutic strategies | #13143 |
| basal | #13155 |
| 005 | #13194 |
| positron | #13197 |
| tomography pet | #13207 |
| circadian | #13222 |
| md | #13224 |
| caused | #13226 |
| hypotheses | #13238 |
| infused | #13242 |
| ischemic | #13289 |
| subjected | #13291 |
| methionine | #13299 |
| disrupted | #13336 |
| animals biomarkers | #13337 |
| normal controls | #13360 |
| anticonvulsants | #13440 |
| downregulation | #13444 |
| neurodegenerative | #13467 |
| reduction | #13499 |
| 23 patients | #13506 |
| chronic | #13511 |
| histocytochemistry | #13552 |
| psychomotor | #13555 |
| tissue | #13620 |
| sodium | #13631 |
| interleukin1 | #13734 |
| alpha | #13754 |
| cerebrovascular | #13767 |
| agonist | #13768 |
| partially | #13885 |
| oxidant | #13907 |
| postural | #13923 |
| mainstay | #13926 |
| sulfate | #13971 |
| nerve | #14045 |
| necrosis | #14050 |
| improvement | #14081 |
| gray | #14104 |
| hypothesize | #14117 |
| μmol | #14145 |
| skeletal | #14152 |
| alcohol drinking | #14214 |
| exposure | #14214 |
| electroencephalography | #14223 |
| sulfhydryl | #14242 |
| glia | #14250 |
| deficient mice | #14274 |
| blot analysis | #14352 |
| cytokine production | #14379 |
| multifactorial | #14398 |
| p002 | #14416 |
| damage | #14417 |
| enzyme inhibitors | #14422 |
| normalized | #14430 |
| dinoprostone | #14442 |
| permanent | #14471 |
| limbic | #14474 |
| cingulate | #14502 |
| healthrelated quality | #14573 |
| release | #14673 |
| 11 patients | #14695 |
| pge2 | #14705 |
| male | #14712 |
| ethanol | #14751 |
| chronic disease | #14773 |
| alzheimer disease | #14778 |
| cell count | #14785 |
| learning memory | #14831 |
| triphosphate animals | #14839 |
| vivo studies | #14851 |
| understood | #14879 |
| uric | #14905 |
| nmol | #14931 |
| agonists | #14948 |
| subcortical | #14957 |
| imbalance | #14958 |
| weighted | #15064 |
| manifestations | #15066 |
| lactation | #15115 |
| psychiatric | #15192 |
| creatine | #15221 |
| fluid | #15257 |
| cytokines | #15272 |
| triphosphatases | #15273 |
| intake | #15351 |
| protein tyrosine | #15367 |
| tissues | #15409 |
| localized | #15466 |
| ester | #15533 |
| synapses | #15538 |
| intellectual | #15568 |
| 042 | #15583 |
| evoked potentials | #15595 |
| prophylaxis | #15602 |
| clamp | #15646 |
| drinking | #15676 |
| sclerosis | #15727 |
| cholestasis | #15758 |
| nafld | #15783 |
| adenosine | #15804 |
| signs | #15804 |
| hypothesis | #15809 |
| trace | #15853 |
| chromatography | #15875 |
| exert | #15905 |
| appeared | #15927 |
| degeneration | #15939 |
| subcutaneously | #15941 |
| vivo vitro | #16006 |
| magnetic resonance | #16007 |
| reflects | #16036 |
| killed | #16092 |
| released | #16133 |
| parkinsons disease | #16161 |
| plays | #16220 |
| randomized controlled | #16247 |
| therapeutic | #16276 |
| 0001 | #16290 |
| hepatectomy | #16303 |
| muscle skeletal | #16331 |
| 1 week | #16336 |
| dorsal | #16343 |
| symptoms | #16440 |
| cytosolic | #16446 |
| aspect | #16495 |
| hepatitis chronic | #16549 |
| 5 | #16588 |
| transport | #16615 |
| abnormalities | #16625 |
| nucleus accumbens | #16636 |
| induction | #16656 |
| inadequate | #16667 |
| involves | #16686 |
| hepatocyte | #16740 |
| psychometrics | #16793 |
| decreasing | #16803 |
| cd40 | #16918 |
| random allocation | #16959 |
| pet | #17001 |
| mechanism | #17020 |
| spontaneous | #17046 |
| folic | #17100 |
| 10 patients | #17114 |
| organ | #17129 |
| 05 | #17137 |
| administered | #17168 |
| impairment | #17220 |
| transported | #17290 |
| reduces | #17300 |
| prominent | #17312 |
| publication aged aged | #17315 |
| tnfα | #17356 |
| diagnose | #17452 |
| humans | #17580 |
| parkinson | #17599 |
| mitochondrial | #17645 |
| incubation | #17654 |
| evoked | #17725 |
| modulates | #17799 |
| stimulatory | #17860 |
| commonly | #17870 |
| spectroscopy | #18016 |
| alter | #18029 |
| removed | #18045 |
| pharmacological | #18082 |
| 21 patients | #18092 |
| enzyme | #18126 |
| cognition disorders | #18188 |
| adult brain | #18254 |
| hepatocytes | #18338 |
| prevent | #18353 |
| blood samples | #18374 |
| moderately | #18395 |
| putative | #18427 |
| partly | #18450 |
| suffer | #18502 |
| stimulate | #18563 |
| animals biological | #18741 |
| neurodegenerative diseases | #18774 |
| depressed | #18788 |
| metalloproteinase | #18921 |
| vein | #19240 |
| ascorbic | #19380 |
| plasma | #19440 |
| 7 | #19485 |
| blot | #19526 |
| correlated | #19582 |
| membrane potentials | #19625 |
| serves | #19635 |
| depleted | #19648 |
| neuropsychological tests | #19672 |
| traumatic brain injury | #19727 |
| mm | #19825 |
| animals calcium | #19827 |
| soluble | #20005 |
| acetic | #20054 |
| frequently | #20106 |
| tumor necrosis factor | #20133 |
| serine | #20180 |
| dosedependent manner | #20198 |
| vitro techniques | #20371 |
| controversial | #20390 |
| motor | #20407 |
| radical | #20464 |
| ventral | #20527 |
| micrograms | #20674 |
| circulation | #20783 |
| raised | #20843 |
| inducible | #20861 |
| hypothalamic | #20873 |
| oxidation reduction | #20882 |
| counts | #20909 |
| brain mapping | #21000 |
| reactive oxygen | #21049 |
| 16 patients | #21061 |
| underlying mechanisms | #21109 |
| weeks | #21219 |
| labeled | #21292 |
| rodent | #21335 |
| method female | #21700 |
| maximal | #21940 |
| species ros | #22112 |
| vivo | #22128 |
| blood | #22216 |
| response relationship | #22303 |
| inflammation | #22526 |
| 073 | #22553 |
| induced cell | #22589 |
| 13 patients | #22656 |
| activation | #23016 |
| sufficient | #23212 |
| male membrane | #23275 |
| gastrointestinal | #23302 |
| imaging mri | #23302 |
| inflammatory | #23317 |
| intravenously | #23392 |
| infusions intravenous | #23567 |
| releasing | #23665 |
| magnetic resonance imaging | #23801 |
| intracellular | #24009 |
| cellular | #24252 |
| reducing | #24301 |
| c57bl | #24413 |
| correlate | #24434 |
| displayed | #24599 |
| unable | #24707 |
| 096 | #24715 |
| assess | #24780 |
| 12 patients | #24814 |
| activity | #25360 |
| body | #25376 |
| acquired | #25673 |
| modify | #25866 |
| limiting | #25928 |
| inhibit | #26079 |
| inbred c57bl | #26079 |
| modulated | #26122 |
| remain | #26178 |
| immunohistochemical | #26211 |
| cognitive | #26948 |
| represents | #26971 |
| management | #27196 |
| reflecting | #27352 |
| mental | #27490 |
| improves | #27652 |
| preventing | #27673 |
| behavioral | #27813 |
| hydrogen ion | #28292 |
| concluded | #28335 |
| proven | #28570 |
| aims | #28575 |
| evaluate | #28931 |
| proteins mice | #28975 |
| ion concentration | #29194 |
| magnetic | #29339 |
| mechanisms underlying | #29900 |
| subcellular | #29913 |
| mice inbred | #30075 |
| stained | #30210 |
| quantitatively | #30454 |
| arterial | #30516 |
| abnormal | #30579 |
| corrected | #30667 |
| humans hydrogen | #30710 |
| demonstrated | #30993 |
| sensitive | #31344 |
| resonance | #31346 |
| induces | #31608 |
| cultured | #31958 |
| enzyme activation | #32060 |
| markedly | #32813 |
| animals apoptosis | #33677 |
| remains | #34554 |
| unclear | #34875 |
| subsequent | #35401 |
| hypothesized | #36243 |
| treated | #36316 |
| inhibited | #36986 |
| linked | #37013 |
| inbred c57bl mice | #39261 |
| induce | #39552 |
| aged | #56385 |
Jalankan laporan | |
Prominent publications by Roger F Butterworth∗
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients
[ PUBLICATION ]
Modulation of soluble guanylate cyclase (sGC) by nitric oxide (NO) is altered in brain from experimental animals with hyperammonemia with or without liver failure. The aim of this work was to assess the content and modulation of sGC in brain in chronic liver failure in humans. Expression of the alpha-1, alpha-2, and beta-1 subunits of sGC was measured by immunoblotting in autopsied frontal cortex and cerebellum from cirrhotic patients and controls. The contents of alpha-1 and alpha-2 ...
| Dikenal sebagai Guanylate Cyclase | Cirrhotic Patients | Modulation Sgc | Nitric Oxide Brain | Cerebellum Activation |
Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been suggested that oxidative/nitrosative stress is involved. In the present study we evaluated the role of oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting from hepatic devascularization. We also studied the effect of hypothermia, a ...
| Dikenal sebagai Brain Edema | Alf Rats | Nitrosative Stress | Liver Failure | Coma Stages |
KOL-Index: 13463
Acute liver failure (ALF) results in alterations of energy metabolites and of glucose-derived amino acid neurotransmitters in brain. However, the dynamics of changes in glucose metabolism remain unclear. The present study was undertaken using (1)H and (13)C nuclear magnetic resonance (NMR) spectroscopy to determine the rates of incorporation of glucose into amino acids and lactate via cell-specific pathways in relation to the severity of encephalopathy and brain edema in rats with ALF ...
| Dikenal sebagai Brain Lactate | Acute Liver | Magnetic Resonance | Coma Stages | Amino Acids |
Effects of hypothermia on brain glucose metabolism in acute liver failure: a 1H/13C-nuclear magnetic resonance study
[ PUBLICATION ]
BACKGROUND & AIMS: Mild hypothermia has a protective effect on brain edema and encephalopathy in both experimental and human acute liver failure. The goals of the present study were to examine the effects of mild hypothermia (35 degrees C) on brain metabolic pathways using combined (1)H and (13)C-Nuclear Magnetic Resonance (NMR) spectroscopy, a technique which allows the study not only of metabolite concentrations but also their de novo synthesis via cell-specific pathways in the ...
| Dikenal sebagai Acute Liver | Mild Hypothermia | Brain Glucose Metabolism | Magnetic Resonance | Frontal Cortex |
Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure
[ PUBLICATION ]
It has been proposed that alterations of excitatory and inhibitory amino acids play a role in the pathogenesis of hepatic encephalopathy in acute liver failure. To evaluate this possibility, in vivo cerebral microdialysis was used to sample extracellular concentrations of amino acids in the frontal cortex of unanesthetized rats at various times during the progression of encephalopathy resulting from acute liver failure. Liver failure was induced by portacaval anastomosis followed 24 ...
| Dikenal sebagai Amino Acids | Frontal Cortex | Acute Liver Failure | Extracellular Concentrations | Hepatic Encephalopathy |
KOL-Index: 12801
Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF). To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). ...
| Dikenal sebagai Mild Hypothermia | Brain Edema | Acute Liver | Rats Alf | Hepatic Encephalopathy |
Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis
[ PUBLICATION ]
Brain edema, leading to intracranial hypertension and brain herniation, is a major cause of death in fulminant liver failure. Astrocyte swelling is a prominent neuropathological feature in experimental fulminant liver failure. It has been postulated that the osmotic effects of glutamine, generated in astrocytes from ammonia and glutamate in a reaction catalyzed by glutamine synthetase, could mediate brain swelling. Normal rats and rats that received a portacaval anastomosis were infused ...
| Dikenal sebagai Intracranial Hypertension | Brain Edema | Portacaval Anastomosis | Ammonium Acetate | Osmotic Effects |
Effect of Portacaval Anastomosis on Glutamine Synthetase Protein and Gene Expression in Brain, Liver and Skeletal Muscle
[ PUBLICATION ]
The effects of chronic liver insufficiency resulting from end-to-side portacaval anastomosis (PCA) on glutamine synthetase (GS) activities, protein and gene expression were studied in brain, liver and skeletal muscle of male adult rats. Four weeks following PCA, activities of GS in cerebral cortex and cerebellum were reduced by 32% and 37% (p<0.05) respectively whereas GS activities in muscle were increased by 52% (p<0.05). GS activities in liver were decreased by up to 90% (p<0.01), a ...
| Dikenal sebagai Skeletal Muscle | Portacaval Anastomosis | Gene Expression | Surgical Rna | Pca Rats |
Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been recently proposed that microglia-derived proinflammatory cytokines are involved. In the present study we evaluated the role of microglial activation and the protective effect of the anti-inflammatory drug minocycline in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting ...
| Dikenal sebagai Brain Edema | Liver Failure | Rats Alf | Microglial Activation | Pathogenesis Hepatic Encephalopathy |
KOL-Index: 11822
There is evidence to suggest that, in acute liver failure (ALF), brain ammonia and proinflammatory cytokines may act synergistically to cause brain edema and its complications (intracranial hypertension, brain herniation). However, the molecular mechanisms involved remain to be established. In order to address this issue, semi-quantitative RT-PCR was used to measure the expression of genes coding for astrocytic proteins with an established role in cell volume regulation in cerebral ...
| Dikenal sebagai Brain Edema | Liver Failure | Proinflammatory Cytokines | Astrocytic Proteins | Cultured Astrocytes |
KOL-Index: 11726
Although earlier studies on thiamine deficiency have reported increases in extracellular glutamate concentration in the thalamus, a vulnerable region of the brain in this disorder, the mechanism by which this occurs has remained unresolved. Treatment with pyrithiamine, a central thiamine antagonist, resulted in a 71 and 55% decrease in protein levels of the astrocyte glutamate transporters GLT-1 and GLAST, respectively, by immunoblotting in the medial thalamus of day 14 symptomatic rats ...
| Dikenal sebagai Medial Thalamus | Glutamate Transporter | Glt1 Glast | Spraguedawley Statistics | Protein Levels |
KOL-Index: 11620
N-acetylcysteine (NAC) is an effective antidote to treat acetaminophen (APAP)-induced acute liver failure (ALF). NAC is hepatoprotective and prevents the neurological complications of ALF, namely hepatic encephalopathy and brain edema. The protective effect of NAC and its mechanisms of action in ALF due to other toxins, however, are still controversial. In the present study, we investigated the effects of NAC in relation to liver pathology, hepatic and cerebral glutathione, plasma ...
| Dikenal sebagai Liver Failure | Nac Alf | Induced Acute | Aom Mice | Brain Edema |
Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
[ PUBLICATION ]
The pathogenesis of brain edema in acute liver failure is poorly understood. We have previously shown that rats with ischemic acute liver failure (portacaval anastomosis followed by hepatic artery ligation) exhibit brain edema and intracranial hypertension, with swelling of cortical astrocytes as the most prominent neuropathological abnormality. Because ammonia has been shown to induce swelling of astrocytes in vivo and in vitro, we examined the relationship between brain ammonia, amino ...
| Dikenal sebagai Amino Acids | Brain Edema | Portacaval Anastomosis | Liver Failure | Glutamine Alanine |
Ammonia induces MK‐801‐sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes
[ PUBLICATION ]
Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+]i, IkB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the ...
| Dikenal sebagai Rat Astrocytes | Glutamine Synthetase | Protein Tyrosine | Ammonia Induces | Oxide Nitric |
Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: Role of glutamine redefined
[ PUBLICATION ]
Acute liver failure (ALF) is characterized neuropathologically by cytotoxic brain edema and biochemically by increased brain ammonia and its detoxification product, glutamine. The osmotic actions of increased glutamine synthesis in astrocytes are considered to be causally related to brain edema and its complications (intracranial hypertension, brain herniation) in ALF. However studies using multinuclear (1)H- and (13)C-NMR spectroscopy demonstrate that neither brain glutamine ...
| Dikenal sebagai Brain Edema | Acute Liver Failure | Hepatic Encephalopathy | Intracranial Hypertension | Glutamine Synthesis |
Orang -orang kunci untuk Hepatic Encephalopathy
Top Kols di dunia
Pilih frasa pencarian hepatic encephalopathy , hepatic encephalopathy patients , hepatic encephalopathy humans , hepatic encephalopathy 95 , hepatic encephalopathy rats
Roger F Butterworth∗:Dampak ahli
Konsep yang manaRoger F Butterworth∗memiliki pengaruh langsung:Hepatic encephalopathy, Acute liver failure, Liver failure, Thiamine deficiency, Cirrhotic patients, Brain edema, Portacaval anastomosis, Mild hypothermia.
Roger F Butterworth∗:Dampak Kol
Konsep yang terkait dengan karya penulis lain yang manafor which Roger F Butterworth∗ memiliki pengaruh:Hepatic encephalopathy, Acute liver failure, Thiamine deficiency, Liver cirrhosis, Oxidative stress, Brain edema, Cirrhotic patients.
Tools
Apakah ini profil Anda? Klaim profil Anda Salin URL Sematkan tautan ke profil Anda |